##gff-version 3								
##gvf-version 1.10								
##species https://www.ncbi.nlm.nih.gov/Taxonomy/Browser/wwwtax.cgi?id=2697049								
#seqid	#source	#type	#start	#end	#score	#strand	#phase	#attributes
NC_045512.2	.	snp	177	177	.	+	.	ID=ID_0;Name=g.T-89C;alias=n/a;gene=intergenic;protein_name=n/a;protein_symbol=n/a;protein_id=n/a;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=15;dp=15;sample_size=16;Reference_seq=T;Variant_seq=C;nt_name=g.T-89C;aa_name=;hgvs_nt=NC_045512.2:g.89T>C;hgvs_aa=n/a;hgvs_alias=n/a;vcf_gene=ORF1ab;mutation_type=;viral_lineage=B.1.621.2;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=True;variant=Mu;variant_type=VOI;voi_designation_date=30-Aug-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	241	241	.	+	.	ID=ID_1;Name=g.C-25T;alias=n/a;gene=intergenic;protein_name=n/a;protein_symbol=n/a;protein_id=n/a;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=15;dp=15;sample_size=16;Reference_seq=C;Variant_seq=T;nt_name=g.C-25T;aa_name=;hgvs_nt=NC_045512.2:g.25C>T;hgvs_aa=n/a;hgvs_alias=n/a;vcf_gene=ORF1ab;mutation_type=;viral_lineage=B.1.621.2;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=True;variant=Mu;variant_type=VOI;voi_designation_date=30-Aug-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	1902	1902	.	+	.	ID=ID_2;Name=S546L;alias=S366L;gene=ORF1ab;protein_name=ORF1ab polyprotein;protein_symbol=ORF1a;protein_id=YP_009724389.1;ps_filter=n/a;ps_exc=n/a;mat_pep=nsp2;mat_pep_desc=produced by both pp1a and pp1ab;mat_pep_acc=id-YP_009724389.1:181..818;ro=14;ao=1;dp=15;sample_size=16;Reference_seq=C;Variant_seq=T;nt_name=g.C1637T;aa_name=p.S546L;hgvs_nt=NC_045512.2:g.1637C>T;hgvs_aa=YP_009724389.1:p.Ser546Leu;hgvs_alias=YP_009724389.1:Ser366Leu;vcf_gene=ORF1ab;mutation_type=MISSENSE;viral_lineage=B.1.621.2;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.06666666666666667;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=False;variant=Mu;variant_type=VOI;voi_designation_date=30-Aug-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	2700	2700	.	+	.	ID=ID_3;Name=T812I;alias=T632I;gene=ORF1ab;protein_name=ORF1ab polyprotein;protein_symbol=ORF1a;protein_id=YP_009724389.1;ps_filter=n/a;ps_exc=n/a;mat_pep=nsp2;mat_pep_desc=produced by both pp1a and pp1ab;mat_pep_acc=id-YP_009724389.1:181..818;ro=0;ao=15;dp=15;sample_size=16;Reference_seq=C;Variant_seq=T;nt_name=g.C2435T;aa_name=p.T812I;hgvs_nt=NC_045512.2:g.2435C>T;hgvs_aa=YP_009724389.1:p.Thr812Ile;hgvs_alias=YP_009724389.1:Thr632Ile;vcf_gene=ORF1ab;mutation_type=MISSENSE;viral_lineage=B.1.621.2;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=True;variant=Mu;variant_type=VOI;voi_designation_date=30-Aug-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	2945	2945	.	+	.	ID=ID_4;Name=G894S;alias=n/a;gene=ORF1ab;protein_name=ORF1ab polyprotein;protein_symbol=ORF1a;protein_id=YP_009724389.1;ps_filter=n/a;ps_exc=n/a;mat_pep=PL_pro;mat_pep_desc=former nsp1%3B conserved domains are: N-terminal acidic (Ac)%2C predicted phosphoesterase%2C papain-like proteinase%2C Y-domain%2C transmembrane domain 1 (TM1)%2C adenosine diphosphate-ribose 1''-phosphatase (ADRP)%3B produced by both pp1a and pp1ab;mat_pep_acc=id-YP_009724389.1:819..2763;ro=14;ao=1;dp=15;sample_size=16;Reference_seq=G;Variant_seq=A;nt_name=g.G2680A;aa_name=p.G894S;hgvs_nt=NC_045512.2:g.2680G>A;hgvs_aa=YP_009724389.1:p.Gly894Ser;hgvs_alias=n/a;vcf_gene=ORF1ab;mutation_type=MISSENSE;viral_lineage=B.1.621.2;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.06666666666666667;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=False;variant=Mu;variant_type=VOI;voi_designation_date=30-Aug-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	3037	3037	.	+	.	ID=ID_5;Name=F924F;alias=n/a;gene=ORF1ab;protein_name=ORF1ab polyprotein;protein_symbol=ORF1a;protein_id=YP_009724389.1;ps_filter=n/a;ps_exc=n/a;mat_pep=PL_pro;mat_pep_desc=former nsp1%3B conserved domains are: N-terminal acidic (Ac)%2C predicted phosphoesterase%2C papain-like proteinase%2C Y-domain%2C transmembrane domain 1 (TM1)%2C adenosine diphosphate-ribose 1''-phosphatase (ADRP)%3B produced by both pp1a and pp1ab;mat_pep_acc=id-YP_009724389.1:819..2763;ro=0;ao=15;dp=15;sample_size=16;Reference_seq=C;Variant_seq=T;nt_name=g.C2772T;aa_name=p.F924F;hgvs_nt=NC_045512.2:g.2772C>T;hgvs_aa=YP_009724389.1:p.Phe924Phe;hgvs_alias=n/a;vcf_gene=ORF1ab;mutation_type=SILENT;viral_lineage=B.1.621.2;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=True;variant=Mu;variant_type=VOI;voi_designation_date=30-Aug-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	3428	3428	.	+	.	ID=ID_6;Name=T1055A;alias=n/a;gene=ORF1ab;protein_name=ORF1ab polyprotein;protein_symbol=ORF1a;protein_id=YP_009724389.1;ps_filter=n/a;ps_exc=n/a;mat_pep=PL_pro;mat_pep_desc=former nsp1%3B conserved domains are: N-terminal acidic (Ac)%2C predicted phosphoesterase%2C papain-like proteinase%2C Y-domain%2C transmembrane domain 1 (TM1)%2C adenosine diphosphate-ribose 1''-phosphatase (ADRP)%3B produced by both pp1a and pp1ab;mat_pep_acc=id-YP_009724389.1:819..2763;ro=0;ao=15;dp=15;sample_size=16;Reference_seq=A;Variant_seq=G;nt_name=g.A3163G;aa_name=p.T1055A;hgvs_nt=NC_045512.2:g.3163A>G;hgvs_aa=YP_009724389.1:p.Thr1055Ala;hgvs_alias=n/a;vcf_gene=ORF1ab;mutation_type=MISSENSE;viral_lineage=B.1.621.2;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=True;variant=Mu;variant_type=VOI;voi_designation_date=30-Aug-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	4878	4878	.	+	.	ID=ID_7;Name=T1538I;alias=n/a;gene=ORF1ab;protein_name=ORF1ab polyprotein;protein_symbol=ORF1a;protein_id=YP_009724389.1;ps_filter=n/a;ps_exc=n/a;mat_pep=PL_pro;mat_pep_desc=former nsp1%3B conserved domains are: N-terminal acidic (Ac)%2C predicted phosphoesterase%2C papain-like proteinase%2C Y-domain%2C transmembrane domain 1 (TM1)%2C adenosine diphosphate-ribose 1''-phosphatase (ADRP)%3B produced by both pp1a and pp1ab;mat_pep_acc=id-YP_009724389.1:819..2763;ro=0;ao=15;dp=15;sample_size=16;Reference_seq=C;Variant_seq=T;nt_name=g.C4613T;aa_name=p.T1538I;hgvs_nt=NC_045512.2:g.4613C>T;hgvs_aa=YP_009724389.1:p.Thr1538Ile;hgvs_alias=n/a;vcf_gene=ORF1ab;mutation_type=MISSENSE;viral_lineage=B.1.621.2;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=True;variant=Mu;variant_type=VOI;voi_designation_date=30-Aug-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	5144	5144	.	+	.	ID=ID_8;Name=L1627L;alias=n/a;gene=ORF1ab;protein_name=ORF1ab polyprotein;protein_symbol=ORF1a;protein_id=YP_009724389.1;ps_filter=n/a;ps_exc=n/a;mat_pep=PL_pro;mat_pep_desc=former nsp1%3B conserved domains are: N-terminal acidic (Ac)%2C predicted phosphoesterase%2C papain-like proteinase%2C Y-domain%2C transmembrane domain 1 (TM1)%2C adenosine diphosphate-ribose 1''-phosphatase (ADRP)%3B produced by both pp1a and pp1ab;mat_pep_acc=id-YP_009724389.1:819..2763;ro=1;ao=14;dp=15;sample_size=16;Reference_seq=C;Variant_seq=T;nt_name=g.C4879T;aa_name=p.L1627L;hgvs_nt=NC_045512.2:g.4879C>T;hgvs_aa=YP_009724389.1:p.Leu1627Leu;hgvs_alias=n/a;vcf_gene=ORF1ab;mutation_type=SILENT;viral_lineage=B.1.621.2;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.9333333333333333;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=True;variant=Mu;variant_type=VOI;voi_designation_date=30-Aug-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	5192	5192	.	+	.	ID=ID_9;Name=L1643L;alias=n/a;gene=ORF1ab;protein_name=ORF1ab polyprotein;protein_symbol=ORF1a;protein_id=YP_009724389.1;ps_filter=n/a;ps_exc=n/a;mat_pep=PL_pro;mat_pep_desc=former nsp1%3B conserved domains are: N-terminal acidic (Ac)%2C predicted phosphoesterase%2C papain-like proteinase%2C Y-domain%2C transmembrane domain 1 (TM1)%2C adenosine diphosphate-ribose 1''-phosphatase (ADRP)%3B produced by both pp1a and pp1ab;mat_pep_acc=id-YP_009724389.1:819..2763;ro=0;ao=15;dp=15;sample_size=16;Reference_seq=C;Variant_seq=T;nt_name=g.C4927T;aa_name=p.L1643L;hgvs_nt=NC_045512.2:g.4927C>T;hgvs_aa=YP_009724389.1:p.Leu1643Leu;hgvs_alias=n/a;vcf_gene=ORF1ab;mutation_type=SILENT;viral_lineage=B.1.621.2;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=True;variant=Mu;variant_type=VOI;voi_designation_date=30-Aug-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	6037	6037	.	+	.	ID=ID_10;Name=S1924S;alias=n/a;gene=ORF1ab;protein_name=ORF1ab polyprotein;protein_symbol=ORF1a;protein_id=YP_009724389.1;ps_filter=n/a;ps_exc=n/a;mat_pep=PL_pro;mat_pep_desc=former nsp1%3B conserved domains are: N-terminal acidic (Ac)%2C predicted phosphoesterase%2C papain-like proteinase%2C Y-domain%2C transmembrane domain 1 (TM1)%2C adenosine diphosphate-ribose 1''-phosphatase (ADRP)%3B produced by both pp1a and pp1ab;mat_pep_acc=id-YP_009724389.1:819..2763;ro=0;ao=15;dp=15;sample_size=16;Reference_seq=C;Variant_seq=T;nt_name=g.C5772T;aa_name=p.S1924S;hgvs_nt=NC_045512.2:g.5772C>T;hgvs_aa=YP_009724389.1:p.Ser1924Ser;hgvs_alias=n/a;vcf_gene=ORF1ab;mutation_type=SILENT;viral_lineage=B.1.621.2;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=True;variant=Mu;variant_type=VOI;voi_designation_date=30-Aug-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	6358	6358	.	+	.	ID=ID_11;Name=E2031D;alias=n/a;gene=ORF1ab;protein_name=ORF1ab polyprotein;protein_symbol=ORF1a;protein_id=YP_009724389.1;ps_filter=n/a;ps_exc=n/a;mat_pep=PL_pro;mat_pep_desc=former nsp1%3B conserved domains are: N-terminal acidic (Ac)%2C predicted phosphoesterase%2C papain-like proteinase%2C Y-domain%2C transmembrane domain 1 (TM1)%2C adenosine diphosphate-ribose 1''-phosphatase (ADRP)%3B produced by both pp1a and pp1ab;mat_pep_acc=id-YP_009724389.1:819..2763;ro=14;ao=1;dp=15;sample_size=16;Reference_seq=G;Variant_seq=T;nt_name=g.G6093T;aa_name=p.E2031D;hgvs_nt=NC_045512.2:g.6093G>T;hgvs_aa=YP_009724389.1:p.Glu2031Asp;hgvs_alias=n/a;vcf_gene=ORF1ab;mutation_type=MISSENSE;viral_lineage=B.1.621.2;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.06666666666666667;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=False;variant=Mu;variant_type=VOI;voi_designation_date=30-Aug-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	10029	10029	.	+	.	ID=ID_12;Name=T3255I;alias=T492I;gene=ORF1ab;protein_name=ORF1ab polyprotein;protein_symbol=ORF1a;protein_id=YP_009724389.1;ps_filter=n/a;ps_exc=n/a;mat_pep=nsp4;mat_pep_desc=nsp4B_TM%3B contains transmembrane domain 2 (TM2)%3B produced by both pp1a and pp1ab;mat_pep_acc=id-YP_009724389.1:2764..3263;ro=0;ao=15;dp=15;sample_size=16;Reference_seq=C;Variant_seq=T;nt_name=g.C9764T;aa_name=p.T3255I;hgvs_nt=NC_045512.2:g.9764C>T;hgvs_aa=YP_009724389.1:p.Thr3255Ile;hgvs_alias=YP_009724389.1:Thr492Ile;vcf_gene=ORF1ab;mutation_type=MISSENSE;viral_lineage=B.1.621.2;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=True;variant=Mu;variant_type=VOI;voi_designation_date=30-Aug-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	11020	11020	.	+	.	ID=ID_13;Name=L3585L;alias=L16L;gene=ORF1ab;protein_name=ORF1ab polyprotein;protein_symbol=ORF1a;protein_id=YP_009724389.1;ps_filter=n/a;ps_exc=n/a;mat_pep=nsp6;mat_pep_desc=nsp6_TM%3B putative transmembrane domain%3B produced by both pp1a and pp1ab;mat_pep_acc=id-YP_009724389.1:3570..3859;ro=1;ao=14;dp=15;sample_size=16;Reference_seq=C;Variant_seq=T;nt_name=g.C10755T;aa_name=p.L3585L;hgvs_nt=NC_045512.2:g.10755C>T;hgvs_aa=YP_009724389.1:p.Leu3585Leu;hgvs_alias=YP_009724389.1:Leu16Leu;vcf_gene=ORF1ab;mutation_type=SILENT;viral_lineage=B.1.621.2;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.9333333333333333;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=True;variant=Mu;variant_type=VOI;voi_designation_date=30-Aug-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	11083	11083	.	+	.	ID=ID_14;Name=L3606F;alias=L37F;gene=ORF1ab;protein_name=ORF1ab polyprotein;protein_symbol=ORF1a;protein_id=YP_009724389.1;ps_filter=n/a;ps_exc=n/a;mat_pep=nsp6;mat_pep_desc=nsp6_TM%3B putative transmembrane domain%3B produced by both pp1a and pp1ab;mat_pep_acc=id-YP_009724389.1:3570..3859;ro=14;ao=1;dp=15;sample_size=16;Reference_seq=G;Variant_seq=T;nt_name=g.G10818T;aa_name=p.L3606F;hgvs_nt=NC_045512.2:g.10818G>T;hgvs_aa=YP_009724389.1:p.Leu3606Phe;hgvs_alias=YP_009724389.1:Leu37Phe;vcf_gene=ORF1ab;mutation_type=MISSENSE;viral_lineage=B.1.621.2;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.06666666666666667;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=False;variant=Mu;variant_type=VOI;voi_designation_date=30-Aug-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	11152	11152	.	+	.	ID=ID_15;Name=V3629V;alias=V60V;gene=ORF1ab;protein_name=ORF1ab polyprotein;protein_symbol=ORF1a;protein_id=YP_009724389.1;ps_filter=n/a;ps_exc=n/a;mat_pep=nsp6;mat_pep_desc=nsp6_TM%3B putative transmembrane domain%3B produced by both pp1a and pp1ab;mat_pep_acc=id-YP_009724389.1:3570..3859;ro=1;ao=14;dp=15;sample_size=16;Reference_seq=C;Variant_seq=T;nt_name=g.C10887T;aa_name=p.V3629V;hgvs_nt=NC_045512.2:g.10887C>T;hgvs_aa=YP_009724389.1:p.Val3629Val;hgvs_alias=YP_009724389.1:Val60Val;vcf_gene=ORF1ab;mutation_type=SILENT;viral_lineage=B.1.621.2;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.9333333333333333;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=True;variant=Mu;variant_type=VOI;voi_designation_date=30-Aug-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	11451	11451	.	+	.	ID=ID_16;Name=Q3729R;alias=Q160R;gene=ORF1ab;protein_name=ORF1ab polyprotein;protein_symbol=ORF1a;protein_id=YP_009724389.1;ps_filter=n/a;ps_exc=n/a;mat_pep=nsp6;mat_pep_desc=nsp6_TM%3B putative transmembrane domain%3B produced by both pp1a and pp1ab;mat_pep_acc=id-YP_009724389.1:3570..3859;ro=0;ao=15;dp=15;sample_size=16;Reference_seq=A;Variant_seq=G;nt_name=g.A11186G;aa_name=p.Q3729R;hgvs_nt=NC_045512.2:g.11186A>G;hgvs_aa=YP_009724389.1:p.Gln3729Arg;hgvs_alias=YP_009724389.1:Gln160Arg;vcf_gene=ORF1ab;mutation_type=MISSENSE;viral_lineage=B.1.621.2;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=True;variant=Mu;variant_type=VOI;voi_designation_date=30-Aug-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	13057	13057	.	+	.	ID=ID_17;Name=S4264S;alias=S11S;gene=ORF1ab;protein_name=ORF1ab polyprotein;protein_symbol=ORF1a;protein_id=YP_009724389.1;ps_filter=n/a;ps_exc=n/a;mat_pep=nsp10;mat_pep_desc=nsp10_CysHis%3B formerly known as growth-factor-like protein (GFL)%3B produced by both pp1a and pp1ab;mat_pep_acc=id-YP_009724389.1:4254..4392;ro=0;ao=15;dp=15;sample_size=16;Reference_seq=A;Variant_seq=T;nt_name=g.A12792T;aa_name=p.S4264S;hgvs_nt=NC_045512.2:g.12792A>T;hgvs_aa=YP_009724389.1:p.Ser4264Ser;hgvs_alias=YP_009724389.1:Ser11Ser;vcf_gene=ORF1ab;mutation_type=SILENT;viral_lineage=B.1.621.2;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=True;variant=Mu;variant_type=VOI;voi_designation_date=30-Aug-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	13944	13944	.	+	.	ID=ID_18;Name=N4560N;alias=n/a;gene=ORF1ab;protein_name=ORF1ab polyprotein-i;protein_symbol=ORF1b;protein_id=YP_009724389.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=10;ao=5;dp=15;sample_size=16;Reference_seq=C;Variant_seq=T;nt_name=g.C13680T;aa_name=p.N4560N;hgvs_nt=NC_045512.2:g.13680C>T;hgvs_aa=YP_009724389.1:p.Asn4560Asn;hgvs_alias=n/a;vcf_gene=ORF1ab;mutation_type=SILENT;viral_lineage=B.1.621.2;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.3333333333333333;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=False;variant=Mu;variant_type=VOI;voi_designation_date=30-Aug-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	14408	14408	.	+	.	ID=ID_19;Name=P4715L;alias=n/a;gene=ORF1ab;protein_name=ORF1ab polyprotein-i;protein_symbol=ORF1b;protein_id=YP_009724389.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=15;dp=15;sample_size=16;Reference_seq=C;Variant_seq=T;nt_name=g.C14144T;aa_name=p.P4715L;hgvs_nt=NC_045512.2:g.14144C>T;hgvs_aa=YP_009724389.1:p.Pro4715Leu;hgvs_alias=n/a;vcf_gene=ORF1ab;mutation_type=MISSENSE;viral_lineage=B.1.621.2;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=True;variant=Mu;variant_type=VOI;voi_designation_date=30-Aug-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	14651	14651	.	+	.	ID=ID_20;Name=N4796S;alias=n/a;gene=ORF1ab;protein_name=ORF1ab polyprotein-i;protein_symbol=ORF1b;protein_id=YP_009724389.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=14;ao=1;dp=15;sample_size=16;Reference_seq=A;Variant_seq=G;nt_name=g.A14387G;aa_name=p.N4796S;hgvs_nt=NC_045512.2:g.14387A>G;hgvs_aa=YP_009724389.1:p.Asn4796Ser;hgvs_alias=n/a;vcf_gene=ORF1ab;mutation_type=MISSENSE;viral_lineage=B.1.621.2;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.06666666666666667;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=False;variant=Mu;variant_type=VOI;voi_designation_date=30-Aug-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	15540	15540	.	+	.	ID=ID_21;Name=V5092V;alias=n/a;gene=ORF1ab;protein_name=ORF1ab polyprotein-i;protein_symbol=ORF1b;protein_id=YP_009724389.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=14;ao=1;dp=15;sample_size=16;Reference_seq=C;Variant_seq=T;nt_name=g.C15276T;aa_name=p.V5092V;hgvs_nt=NC_045512.2:g.15276C>T;hgvs_aa=YP_009724389.1:p.Val5092Val;hgvs_alias=n/a;vcf_gene=ORF1ab;mutation_type=SILENT;viral_lineage=B.1.621.2;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.06666666666666667;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=False;variant=Mu;variant_type=VOI;voi_designation_date=30-Aug-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	17491	17491	.	+	.	ID=ID_22;Name=P5743S;alias=P419S;gene=ORF1ab;protein_name=ORF1ab polyprotein-i;protein_symbol=ORF1b;protein_id=YP_009724389.1;ps_filter=n/a;ps_exc=n/a;mat_pep=nsp13;mat_pep_desc=nsp13_ZBD%2C nsp13_TB%2C and nsp_HEL1core%3B zinc-binding domain (ZD)%2C NTPase/helicase domain (HEL)%2C RNA 5'-triphosphatase%3B produced by pp1ab only;mat_pep_acc=id-YP_009724389.1:5325..5925;ro=0;ao=15;dp=15;sample_size=16;Reference_seq=C;Variant_seq=T;nt_name=g.C17227T;aa_name=p.P5743S;hgvs_nt=NC_045512.2:g.17227C>T;hgvs_aa=YP_009724389.1:p.Pro5743Ser;hgvs_alias=YP_009724389.1:Pro419Ser;vcf_gene=ORF1ab;mutation_type=MISSENSE;viral_lineage=B.1.621.2;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=True;variant=Mu;variant_type=VOI;voi_designation_date=30-Aug-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	17707	17707	.	+	.	ID=ID_23;Name=P5815S;alias=P491S;gene=ORF1ab;protein_name=ORF1ab polyprotein-i;protein_symbol=ORF1b;protein_id=YP_009724389.1;ps_filter=n/a;ps_exc=n/a;mat_pep=nsp13;mat_pep_desc=nsp13_ZBD%2C nsp13_TB%2C and nsp_HEL1core%3B zinc-binding domain (ZD)%2C NTPase/helicase domain (HEL)%2C RNA 5'-triphosphatase%3B produced by pp1ab only;mat_pep_acc=id-YP_009724389.1:5325..5925;ro=0;ao=15;dp=15;sample_size=16;Reference_seq=C;Variant_seq=T;nt_name=g.C17443T;aa_name=p.P5815S;hgvs_nt=NC_045512.2:g.17443C>T;hgvs_aa=YP_009724389.1:p.Pro5815Ser;hgvs_alias=YP_009724389.1:Pro491Ser;vcf_gene=ORF1ab;mutation_type=MISSENSE;viral_lineage=B.1.621.2;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=True;variant=Mu;variant_type=VOI;voi_designation_date=30-Aug-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	18877	18877	.	+	.	ID=ID_24;Name=L6205L;alias=L280L;gene=ORF1ab;protein_name=ORF1ab polyprotein-i;protein_symbol=ORF1b;protein_id=YP_009724389.1;ps_filter=n/a;ps_exc=n/a;mat_pep=nsp14;mat_pep_desc=nsp14A2_ExoN and nsp14B_NMT%3B produced by pp1ab only;mat_pep_acc=id-YP_009724389.1:5926..6452;ro=0;ao=15;dp=15;sample_size=16;Reference_seq=C;Variant_seq=T;nt_name=g.C18613T;aa_name=p.L6205L;hgvs_nt=NC_045512.2:g.18613C>T;hgvs_aa=YP_009724389.1:p.Leu6205Leu;hgvs_alias=YP_009724389.1:Leu280Leu;vcf_gene=ORF1ab;mutation_type=SILENT;viral_lineage=B.1.621.2;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=True;variant=Mu;variant_type=VOI;voi_designation_date=30-Aug-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	19035	19035	.	+	.	ID=ID_25;Name=I6257I;alias=I332I;gene=ORF1ab;protein_name=ORF1ab polyprotein-i;protein_symbol=ORF1b;protein_id=YP_009724389.1;ps_filter=n/a;ps_exc=n/a;mat_pep=nsp14;mat_pep_desc=nsp14A2_ExoN and nsp14B_NMT%3B produced by pp1ab only;mat_pep_acc=id-YP_009724389.1:5926..6452;ro=0;ao=15;dp=15;sample_size=16;Reference_seq=T;Variant_seq=C;nt_name=g.T18771C;aa_name=p.I6257I;hgvs_nt=NC_045512.2:g.18771T>C;hgvs_aa=YP_009724389.1:p.Ile6257Ile;hgvs_alias=YP_009724389.1:Ile332Ile;vcf_gene=ORF1ab;mutation_type=SILENT;viral_lineage=B.1.621.2;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=True;variant=Mu;variant_type=VOI;voi_designation_date=30-Aug-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	19186	19186	.	+	.	ID=ID_26;Name=L6308L;alias=L383L;gene=ORF1ab;protein_name=ORF1ab polyprotein-i;protein_symbol=ORF1b;protein_id=YP_009724389.1;ps_filter=n/a;ps_exc=n/a;mat_pep=nsp14;mat_pep_desc=nsp14A2_ExoN and nsp14B_NMT%3B produced by pp1ab only;mat_pep_acc=id-YP_009724389.1:5926..6452;ro=14;ao=1;dp=15;sample_size=16;Reference_seq=C;Variant_seq=T;nt_name=g.C18922T;aa_name=p.L6308L;hgvs_nt=NC_045512.2:g.18922C>T;hgvs_aa=YP_009724389.1:p.Leu6308Leu;hgvs_alias=YP_009724389.1:Leu383Leu;vcf_gene=ORF1ab;mutation_type=SILENT;viral_lineage=B.1.621.2;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.06666666666666667;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=False;variant=Mu;variant_type=VOI;voi_designation_date=30-Aug-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	19862	19862	.	+	.	ID=ID_27;Name=A6533V;alias=A81V;gene=ORF1ab;protein_name=ORF1ab polyprotein-i;protein_symbol=ORF1b;protein_id=YP_009724389.1;ps_filter=n/a;ps_exc=n/a;mat_pep=nsp15;mat_pep_desc=nsp15-A1 and nsp15B-NendoU%3B produced by pp1ab only;mat_pep_acc=id-YP_009724389.1:6453..6798;ro=14;ao=1;dp=15;sample_size=16;Reference_seq=C;Variant_seq=T;nt_name=g.C19598T;aa_name=p.A6533V;hgvs_nt=NC_045512.2:g.19598C>T;hgvs_aa=YP_009724389.1:p.Ala6533Val;hgvs_alias=YP_009724389.1:Ala81Val;vcf_gene=ORF1ab;mutation_type=MISSENSE;viral_lineage=B.1.621.2;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.06666666666666667;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=False;variant=Mu;variant_type=VOI;voi_designation_date=30-Aug-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	20148	20148	.	+	.	ID=ID_28;Name=F6628F;alias=F176F;gene=ORF1ab;protein_name=ORF1ab polyprotein-i;protein_symbol=ORF1b;protein_id=YP_009724389.1;ps_filter=n/a;ps_exc=n/a;mat_pep=nsp15;mat_pep_desc=nsp15-A1 and nsp15B-NendoU%3B produced by pp1ab only;mat_pep_acc=id-YP_009724389.1:6453..6798;ro=0;ao=15;dp=15;sample_size=16;Reference_seq=C;Variant_seq=T;nt_name=g.C19884T;aa_name=p.F6628F;hgvs_nt=NC_045512.2:g.19884C>T;hgvs_aa=YP_009724389.1:p.Phe6628Phe;hgvs_alias=YP_009724389.1:Phe176Phe;vcf_gene=ORF1ab;mutation_type=SILENT;viral_lineage=B.1.621.2;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=True;variant=Mu;variant_type=VOI;voi_designation_date=30-Aug-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	21846	21846	.	+	.	ID=ID_29;Name=T95I;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=1;dp=1;sample_size=16;Reference_seq=C;Variant_seq=T;nt_name=g.C284T;aa_name=p.T95I;hgvs_nt=NC_045512.2:g.284C>T;hgvs_aa=YP_009724390.1:p.Thr95Ile;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.621.2;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=ACE2 receptor binding affinity;source=https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1;citation=Gong et al. (2021);comb_mutation=D614G;function_description=Using flow cytometry and ACE2 ectodomains-Fc portion IgG complex, this variant showed a 1.33x decrease in binding (KD) relative to D614G.;heterozygosity=False;clade_defining=True;variant=Mu;variant_type=VOI;voi_designation_date=30-Aug-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	21846	21846	.	+	.	ID=ID_29;Name=T95I;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=1;dp=1;sample_size=16;Reference_seq=C;Variant_seq=T;nt_name=g.C284T;aa_name=p.T95I;hgvs_nt=NC_045512.2:g.284C>T;hgvs_aa=YP_009724390.1:p.Thr95Ile;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.621.2;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=convalescent plasma binding;source=https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1;citation=Gong et al. (2021);comb_mutation=D614G;function_description=No change in Spike binding (relative to D614G alone) by 5 plasma collected 8 months post-symptom-onset.;heterozygosity=False;clade_defining=True;variant=Mu;variant_type=VOI;voi_designation_date=30-Aug-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	21846	21846	.	+	.	ID=ID_29;Name=T95I;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=1;dp=1;sample_size=16;Reference_seq=C;Variant_seq=T;nt_name=g.C284T;aa_name=p.T95I;hgvs_nt=NC_045512.2:g.284C>T;hgvs_aa=YP_009724390.1:p.Thr95Ile;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.621.2;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=vaccinee plasma binding;source=https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1;citation=Gong et al. (2021);comb_mutation=D614G;function_description=1.16x increase in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in previously non-seroconverted subjects.  1.02x decrease in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in post-infection vaccinees.;heterozygosity=False;clade_defining=True;variant=Mu;variant_type=VOI;voi_designation_date=30-Aug-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	complex	21992	21992	.	+	.	ID=ID_30;Name=Y144_Y145delinsN;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=1;dp=1;sample_size=16;Reference_seq=TATT;Variant_seq=A;nt_name=g.TATT430_433A;aa_name=p.Y144_Y145delinsN;hgvs_nt=n/a;hgvs_aa=YP_009724390.1:p.Tyr144_Tyr145delinsAsn;hgvs_alias=n/a;vcf_gene=S;mutation_type=;viral_lineage=B.1.621.2;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=True;variant=Mu;variant_type=VOI;voi_designation_date=30-Aug-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	22450	22450	.	+	.	ID=ID_31;Name=L296L;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=1;dp=1;sample_size=16;Reference_seq=C;Variant_seq=T;nt_name=g.C888T;aa_name=p.L296L;hgvs_nt=NC_045512.2:g.888C>T;hgvs_aa=YP_009724390.1:p.Leu296Leu;hgvs_alias=n/a;vcf_gene=S;mutation_type=SILENT;viral_lineage=B.1.621.2;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=True;variant=Mu;variant_type=VOI;voi_designation_date=30-Aug-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	complex	22597	22597	.	+	.	ID=ID_32;Name=R346K;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=14;dp=15;sample_size=16;Reference_seq=CAG;Variant_seq=AAA;nt_name=g.G1037A;aa_name=p.R346K;hgvs_nt=NC_045512.2:g.1037G>A;hgvs_aa=YP_009724390.1:p.Arg346Lys;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.621.2;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.9333333333333333;function_category=monoclonal antibody serial passage escape;source=https://www.biorxiv.org/content/10.1101/2020.11.06.372037v2;citation=Liu et al. (2021);comb_mutation=E484K;function_description=In serial experiment of mAb 2B04 resistent mutation isolate E48K then selected against mAb 2H04, this combination caused escape from both mAbs, even though incubation simultaneously with both mAbs failed to yield this combination.;heterozygosity=False;clade_defining=True;variant=Mu;variant_type=VOI;voi_designation_date=30-Aug-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	complex	22597	22597	.	+	.	ID=ID_33;Name=R346K;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=14;dp=15;sample_size=16;Reference_seq=CAG;Variant_seq=AAA;nt_name=g.G1037A;aa_name=p.R346K;hgvs_nt=NC_045512.2:g.1037G>A;hgvs_aa=YP_009724390.1:p.Arg346Lys;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.621.2;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.9333333333333333;function_category=monoclonal antibody serial passage escape;source=https://www.biorxiv.org/content/10.1101/2020.07.21.214759v1.full.pdf;citation=Weisblum et al. (2020);comb_mutation=;function_description=Strong positive selection (up to 53% of supernatant sequences) under two rounds of C135 monoclonal antibody passage, overall 70% switch away from R346 to S, K or M;heterozygosity=False;clade_defining=True;variant=Mu;variant_type=VOI;voi_designation_date=30-Aug-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	complex	22597	22597	.	+	.	ID=ID_33;Name=R346K;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=14;dp=15;sample_size=16;Reference_seq=CAG;Variant_seq=AAA;nt_name=g.G1037A;aa_name=p.R346K;hgvs_nt=NC_045512.2:g.1037G>A;hgvs_aa=YP_009724390.1:p.Arg346Lys;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.621.2;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.9333333333333333;function_category=gene expression increase;source=https://doi.org/10.1016/j.cell.2020.08.012;citation=Starr et al. (2020);comb_mutation=;function_description=Experimentally, Spike gene expression increased 0.12 fold;heterozygosity=False;clade_defining=True;variant=Mu;variant_type=VOI;voi_designation_date=30-Aug-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	22597	22597	.	+	.	ID=ID_32;Name=R346K;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=1;dp=15;sample_size=16;Reference_seq=CAG;Variant_seq=CAA;nt_name=g.CAG1035_1037AAA;aa_name=p.R346K;hgvs_nt=n/a;hgvs_aa=YP_009724390.1:p.Arg346Lys;hgvs_alias=n/a;vcf_gene=S;mutation_type=;viral_lineage=B.1.621.2;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.06666666666666667;function_category=monoclonal antibody serial passage escape;source=https://www.biorxiv.org/content/10.1101/2020.11.06.372037v2;citation=Liu et al. (2021);comb_mutation=E484K;function_description=In serial experiment of mAb 2B04 resistent mutation isolate E48K then selected against mAb 2H04, this combination caused escape from both mAbs, even though incubation simultaneously with both mAbs failed to yield this combination.;heterozygosity=False;clade_defining=False;variant=Mu;variant_type=VOI;voi_designation_date=30-Aug-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	22597	22597	.	+	.	ID=ID_33;Name=R346K;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=1;dp=15;sample_size=16;Reference_seq=CAG;Variant_seq=CAA;nt_name=g.CAG1035_1037AAA;aa_name=p.R346K;hgvs_nt=n/a;hgvs_aa=YP_009724390.1:p.Arg346Lys;hgvs_alias=n/a;vcf_gene=S;mutation_type=;viral_lineage=B.1.621.2;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.06666666666666667;function_category=monoclonal antibody serial passage escape;source=https://www.biorxiv.org/content/10.1101/2020.07.21.214759v1.full.pdf;citation=Weisblum et al. (2020);comb_mutation=;function_description=Strong positive selection (up to 53% of supernatant sequences) under two rounds of C135 monoclonal antibody passage, overall 70% switch away from R346 to S, K or M;heterozygosity=False;clade_defining=False;variant=Mu;variant_type=VOI;voi_designation_date=30-Aug-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	22597	22597	.	+	.	ID=ID_33;Name=R346K;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=1;dp=15;sample_size=16;Reference_seq=CAG;Variant_seq=CAA;nt_name=g.CAG1035_1037AAA;aa_name=p.R346K;hgvs_nt=n/a;hgvs_aa=YP_009724390.1:p.Arg346Lys;hgvs_alias=n/a;vcf_gene=S;mutation_type=;viral_lineage=B.1.621.2;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.06666666666666667;function_category=gene expression increase;source=https://doi.org/10.1016/j.cell.2020.08.012;citation=Starr et al. (2020);comb_mutation=;function_description=Experimentally, Spike gene expression increased 0.12 fold;heterozygosity=False;clade_defining=False;variant=Mu;variant_type=VOI;voi_designation_date=30-Aug-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	22907	22907	.	+	.	ID=ID_34;Name=Y449N;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=15;dp=15;sample_size=16;Reference_seq=T;Variant_seq=A;nt_name=g.T1345A;aa_name=p.Y449N;hgvs_nt=NC_045512.2:g.1345T>A;hgvs_aa=YP_009724390.1:p.Tyr449Asn;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.621.2;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=gene expression increase;source=https://doi.org/10.1016/j.cell.2020.08.012;citation=Starr et al. (2020);comb_mutation=;function_description=Experimentally, Spike gene expression increased 0.07 fold;heterozygosity=False;clade_defining=True;variant=Mu;variant_type=VOI;voi_designation_date=30-Aug-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	23012	23012	.	+	.	ID=ID_35;Name=E484K;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=15;dp=15;sample_size=16;Reference_seq=G;Variant_seq=A;nt_name=g.G1450A;aa_name=p.E484K;hgvs_nt=NC_045512.2:g.1450G>A;hgvs_aa=YP_009724390.1:p.Glu484Lys;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.621.2;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=T cell evasion;source=https://science.sciencemag.org/content/early/2021/04/29/science.abh1282;citation=Reynolds et al. (2021);comb_mutation=;function_description=Analyzing responses to the E484K mutation seen in B.1.351 and P.1 variants, we noted that it did  not fall in a region predicted to bind the HLAII alleles tested (table S4). The mutation appeared  to have no substantial or differential impact on T cell responses.;heterozygosity=False;clade_defining=True;variant=Mu;variant_type=VOI;voi_designation_date=30-Aug-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	23012	23012	.	+	.	ID=ID_35;Name=E484K;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=15;dp=15;sample_size=16;Reference_seq=G;Variant_seq=A;nt_name=g.G1450A;aa_name=p.E484K;hgvs_nt=NC_045512.2:g.1450G>A;hgvs_aa=YP_009724390.1:p.Glu484Lys;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.621.2;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=antibody epitope effects;source=https://www.biorxiv.org/content/10.1101/2021.03.22.436481v1;citation=Sun et al. (2021);comb_mutation=;function_description=Complete loss of binding in ELISA by the variant against monoclonal antibody VH-Fc ab8;heterozygosity=False;clade_defining=True;variant=Mu;variant_type=VOI;voi_designation_date=30-Aug-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	23012	23012	.	+	.	ID=ID_35;Name=E484K;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=15;dp=15;sample_size=16;Reference_seq=G;Variant_seq=A;nt_name=g.G1450A;aa_name=p.E484K;hgvs_nt=NC_045512.2:g.1450G>A;hgvs_aa=YP_009724390.1:p.Glu484Lys;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.621.2;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=antibody epitope effects;source=https://www.nature.com/articles/s41586-021-03412-7;citation=Collier et al. (2021);comb_mutation=;function_description=Of 50 mAbs tested, major loss of neutralization observed for S2N28, S2X615, S2N12, S2X192, S2H7, S2X16, S2X58, S2H70, S2X613, S2D19, S2N22, S2D32, S2H58, S2M11, S2D106, S2X30.;heterozygosity=False;clade_defining=True;variant=Mu;variant_type=VOI;voi_designation_date=30-Aug-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	23012	23012	.	+	.	ID=ID_35;Name=E484K;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=15;dp=15;sample_size=16;Reference_seq=G;Variant_seq=A;nt_name=g.G1450A;aa_name=p.E484K;hgvs_nt=NC_045512.2:g.1450G>A;hgvs_aa=YP_009724390.1:p.Glu484Lys;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.621.2;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=antibody epitope effects;source=https://www.biorxiv.org/content/10.1101/2021.04.19.440481v1;citation=Li et al. (2021);comb_mutation=;function_description=Monoclonal antibodies 13G9 and 58G6 maintain fairly high neutralization potency, compared to others interfacing with E484K.;heterozygosity=False;clade_defining=True;variant=Mu;variant_type=VOI;voi_designation_date=30-Aug-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	23012	23012	.	+	.	ID=ID_36;Name=E484K;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=15;dp=15;sample_size=16;Reference_seq=G;Variant_seq=A;nt_name=g.G1450A;aa_name=p.E484K;hgvs_nt=NC_045512.2:g.1450G>A;hgvs_aa=YP_009724390.1:p.Glu484Lys;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.621.2;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=antibody epitope effects;source=https://www.nature.com/articles/s41591-021-01294-w;citation=Chen et al. (2021);comb_mutation=N501Y;function_description=Ablates Class 1 receptor-binding-motif targeting antibodies COV2-2050, 1B07, COVOX-384, and S2H58. Ablates Class 3 N-terminal domain targeting antibody COV2-2489, diminishes COV2-2676.;heterozygosity=False;clade_defining=True;variant=Mu;variant_type=VOI;voi_designation_date=30-Aug-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	23012	23012	.	+	.	ID=ID_35;Name=E484K;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=15;dp=15;sample_size=16;Reference_seq=G;Variant_seq=A;nt_name=g.G1450A;aa_name=p.E484K;hgvs_nt=NC_045512.2:g.1450G>A;hgvs_aa=YP_009724390.1:p.Glu484Lys;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.621.2;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=antibody epitope effects;source=https://www.biorxiv.org/content/10.1101/2020.11.03.367391v2;citation=Gaebler et al. (2021);comb_mutation=;function_description=Ablates binding by class 2 mAbs such as C144 that directly interfere with ACE2 binding,  but clonal somatic mutations of memory B cells at 6.2 months (evolving humoral immune response)  show pronounced increase in binding to the variant.;heterozygosity=False;clade_defining=True;variant=Mu;variant_type=VOI;voi_designation_date=30-Aug-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	23012	23012	.	+	.	ID=ID_35;Name=E484K;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=15;dp=15;sample_size=16;Reference_seq=G;Variant_seq=A;nt_name=g.G1450A;aa_name=p.E484K;hgvs_nt=NC_045512.2:g.1450G>A;hgvs_aa=YP_009724390.1:p.Glu484Lys;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.621.2;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=antibody epitope effects;source=https://www.biorxiv.org/content/10.1101/2020.11.06.372037v2;citation=Liu et al. (2020);comb_mutation=;function_description=Mutant screen in neutralization assay with a broad range of monoclonal antibodies shows high resistence to 4 antibodies,  and broad low level resistence against much of the rest of the panel.;heterozygosity=False;clade_defining=True;variant=Mu;variant_type=VOI;voi_designation_date=30-Aug-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	23012	23012	.	+	.	ID=ID_35;Name=E484K;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=15;dp=15;sample_size=16;Reference_seq=G;Variant_seq=A;nt_name=g.G1450A;aa_name=p.E484K;hgvs_nt=NC_045512.2:g.1450G>A;hgvs_aa=YP_009724390.1:p.Glu484Lys;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.621.2;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=antibody epitope effects;source=https://www.biorxiv.org/content/10.1101/2021.01.15.426911v2;citation=Wang et al. (2021);comb_mutation=;function_description=Resistent to all seven class 2 (Spike 'up' or 'down' conformation, RBD targeting) antibodies tested, with 10-fold  or greater reduction in neutralization (plus notable reudction in two unclassfied mAbs).;heterozygosity=False;clade_defining=True;variant=Mu;variant_type=VOI;voi_designation_date=30-Aug-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	23012	23012	.	+	.	ID=ID_35;Name=E484K;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=15;dp=15;sample_size=16;Reference_seq=G;Variant_seq=A;nt_name=g.G1450A;aa_name=p.E484K;hgvs_nt=NC_045512.2:g.1450G>A;hgvs_aa=YP_009724390.1:p.Glu484Lys;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.621.2;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=antibody epitope effects;source=https://www.nature.com/articles/s41591-021-01294-w;citation=Chen et al. (2021);comb_mutation=;function_description=Ablates Class 1 receptor-binding-motif targeting antibodies COV2-2050, 1B07, COVOX-384 and S2H58.;heterozygosity=False;clade_defining=True;variant=Mu;variant_type=VOI;voi_designation_date=30-Aug-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	23012	23012	.	+	.	ID=ID_35;Name=E484K;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=15;dp=15;sample_size=16;Reference_seq=G;Variant_seq=A;nt_name=g.G1450A;aa_name=p.E484K;hgvs_nt=NC_045512.2:g.1450G>A;hgvs_aa=YP_009724390.1:p.Glu484Lys;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.621.2;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=antibody epitope effects;source=https://www.nature.com/articles/s41586-021-03398-2;citation=Wang et al. (2021);comb_mutation=;function_description=Pseudotyped virus model ablates neutralization by RBD-directed mAbs 4-20, 2-4, 2-43, 2-30, 2-15, LY-Cov555, C121. Pseudotyped virus model impairs neutralization by RBD-directed mAb COV2-2196 (somewhat more than fully pseudotyped B.1.351 or live virus);heterozygosity=False;clade_defining=True;variant=Mu;variant_type=VOI;voi_designation_date=30-Aug-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	23012	23012	.	+	.	ID=ID_35;Name=E484K;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=15;dp=15;sample_size=16;Reference_seq=G;Variant_seq=A;nt_name=g.G1450A;aa_name=p.E484K;hgvs_nt=NC_045512.2:g.1450G>A;hgvs_aa=YP_009724390.1:p.Glu484Lys;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.621.2;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=antibody epitope effects;source=https://science.sciencemag.org/content/371/6531/823;citation=Rappazzo et al. (2021);comb_mutation=;function_description=Massive reduction in binding efficiency vs wild type for mAb LY-CoV555.;heterozygosity=False;clade_defining=True;variant=Mu;variant_type=VOI;voi_designation_date=30-Aug-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	23012	23012	.	+	.	ID=ID_37;Name=E484K;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=15;dp=15;sample_size=16;Reference_seq=G;Variant_seq=A;nt_name=g.G1450A;aa_name=p.E484K;hgvs_nt=NC_045512.2:g.1450G>A;hgvs_aa=YP_009724390.1:p.Glu484Lys;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.621.2;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=syncytium formation;source=https://dx.doi.org/10.3390%2Fv13040633;citation=Kim et al. (2021);comb_mutation=N501Y,D614G;function_description=~50% Vero cell-cell membrane fusion assay under infection with VSV pseudotyped virus relative to wild type, signficantly higher than D614G.;heterozygosity=False;clade_defining=True;variant=Mu;variant_type=VOI;voi_designation_date=30-Aug-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	23012	23012	.	+	.	ID=ID_38;Name=E484K;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=15;dp=15;sample_size=16;Reference_seq=G;Variant_seq=A;nt_name=g.G1450A;aa_name=p.E484K;hgvs_nt=NC_045512.2:g.1450G>A;hgvs_aa=YP_009724390.1:p.Glu484Lys;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.621.2;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=ACE2 receptor binding affinity;source=https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1;citation=Gong et al. (2021);comb_mutation=D614G;function_description=This variant appears twice in the experiments, with slightly different affinities (both ~1.2x decrease in binding relative to D614G)  using flow cytometry and ACE2 ectodomains-Fc portion IgG complex.;heterozygosity=False;clade_defining=True;variant=Mu;variant_type=VOI;voi_designation_date=30-Aug-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	23012	23012	.	+	.	ID=ID_36;Name=E484K;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=15;dp=15;sample_size=16;Reference_seq=G;Variant_seq=A;nt_name=g.G1450A;aa_name=p.E484K;hgvs_nt=NC_045512.2:g.1450G>A;hgvs_aa=YP_009724390.1:p.Glu484Lys;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.621.2;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=ACE2 receptor binding affinity;source=https://www.biorxiv.org/content/10.1101/2021.05.18.444646v1;citation=Barton et al. (2021);comb_mutation=N501Y;function_description=In the case of VOC B.1.1.7+E484K, the addition of the E484K mutation to N501Y further increased the affinity, to ~15 fold higher than WT RBD (KD ~5 nM), by further increasing the k(on) as measured by surface plasmon resonance. Because the higher k(on) could result in mass transfer limiting binding, we confirmed that the kinetic measurement for this variant was not substantially affected by varying levels of immobilization.;heterozygosity=False;clade_defining=True;variant=Mu;variant_type=VOI;voi_designation_date=30-Aug-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	23012	23012	.	+	.	ID=ID_35;Name=E484K;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=15;dp=15;sample_size=16;Reference_seq=G;Variant_seq=A;nt_name=g.G1450A;aa_name=p.E484K;hgvs_nt=NC_045512.2:g.1450G>A;hgvs_aa=YP_009724390.1:p.Glu484Lys;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.621.2;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=ACE2 receptor binding affinity;source=https://www.biorxiv.org/content/10.1101/2021.02.16.431305v1;citation=Liu et al. (2021);comb_mutation=;function_description=Studying the key covariants in lineage of concern 501Y.V2,  observed about 2-fold increase in ACE2 binding vs wildtype, but greatly decreased mAb binding, suggesting evolutionary optimum tension between  immune evasion and ACE2 binding affinity as the N501Y variant alone has 10x increase in affinity but no effect on tested mAb binding.;heterozygosity=False;clade_defining=True;variant=Mu;variant_type=VOI;voi_designation_date=30-Aug-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	23012	23012	.	+	.	ID=ID_35;Name=E484K;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=15;dp=15;sample_size=16;Reference_seq=G;Variant_seq=A;nt_name=g.G1450A;aa_name=p.E484K;hgvs_nt=NC_045512.2:g.1450G>A;hgvs_aa=YP_009724390.1:p.Glu484Lys;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.621.2;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=ACE2 receptor binding affinity;source=https://www.biorxiv.org/content/10.1101/2021.02.14.431117v2;citation=Tian et al. (2021);comb_mutation=;function_description=Reported slight increase in affinity compared to wild-type RBD on the cell surface (Kd ;heterozygosity=False;clade_defining=True;variant=Mu;variant_type=VOI;voi_designation_date=30-Aug-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	23012	23012	.	+	.	ID=ID_35;Name=E484K;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=15;dp=15;sample_size=16;Reference_seq=G;Variant_seq=A;nt_name=g.G1450A;aa_name=p.E484K;hgvs_nt=NC_045512.2:g.1450G>A;hgvs_aa=YP_009724390.1:p.Glu484Lys;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.621.2;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=ACE2 receptor binding affinity;source=https://www.biorxiv.org/content/10.1101/2021.03.04.433887v1;citation=Vogel et al. (2021);comb_mutation=;function_description=The affinity of ACE2 for this mutation combination was twice as high as for wild type. Having in mind that the affinity of SARS-CoV-2 for ACE2 is only 4-fold higher compared to SARS-CoV-1, this factor of 2 is expected to be biologically significant.;heterozygosity=False;clade_defining=True;variant=Mu;variant_type=VOI;voi_designation_date=30-Aug-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	23012	23012	.	+	.	ID=ID_35;Name=E484K;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=15;dp=15;sample_size=16;Reference_seq=G;Variant_seq=A;nt_name=g.G1450A;aa_name=p.E484K;hgvs_nt=NC_045512.2:g.1450G>A;hgvs_aa=YP_009724390.1:p.Glu484Lys;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.621.2;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=ACE2 receptor binding affinity;source=https://www.biorxiv.org/content/10.1101/2021.02.22.432357v1;citation=Laffeber et al. (2021);comb_mutation=;function_description=RBD containing the N501Y mutation results in 9-fold stronger binding to the hACE2 receptor than  wild type RBD. The E484K mutation does not significantly influence the affinity for the receptor,  while K417N attenuates affinity. As a result, RBD from B.1.351 containing all three mutations binds  3-fold stronger to hACE2 than wild type RBD but 3-fold weaker than N501Y.;heterozygosity=False;clade_defining=True;variant=Mu;variant_type=VOI;voi_designation_date=30-Aug-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	23012	23012	.	+	.	ID=ID_35;Name=E484K;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=15;dp=15;sample_size=16;Reference_seq=G;Variant_seq=A;nt_name=g.G1450A;aa_name=p.E484K;hgvs_nt=NC_045512.2:g.1450G>A;hgvs_aa=YP_009724390.1:p.Glu484Lys;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.621.2;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=ACE2 receptor binding affinity;source=https://www.biorxiv.org/content/10.1101/2021.02.22.432359v1;citation=Ramanathan et al. (2021);comb_mutation=;function_description=Using Mircoscale Thermopheresis, the B.1.351 variant harboring three mutations, binds ACE2 at nearly  five-fold greater affinity than the original SARS-COV-2 RBD (Kd 87.6, vs 402.5 nM).;heterozygosity=False;clade_defining=True;variant=Mu;variant_type=VOI;voi_designation_date=30-Aug-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	23012	23012	.	+	.	ID=ID_35;Name=E484K;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=15;dp=15;sample_size=16;Reference_seq=G;Variant_seq=A;nt_name=g.G1450A;aa_name=p.E484K;hgvs_nt=NC_045512.2:g.1450G>A;hgvs_aa=YP_009724390.1:p.Glu484Lys;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.621.2;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=ACE2 receptor binding affinity;source=https://www.nature.com/articles/s41586-021-03412-7;citation=Collier et al. (2021);comb_mutation=;function_description=This combination showed ~3x increase binding to ACE2 vs wild type, about half that of the B.1.1.7 lineage, suggesting that the K417N mutation is slightly detrimental to ACE2 binding, probably as a result of disrupting the salt bridge formed with ACE2 residue D30;heterozygosity=False;clade_defining=True;variant=Mu;variant_type=VOI;voi_designation_date=30-Aug-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	23012	23012	.	+	.	ID=ID_35;Name=E484K;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=15;dp=15;sample_size=16;Reference_seq=G;Variant_seq=A;nt_name=g.G1450A;aa_name=p.E484K;hgvs_nt=NC_045512.2:g.1450G>A;hgvs_aa=YP_009724390.1:p.Glu484Lys;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.621.2;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=ACE2 receptor binding affinity;source=https://www.biorxiv.org/content/10.1101/2021.02.14.431117v2;citation=Tian et al. (2021);comb_mutation=;function_description=Reported moderate increase in affinity compared to wild-type RBD on the cell surface (Kd ;heterozygosity=False;clade_defining=True;variant=Mu;variant_type=VOI;voi_designation_date=30-Aug-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	23012	23012	.	+	.	ID=ID_35;Name=E484K;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=15;dp=15;sample_size=16;Reference_seq=G;Variant_seq=A;nt_name=g.G1450A;aa_name=p.E484K;hgvs_nt=NC_045512.2:g.1450G>A;hgvs_aa=YP_009724390.1:p.Glu484Lys;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.621.2;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=ACE2 receptor binding affinity;source=https://www.biorxiv.org/content/10.1101/2021.01.06.425392;citation=Zahradnik et al. (2021);comb_mutation=;function_description=Among the first selected variants in an in vitro evolution experiment for ACE2 binding.;heterozygosity=False;clade_defining=True;variant=Mu;variant_type=VOI;voi_designation_date=30-Aug-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	23012	23012	.	+	.	ID=ID_35;Name=E484K;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=15;dp=15;sample_size=16;Reference_seq=G;Variant_seq=A;nt_name=g.G1450A;aa_name=p.E484K;hgvs_nt=NC_045512.2:g.1450G>A;hgvs_aa=YP_009724390.1:p.Glu484Lys;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.621.2;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=ACE2 receptor binding affinity;source=https://doi.org/10.1016/j.cell.2020.08.012;citation=Starr et al. (2020);comb_mutation=;function_description=Experimentally, ACE2 binding affinity increased 0.06 fold;heterozygosity=False;clade_defining=True;variant=Mu;variant_type=VOI;voi_designation_date=30-Aug-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	23012	23012	.	+	.	ID=ID_37;Name=E484K;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=15;dp=15;sample_size=16;Reference_seq=G;Variant_seq=A;nt_name=g.G1450A;aa_name=p.E484K;hgvs_nt=NC_045512.2:g.1450G>A;hgvs_aa=YP_009724390.1:p.Glu484Lys;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.621.2;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=trafficking;source=https://dx.doi.org/10.3390%2Fv13040633;citation=Kim et al. (2021);comb_mutation=N501Y,D614G;function_description=~6x more efficient S2 domain cleavage compared to wild type, compared to 4x by D614G alone in Caco-2 cells, mid-range of three cell line tested (Vero and Calu-3). [N501Y+D614G does not show an increase in cleavage, therefore a synergistic effect of the trio is implied];heterozygosity=False;clade_defining=True;variant=Mu;variant_type=VOI;voi_designation_date=30-Aug-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	23012	23012	.	+	.	ID=ID_37;Name=E484K;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=15;dp=15;sample_size=16;Reference_seq=G;Variant_seq=A;nt_name=g.G1450A;aa_name=p.E484K;hgvs_nt=NC_045512.2:g.1450G>A;hgvs_aa=YP_009724390.1:p.Glu484Lys;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.621.2;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=trafficking;source=https://dx.doi.org/10.3390%2Fv13040633;citation=Kim et al. (2021);comb_mutation=N501Y,D614G;function_description=More efficient infectivity (24h) compared to wild type, in Caco-2 cells ~11x, Vero ~10x, and Calu-3 ~11x. Compare to wild type at ~5x across cell types.;heterozygosity=False;clade_defining=True;variant=Mu;variant_type=VOI;voi_designation_date=30-Aug-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	23012	23012	.	+	.	ID=ID_38;Name=E484K;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=15;dp=15;sample_size=16;Reference_seq=G;Variant_seq=A;nt_name=g.G1450A;aa_name=p.E484K;hgvs_nt=NC_045512.2:g.1450G>A;hgvs_aa=YP_009724390.1:p.Glu484Lys;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.621.2;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=trafficking;source=https://dx.doi.org/10.1016%2Fj.chom.2021.03.008;citation=Kuzmina et al. (2021);comb_mutation=D614G;function_description=~2x more infectivity than D614G alone in HEK293T-ACE2 cells 48h post-transduction.;heterozygosity=False;clade_defining=True;variant=Mu;variant_type=VOI;voi_designation_date=30-Aug-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	23012	23012	.	+	.	ID=ID_37;Name=E484K;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=15;dp=15;sample_size=16;Reference_seq=G;Variant_seq=A;nt_name=g.G1450A;aa_name=p.E484K;hgvs_nt=NC_045512.2:g.1450G>A;hgvs_aa=YP_009724390.1:p.Glu484Lys;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.621.2;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=trafficking;source=https://dx.doi.org/10.1016%2Fj.chom.2021.03.008;citation=Kuzmina et al. (2021);comb_mutation=N501Y,D614G;function_description=~12x more infectivity than D614G alone in HEK293T-ACE2 cells 48h post-transduction (~additive effects of 501 and 484).;heterozygosity=False;clade_defining=True;variant=Mu;variant_type=VOI;voi_designation_date=30-Aug-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	23012	23012	.	+	.	ID=ID_35;Name=E484K;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=15;dp=15;sample_size=16;Reference_seq=G;Variant_seq=A;nt_name=g.G1450A;aa_name=p.E484K;hgvs_nt=NC_045512.2:g.1450G>A;hgvs_aa=YP_009724390.1:p.Glu484Lys;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.621.2;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=trafficking;source=https://www.biorxiv.org/content/10.1101/2021.05.08.443253v1;citation=Ferriera et al (2021);comb_mutation=;function_description=This variant alone shows a ~5x decrease in cell entry efficiency (RLU measurement in 293T cells) compared to D614G.;heterozygosity=False;clade_defining=True;variant=Mu;variant_type=VOI;voi_designation_date=30-Aug-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	23012	23012	.	+	.	ID=ID_35;Name=E484K;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=15;dp=15;sample_size=16;Reference_seq=G;Variant_seq=A;nt_name=g.G1450A;aa_name=p.E484K;hgvs_nt=NC_045512.2:g.1450G>A;hgvs_aa=YP_009724390.1:p.Glu484Lys;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.621.2;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=trafficking;source=https://www.biorxiv.org/content/10.1101/2021.02.05.430003v1;citation=Tada et al. (2021);comb_mutation=;function_description=Lentiviral pseudotyped with this individual mutation from B.1.351 was tested on ACE2.293T cells. Luciferase activity was measured two days postinfection,  showing no change in infection rate amongst the cells.;heterozygosity=False;clade_defining=True;variant=Mu;variant_type=VOI;voi_designation_date=30-Aug-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	23012	23012	.	+	.	ID=ID_35;Name=E484K;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=15;dp=15;sample_size=16;Reference_seq=G;Variant_seq=A;nt_name=g.G1450A;aa_name=p.E484K;hgvs_nt=NC_045512.2:g.1450G>A;hgvs_aa=YP_009724390.1:p.Glu484Lys;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.621.2;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=pharmaceutical effectiveness;source=https://www.biorxiv.org/content/10.1101/2021.02.16.431305v1;citation=Liu et al. (2021);comb_mutation=;function_description=This mutated version of RBD completely abolishes the binding to a therapeutic antibody, Bamlanivimab, in vitro.;heterozygosity=False;clade_defining=True;variant=Mu;variant_type=VOI;voi_designation_date=30-Aug-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	23012	23012	.	+	.	ID=ID_35;Name=E484K;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=15;dp=15;sample_size=16;Reference_seq=G;Variant_seq=A;nt_name=g.G1450A;aa_name=p.E484K;hgvs_nt=NC_045512.2:g.1450G>A;hgvs_aa=YP_009724390.1:p.Glu484Lys;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.621.2;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=pharmaceutical effectiveness;source=https://www.biorxiv.org/content/10.1101/2021.04.27.440939v1;citation=Engelhart et al. (2021);comb_mutation=;function_description=Tixagevimab, Regdanvimab and COR-101 display reduced binding affinity to virus pseudotyped as RBD from B.1.351.;heterozygosity=False;clade_defining=True;variant=Mu;variant_type=VOI;voi_designation_date=30-Aug-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	23012	23012	.	+	.	ID=ID_35;Name=E484K;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=15;dp=15;sample_size=16;Reference_seq=G;Variant_seq=A;nt_name=g.G1450A;aa_name=p.E484K;hgvs_nt=NC_045512.2:g.1450G>A;hgvs_aa=YP_009724390.1:p.Glu484Lys;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.621.2;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=pharmaceutical effectiveness;source=https://www.biorxiv.org/content/10.1101/2021.04.27.440939v1;citation=Engelhart et al. (2021);comb_mutation=;function_description=Bamlanivimab (LY-CoV555) lost ~16x binding against this isolated mutation. Casirivimab lost ~16x binding against this isolated mutation.;heterozygosity=False;clade_defining=True;variant=Mu;variant_type=VOI;voi_designation_date=30-Aug-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	23012	23012	.	+	.	ID=ID_36;Name=E484K;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=15;dp=15;sample_size=16;Reference_seq=G;Variant_seq=A;nt_name=g.G1450A;aa_name=p.E484K;hgvs_nt=NC_045512.2:g.1450G>A;hgvs_aa=YP_009724390.1:p.Glu484Lys;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.621.2;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=pharmaceutical effectiveness;source=https://www.biorxiv.org/content/10.1101/2021.04.27.440939v1;citation=Engelhart et al. (2021);comb_mutation=N501Y;function_description=Bamlanivimab (LY-CoV555) lost ~64x binding against this double mutation. COR-101 lost ~50x binding against this double mutation. Casirivimab lost ~250x binding against this double mutation. Estesevimab lost ~16x binding against this double mutation. Regdanvimab lost ~32x binding against this double mutation. Tixagevimab lost ~10x binding against this double mutation.;heterozygosity=False;clade_defining=True;variant=Mu;variant_type=VOI;voi_designation_date=30-Aug-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	23012	23012	.	+	.	ID=ID_35;Name=E484K;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=15;dp=15;sample_size=16;Reference_seq=G;Variant_seq=A;nt_name=g.G1450A;aa_name=p.E484K;hgvs_nt=NC_045512.2:g.1450G>A;hgvs_aa=YP_009724390.1:p.Glu484Lys;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.621.2;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=convalescent plasma escape;source=https://www.biorxiv.org/content/10.1101/2021.08.06.455491v1;citation=Schmidt et al. (2021);comb_mutation=;function_description=Escape mutant found after in passage in plasma pool of 26 convalescents mean 1.5 post symptom onset.;heterozygosity=False;clade_defining=True;variant=Mu;variant_type=VOI;voi_designation_date=30-Aug-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	23012	23012	.	+	.	ID=ID_38;Name=E484K;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=15;dp=15;sample_size=16;Reference_seq=G;Variant_seq=A;nt_name=g.G1450A;aa_name=p.E484K;hgvs_nt=NC_045512.2:g.1450G>A;hgvs_aa=YP_009724390.1:p.Glu484Lys;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.621.2;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=convalescent plasma escape;source=https://www.biorxiv.org/content/10.1101/2021.05.14.444076v1;citation=Tada et al. (2021);comb_mutation=D614G;function_description=Pseudotyped viruses for B.1.618 was 2.5-fold resistant to neutralization by convalescent sera compared to wild type - a finding that was similar to that of the 3-fold resistance of the South Africa B.1.351 variant using the same assay. The resistance of B.1.618 was caused by the E484K mutation, based on results from viruses pseudotyped for individual variants within B.1.618. [details on the convalescent patient sera collection are not abundantly clear in the preprint];heterozygosity=False;clade_defining=True;variant=Mu;variant_type=VOI;voi_designation_date=30-Aug-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	23012	23012	.	+	.	ID=ID_35;Name=E484K;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=15;dp=15;sample_size=16;Reference_seq=G;Variant_seq=A;nt_name=g.G1450A;aa_name=p.E484K;hgvs_nt=NC_045512.2:g.1450G>A;hgvs_aa=YP_009724390.1:p.Glu484Lys;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.621.2;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=convalescent plasma escape;source=https://www.biorxiv.org/content/10.1101/2021.03.19.436183v1;citation=Tang et al. (2021);comb_mutation=;function_description=As measured by surface plasmon resonance, RBD with the E484K mutation alone showed a mean 19.1x decrease in binding affinity for  six batches of hyperimmune immunoglobulin (hCoV-2IG) preparations generated from SARS-CoV-2 convalescent plasma.;heterozygosity=False;clade_defining=True;variant=Mu;variant_type=VOI;voi_designation_date=30-Aug-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	23012	23012	.	+	.	ID=ID_35;Name=E484K;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=15;dp=15;sample_size=16;Reference_seq=G;Variant_seq=A;nt_name=g.G1450A;aa_name=p.E484K;hgvs_nt=NC_045512.2:g.1450G>A;hgvs_aa=YP_009724390.1:p.Glu484Lys;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.621.2;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=convalescent plasma escape;source=https://www.biorxiv.org/content/10.1101/2021.02.05.430003v1;citation=Tada et al. (2021);comb_mutation=;function_description=The only mutation in the B.1.351 lineage that appears to contribute to neutralization reduction (~1.7x across 10 convalescent sera from April 2020 infectees);heterozygosity=False;clade_defining=True;variant=Mu;variant_type=VOI;voi_designation_date=30-Aug-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	23012	23012	.	+	.	ID=ID_35;Name=E484K;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=15;dp=15;sample_size=16;Reference_seq=G;Variant_seq=A;nt_name=g.G1450A;aa_name=p.E484K;hgvs_nt=NC_045512.2:g.1450G>A;hgvs_aa=YP_009724390.1:p.Glu484Lys;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.621.2;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=convalescent plasma escape;source=https://www.biorxiv.org/content/10.1101/2021.04.22.441007v1;citation=Alenquer et al. (2021);comb_mutation=;function_description=Average ~5-fold reduction in neutralization efficacy in convalescent sera of 16 health workers infected in Spring 2020.;heterozygosity=False;clade_defining=True;variant=Mu;variant_type=VOI;voi_designation_date=30-Aug-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	23012	23012	.	+	.	"ID=ID_35;Name=E484K;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=15;dp=15;sample_size=16;Reference_seq=G;Variant_seq=A;nt_name=g.G1450A;aa_name=p.E484K;hgvs_nt=NC_045512.2:g.1450G>A;hgvs_aa=YP_009724390.1:p.Glu484Lys;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.621.2;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=convalescent plasma escape;source=https://www.biorxiv.org/content/10.1101/2021.03.24.436620v1;citation=Zhou et al. (2021);comb_mutation=;function_description=Subtype of the B.1.526 ""New York"" lineage, lentivirus pseudotyped with this mutation combination in showed 3.3x reduction in  IC50 serum dilution concentration for 6 convalescent sera.;heterozygosity=False;clade_defining=True;variant=Mu;variant_type=VOI;voi_designation_date=30-Aug-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;"
NC_045512.2	.	snp	23012	23012	.	+	.	ID=ID_36;Name=E484K;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=15;dp=15;sample_size=16;Reference_seq=G;Variant_seq=A;nt_name=g.G1450A;aa_name=p.E484K;hgvs_nt=NC_045512.2:g.1450G>A;hgvs_aa=YP_009724390.1:p.Glu484Lys;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.621.2;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=convalescent plasma escape;source=https://www.nature.com/articles/s41591-021-01294-w;citation=Chen et al. (2021);comb_mutation=N501Y;function_description=In 19 convalescent human sera ~1mo post infection had mild to moderate resistence against all samples.;heterozygosity=False;clade_defining=True;variant=Mu;variant_type=VOI;voi_designation_date=30-Aug-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	23012	23012	.	+	.	ID=ID_35;Name=E484K;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=15;dp=15;sample_size=16;Reference_seq=G;Variant_seq=A;nt_name=g.G1450A;aa_name=p.E484K;hgvs_nt=NC_045512.2:g.1450G>A;hgvs_aa=YP_009724390.1:p.Glu484Lys;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.621.2;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=convalescent plasma escape;source=https://www.biorxiv.org/content/10.1101/2020.11.06.372037v2;citation=Liu et al. (2021);comb_mutation=;function_description=Remarkably, several of the E484 escape mutants were resistant to neutralization at the highest concentration (1:80 initial dilution) of all 4 convalescent sera tested (triplicate experiments). Against a wider panel of 16 convalescent plasma (no replicates), all but one show major resistance.;heterozygosity=False;clade_defining=True;variant=Mu;variant_type=VOI;voi_designation_date=30-Aug-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	23012	23012	.	+	.	ID=ID_35;Name=E484K;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=15;dp=15;sample_size=16;Reference_seq=G;Variant_seq=A;nt_name=g.G1450A;aa_name=p.E484K;hgvs_nt=NC_045512.2:g.1450G>A;hgvs_aa=YP_009724390.1:p.Glu484Lys;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.621.2;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=convalescent plasma escape;source=https://www.nature.com/articles/s41586-021-03398-2;citation=Wang et al. (2021);comb_mutation=;function_description=The neutralizing activity of 15/20 convalescent sera was significantly lower against this pseudotyped virus model;heterozygosity=False;clade_defining=True;variant=Mu;variant_type=VOI;voi_designation_date=30-Aug-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	23012	23012	.	+	.	"ID=ID_35;Name=E484K;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=15;dp=15;sample_size=16;Reference_seq=G;Variant_seq=A;nt_name=g.G1450A;aa_name=p.E484K;hgvs_nt=NC_045512.2:g.1450G>A;hgvs_aa=YP_009724390.1:p.Glu484Lys;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.621.2;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=convalescent plasma escape;source=https://doi.org/10.1101/2021.01.18.427166;citation=Wibmer et al. (2021);comb_mutation=;function_description=Nearly half (21 of 44, 48%) of early pandemic exposure convalescent plasma/sera failed to neutralize the 501Y.V2 (""South African"") lineage pseudovirus construct Only 3 of 44 convascent sera (those with the highest titer, which correlated direectly with initial infection severity) had high neutralization against this 501Y.V2  PG: note that lineage variant R246I was excluded from the text in reference to these sera assays, not sure if that was an oversight.;heterozygosity=False;clade_defining=True;variant=Mu;variant_type=VOI;voi_designation_date=30-Aug-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;"
NC_045512.2	.	snp	23012	23012	.	+	.	ID=ID_35;Name=E484K;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=15;dp=15;sample_size=16;Reference_seq=G;Variant_seq=A;nt_name=g.G1450A;aa_name=p.E484K;hgvs_nt=NC_045512.2:g.1450G>A;hgvs_aa=YP_009724390.1:p.Glu484Lys;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.621.2;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=convalescent plasma escape;source=https://www.krisp.org.za/manuscripts/MEDRXIV-2021-250224v1-Sigal.pdf;citation=Cele et al. (2021);comb_mutation=;function_description=The 501Y.V2 to first wave IC50 ratio ranged from 6 to 200-fold. Averaging across all 7 participant convalescent sera highlighted the dramatic decrease in sensitivity to neutralization of authentic 501Y.V2 variants. PG: I'm purposefully ignoring D614G and A701V as contributors;heterozygosity=False;clade_defining=True;variant=Mu;variant_type=VOI;voi_designation_date=30-Aug-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	23012	23012	.	+	.	"ID=ID_35;Name=E484K;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=15;dp=15;sample_size=16;Reference_seq=G;Variant_seq=A;nt_name=g.G1450A;aa_name=p.E484K;hgvs_nt=NC_045512.2:g.1450G>A;hgvs_aa=YP_009724390.1:p.Glu484Lys;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.621.2;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=convalescent plasma escape;source=https://doi.org/10.1101/2021.01.18.427166;citation=Wibmer et al. (2021);comb_mutation=;function_description=27% of 44 early pandemic exposure convalescent plasma/sera lose all activity against a RBD triple mutant pseudovirus (RBD mutatants of the 501Y.V2 ""South African"" lineage), while only 23% retained high titres;heterozygosity=False;clade_defining=True;variant=Mu;variant_type=VOI;voi_designation_date=30-Aug-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;"
NC_045512.2	.	snp	23012	23012	.	+	.	ID=ID_35;Name=E484K;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=15;dp=15;sample_size=16;Reference_seq=G;Variant_seq=A;nt_name=g.G1450A;aa_name=p.E484K;hgvs_nt=NC_045512.2:g.1450G>A;hgvs_aa=YP_009724390.1:p.Glu484Lys;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.621.2;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=convalescent plasma escape;source=https://www.biorxiv.org/content/10.1101/2020.12.28.424451;citation=Andreano et al. (2020);comb_mutation=;function_description=This mutation occurred in 100% of sequenced virions after 12 passages and led to a 4-fold decrease in convalescent plasma neutralization activity;heterozygosity=False;clade_defining=True;variant=Mu;variant_type=VOI;voi_designation_date=30-Aug-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	23012	23012	.	+	.	ID=ID_38;Name=E484K;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=15;dp=15;sample_size=16;Reference_seq=G;Variant_seq=A;nt_name=g.G1450A;aa_name=p.E484K;hgvs_nt=NC_045512.2:g.1450G>A;hgvs_aa=YP_009724390.1:p.Glu484Lys;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.621.2;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=convalescent plasma binding;source=https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1;citation=Gong et al. (2021);comb_mutation=D614G;function_description=1.42x increase in Spike binding (relative to D614G alone) by 5 plasma collected 8 months post-symptom-onset.;heterozygosity=False;clade_defining=True;variant=Mu;variant_type=VOI;voi_designation_date=30-Aug-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	23012	23012	.	+	.	ID=ID_38;Name=E484K;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=15;dp=15;sample_size=16;Reference_seq=G;Variant_seq=A;nt_name=g.G1450A;aa_name=p.E484K;hgvs_nt=NC_045512.2:g.1450G>A;hgvs_aa=YP_009724390.1:p.Glu484Lys;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.621.2;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=vaccine neutralization efficacy;source=https://www.biorxiv.org/content/10.1101/2021.05.14.444076v1;citation=Tada et al. (2021);comb_mutation=D614G;function_description=Pseudotyped viruses for B.1.618 was 2.7-fold resistant to neutralization by 6 BNT162b2 vaccine sera 28 days post-booster compared to wild type - a finding that was similar to that of the 3.4-fold resistance of the South Africa B.1.351 variant using the same assay. Neutralization by 3 Moderna vaccine sera 28 days post-booster was 3-fold resistant (vs. 2.2-fold for B.1.351). The resistance of B.1.618 was caused by the E484K mutation, based on results from viruses pseudotyped for individual variants within B.1.618.;heterozygosity=False;clade_defining=True;variant=Mu;variant_type=VOI;voi_designation_date=30-Aug-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	23012	23012	.	+	.	ID=ID_35;Name=E484K;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=15;dp=15;sample_size=16;Reference_seq=G;Variant_seq=A;nt_name=g.G1450A;aa_name=p.E484K;hgvs_nt=NC_045512.2:g.1450G>A;hgvs_aa=YP_009724390.1:p.Glu484Lys;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.621.2;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=vaccine neutralization efficacy;source=https://doi.org/10.1084/jem.20202756;citation=Solfrosi et al. (2021);comb_mutation=;function_description=Neutralizing antibody titers of non-human primate sera after one or two doses of Ad26.COV2.S (Jannsen vaccine)  against the variants containing the E484K substitution in the RBD were present but reduced  (fold reduction between 3.35–7.78, 95% confidence interval all above twofold difference, one-sample t test).;heterozygosity=False;clade_defining=True;variant=Mu;variant_type=VOI;voi_designation_date=30-Aug-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	23012	23012	.	+	.	ID=ID_35;Name=E484K;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=15;dp=15;sample_size=16;Reference_seq=G;Variant_seq=A;nt_name=g.G1450A;aa_name=p.E484K;hgvs_nt=NC_045512.2:g.1450G>A;hgvs_aa=YP_009724390.1:p.Glu484Lys;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.621.2;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=vaccine neutralization efficacy;source=https://dx.doi.org/10.21203%2Frs.3.rs-400230%2Fv1;citation=Ikegame et al. (2021);comb_mutation=;function_description=E484K pseudotyped VSV was tested for neutralization in a clonal HEK-293T ACE2 TMPRSS2 cell line optimized for highly efficient  S-mediated infection. A cohort of 12 Argentinian recipients of the Gamaleya Sputnik V Ad26 / Ad5 vaccine  showed a mean 2.8x decrease in neutralization effiacacy.;heterozygosity=False;clade_defining=True;variant=Mu;variant_type=VOI;voi_designation_date=30-Aug-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	23012	23012	.	+	.	ID=ID_35;Name=E484K;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=15;dp=15;sample_size=16;Reference_seq=G;Variant_seq=A;nt_name=g.G1450A;aa_name=p.E484K;hgvs_nt=NC_045512.2:g.1450G>A;hgvs_aa=YP_009724390.1:p.Glu484Lys;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.621.2;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=vaccine neutralization efficacy;source=https://doi.org/10.1016/S2666-5247(21;citation=Jangra et al. (2021);comb_mutation=;function_description=Human sera from 5 two-dose Pfizer vaccinated individuals (47-68 days post 1st-dose) neutralized this variant 3.4x less relative to reference  USA-WA1/2020 strain. 8 convalescent plasma with weak IgG ELISA titre neutralized this variant 2.4x less relative to reference  USA-WA1/2020 strain. One plasma failed to neutralize at all. 11 convalescent plasma with moderate IgG ELISA titre neutralized this variant 4.2x less relative to reference  USA-WA1/2020 strain.  11 convalescent plasma with high IgG ELISA titre neutralized this variant 2.6x less relative to reference  USA-WA1/2020 strain.;heterozygosity=False;clade_defining=True;variant=Mu;variant_type=VOI;voi_designation_date=30-Aug-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	23012	23012	.	+	.	ID=ID_38;Name=E484K;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=15;dp=15;sample_size=16;Reference_seq=G;Variant_seq=A;nt_name=g.G1450A;aa_name=p.E484K;hgvs_nt=NC_045512.2:g.1450G>A;hgvs_aa=YP_009724390.1:p.Glu484Lys;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.621.2;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=vaccine neutralization efficacy;source=https://dx.doi.org/10.1016%2Fj.chom.2021.03.008;citation=Kuzmina et al. (2021);comb_mutation=D614G;function_description=This variant showed only minor in Pfizer sera (one or two dose) neutralization efficiency vs D614G (using lentivirus pseudotype).;heterozygosity=False;clade_defining=True;variant=Mu;variant_type=VOI;voi_designation_date=30-Aug-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	23012	23012	.	+	.	ID=ID_37;Name=E484K;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=15;dp=15;sample_size=16;Reference_seq=G;Variant_seq=A;nt_name=g.G1450A;aa_name=p.E484K;hgvs_nt=NC_045512.2:g.1450G>A;hgvs_aa=YP_009724390.1:p.Glu484Lys;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.621.2;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=vaccine neutralization efficacy;source=https://dx.doi.org/10.1016%2Fj.chom.2021.03.008;citation=Kuzmina et al. (2021);comb_mutation=N501Y,D614G;function_description=This variant showed >5x decrease in Pfizer sera (3 weeks post-first dose: n ;heterozygosity=False;clade_defining=True;variant=Mu;variant_type=VOI;voi_designation_date=30-Aug-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	23012	23012	.	+	.	ID=ID_35;Name=E484K;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=15;dp=15;sample_size=16;Reference_seq=G;Variant_seq=A;nt_name=g.G1450A;aa_name=p.E484K;hgvs_nt=NC_045512.2:g.1450G>A;hgvs_aa=YP_009724390.1:p.Glu484Lys;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.621.2;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=vaccine neutralization efficacy;source=https://www.biorxiv.org/content/10.1101/2021.05.08.443253v1;citation=Ferreira et al. (2021);comb_mutation=;function_description=Nine stored sera from Pfizer BNT162b2 vaccinees were tested against a range of spike mutation bearing PV. E484K conferred a ten-fold reduction in neutralisation by vaccine sera.;heterozygosity=False;clade_defining=True;variant=Mu;variant_type=VOI;voi_designation_date=30-Aug-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	23012	23012	.	+	.	ID=ID_35;Name=E484K;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=15;dp=15;sample_size=16;Reference_seq=G;Variant_seq=A;nt_name=g.G1450A;aa_name=p.E484K;hgvs_nt=NC_045512.2:g.1450G>A;hgvs_aa=YP_009724390.1:p.Glu484Lys;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.621.2;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=vaccine neutralization efficacy;source=https://www.biorxiv.org/content/10.1101/2021.01.15.426911v2;citation=Wang et al. (2021);comb_mutation=;function_description=In a cohort of 20 patients 8+ weeks after second vaccine dose of Moderna (mRNA-1273) or Pfizer-BioNTech (BNT162b2) vaccines,  ELISA tests show 10x reduced efficacy of a majority of isolated antibodies, but only a modest decrease for vaccine plasma overall.;heterozygosity=False;clade_defining=True;variant=Mu;variant_type=VOI;voi_designation_date=30-Aug-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	23012	23012	.	+	.	ID=ID_36;Name=E484K;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=15;dp=15;sample_size=16;Reference_seq=G;Variant_seq=A;nt_name=g.G1450A;aa_name=p.E484K;hgvs_nt=NC_045512.2:g.1450G>A;hgvs_aa=YP_009724390.1:p.Glu484Lys;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.621.2;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=vaccine neutralization efficacy;source=https://www.nature.com/articles/s41591-021-01294-w;citation=Chen et al. (2021);comb_mutation=N501Y;function_description=The neutralizing activity of vaccine was slightly to significantly lower against this variant combination in sera from all 24 patients with  the BNT162b2 mRNA vaccine. (Fig. 4) [In stark contrast to this combination plus K417N, which had no effect (P<0.0001 vs. P;heterozygosity=False;clade_defining=True;variant=Mu;variant_type=VOI;voi_designation_date=30-Aug-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	23012	23012	.	+	.	ID=ID_36;Name=E484K;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=15;dp=15;sample_size=16;Reference_seq=G;Variant_seq=A;nt_name=g.G1450A;aa_name=p.E484K;hgvs_nt=NC_045512.2:g.1450G>A;hgvs_aa=YP_009724390.1:p.Glu484Lys;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.621.2;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=vaccine neutralization efficacy;source=https://www.nature.com/articles/s41591-021-01270-4;citation=Xie et al. (2021);comb_mutation=N501Y;function_description=In 20 sera from BNT162b2 mRNA vaccine inoculated participants, 6 displayed mild (2x) reductions in neutralization. This variant combination showed the highest reduction, but the magnitude of the differences was small  compared to the >4x differences in HA-inhibition titers that have been used to signal potential need for a strain change in influenza vaccines.;heterozygosity=False;clade_defining=True;variant=Mu;variant_type=VOI;voi_designation_date=30-Aug-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	23012	23012	.	+	.	ID=ID_32;Name=E484K;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=15;dp=15;sample_size=16;Reference_seq=G;Variant_seq=A;nt_name=g.G1450A;aa_name=p.E484K;hgvs_nt=NC_045512.2:g.1450G>A;hgvs_aa=YP_009724390.1:p.Glu484Lys;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.621.2;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=monoclonal antibody serial passage escape;source=https://www.biorxiv.org/content/10.1101/2020.11.06.372037v2;citation=Liu et al. (2021);comb_mutation=R346K;function_description=In serial experiment of mAb 2B04 resistent mutation isolate E48K then selected against mAb 2H04, this combination caused escape from both mAbs, even though incubation simultaneously with both mAbs failed to yield this combination.;heterozygosity=False;clade_defining=True;variant=Mu;variant_type=VOI;voi_designation_date=30-Aug-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	23012	23012	.	+	.	ID=ID_35;Name=E484K;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=15;dp=15;sample_size=16;Reference_seq=G;Variant_seq=A;nt_name=g.G1450A;aa_name=p.E484K;hgvs_nt=NC_045512.2:g.1450G>A;hgvs_aa=YP_009724390.1:p.Glu484Lys;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.621.2;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=monoclonal antibody serial passage escape;source=http://dx.doi.org/10.1126/science.abd0831;citation=Baum et al. (2020);comb_mutation=;function_description=Escape variant 100% appearance in 2 passages against Regeneron monoclonal antibody REGN10989 @ 50ug/mL (99% after one passage);heterozygosity=False;clade_defining=True;variant=Mu;variant_type=VOI;voi_designation_date=30-Aug-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	23012	23012	.	+	.	ID=ID_35;Name=E484K;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=15;dp=15;sample_size=16;Reference_seq=G;Variant_seq=A;nt_name=g.G1450A;aa_name=p.E484K;hgvs_nt=NC_045512.2:g.1450G>A;hgvs_aa=YP_009724390.1:p.Glu484Lys;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.621.2;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=monoclonal antibody serial passage escape;source=https://www.biorxiv.org/content/10.1101/2020.07.21.214759v1.full.pdf;citation=Weisblum et al. (2020);comb_mutation=;function_description=Strong positive selection (up to 50% of supernatant sequences) after C121 monoclonal antibody assay, decreasing in subsequent passages Strong positive selection (up to 44% of supernatant sequences) after after one round of C144 monoclonal antibody passage, then waning on subsequent passages;heterozygosity=False;clade_defining=True;variant=Mu;variant_type=VOI;voi_designation_date=30-Aug-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	23012	23012	.	+	.	ID=ID_35;Name=E484K;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=15;dp=15;sample_size=16;Reference_seq=G;Variant_seq=A;nt_name=g.G1450A;aa_name=p.E484K;hgvs_nt=NC_045512.2:g.1450G>A;hgvs_aa=YP_009724390.1:p.Glu484Lys;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.621.2;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=monoclonal antibody serial passage escape;source=https://www.nature.com/articles/s41586-020-2852-1_reference.pdf?origin;citation=Barnes et al. (2020);comb_mutation=;function_description=The engineered mutation cause 10-fold or more increase in the disassociation constant with many monoclonal antibodies (C144/C002/C121/C104/C110).;heterozygosity=False;clade_defining=True;variant=Mu;variant_type=VOI;voi_designation_date=30-Aug-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	23012	23012	.	+	.	ID=ID_35;Name=E484K;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=15;dp=15;sample_size=16;Reference_seq=G;Variant_seq=A;nt_name=g.G1450A;aa_name=p.E484K;hgvs_nt=NC_045512.2:g.1450G>A;hgvs_aa=YP_009724390.1:p.Glu484Lys;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.621.2;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=monoclonal antibody serial passage escape;source=https://doi.org/10.1016/j.chom.2020.11.007;citation=Greaney et al. (2020);comb_mutation=;function_description=Mildly effective mutant against this position in the RBD for highly neutralizing COV2-2479 monoclonal antibody Effective mutant against this position in the RBD for highly neutralizing COV2-2050 monoclonal antibody;heterozygosity=False;clade_defining=True;variant=Mu;variant_type=VOI;voi_designation_date=30-Aug-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	23012	23012	.	+	.	ID=ID_35;Name=E484K;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=15;dp=15;sample_size=16;Reference_seq=G;Variant_seq=A;nt_name=g.G1450A;aa_name=p.E484K;hgvs_nt=NC_045512.2:g.1450G>A;hgvs_aa=YP_009724390.1:p.Glu484Lys;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.621.2;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=monoclonal antibody serial passage escape;source=https://www.biorxiv.org/content/10.1101/2021.02.17.431683v1;citation=Starr et al. (2021);comb_mutation=;function_description=Escape mutation against monoclonal antibody LY-CoV555 (antibody that forms the basis for Eli Lilly's bamlanivimab);heterozygosity=False;clade_defining=True;variant=Mu;variant_type=VOI;voi_designation_date=30-Aug-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	23012	23012	.	+	.	ID=ID_35;Name=E484K;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=15;dp=15;sample_size=16;Reference_seq=G;Variant_seq=A;nt_name=g.G1450A;aa_name=p.E484K;hgvs_nt=NC_045512.2:g.1450G>A;hgvs_aa=YP_009724390.1:p.Glu484Lys;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.621.2;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=monoclonal antibody serial passage escape;source=https://www.biorxiv.org/content/10.1101/2021.01.15.426911v2;citation=Wang et al. (2021);comb_mutation=;function_description=Class 2 antibodies C627, C602, C671, C643, and class 2/3 antibody C603 selected for the emergence of the E484K mutation in vitro.;heterozygosity=False;clade_defining=True;variant=Mu;variant_type=VOI;voi_designation_date=30-Aug-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	23012	23012	.	+	.	ID=ID_35;Name=E484K;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=15;dp=15;sample_size=16;Reference_seq=G;Variant_seq=A;nt_name=g.G1450A;aa_name=p.E484K;hgvs_nt=NC_045512.2:g.1450G>A;hgvs_aa=YP_009724390.1:p.Glu484Lys;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.621.2;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=virion structure;source=https://www.biorxiv.org/content/10.1101/2021.03.24.436850v1;citation=Spratt et al. (2021);comb_mutation=;function_description=Estimated free energy change (ddG) for this variant is -0.6 kcal/mol (i.e. destabilizing relative to wild type);heterozygosity=False;clade_defining=True;variant=Mu;variant_type=VOI;voi_designation_date=30-Aug-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	23012	23012	.	+	.	ID=ID_38;Name=E484K;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=15;dp=15;sample_size=16;Reference_seq=G;Variant_seq=A;nt_name=g.G1450A;aa_name=p.E484K;hgvs_nt=NC_045512.2:g.1450G>A;hgvs_aa=YP_009724390.1:p.Glu484Lys;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.621.2;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=vaccinee plasma binding;source=https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1;citation=Gong et al. (2021);comb_mutation=D614G;function_description=1.16x increase in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in previously non-seroconverted subjects.  1.06x increase in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in post-infection vaccinees.;heterozygosity=False;clade_defining=True;variant=Mu;variant_type=VOI;voi_designation_date=30-Aug-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	23063	23063	.	+	.	ID=ID_39;Name=N501Y;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=15;dp=15;sample_size=16;Reference_seq=A;Variant_seq=T;nt_name=g.A1501T;aa_name=p.N501Y;hgvs_nt=NC_045512.2:g.1501A>T;hgvs_aa=YP_009724390.1:p.Asn501Tyr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.621.2;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=immunosuppression variant emergence;source=https://www.nejm.org/doi/full/10.1056/NEJMc2031364;citation=Choi et al. (2020);comb_mutation=;function_description=Appeared (day 128) and persisted in chronic (152 day) SARS-CoV-2 infection of immunocompromised patient with severe antiphospholipid syndrome;heterozygosity=False;clade_defining=True;variant=Mu;variant_type=VOI;voi_designation_date=30-Aug-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	23063	23063	.	+	.	ID=ID_39;Name=N501Y;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=15;dp=15;sample_size=16;Reference_seq=A;Variant_seq=T;nt_name=g.A1501T;aa_name=p.N501Y;hgvs_nt=NC_045512.2:g.1501A>T;hgvs_aa=YP_009724390.1:p.Asn501Tyr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.621.2;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=T cell evasion;source=https://science.sciencemag.org/content/early/2021/04/29/science.abh1282;citation=Reynolds et al. (2021);comb_mutation=;function_description=Vaccinated, but not post-infection sera, show decreased average T cell response to an N501Y peptide. When we primed transgenic mice expressing human HLA-DRB1*0401 with the Wuhan Hu-1 peptide pool,  T cell responses to the B.1.1.7 variant peptide pool were significantly reduced (p ;heterozygosity=False;clade_defining=True;variant=Mu;variant_type=VOI;voi_designation_date=30-Aug-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	23063	23063	.	+	.	ID=ID_39;Name=N501Y;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=15;dp=15;sample_size=16;Reference_seq=A;Variant_seq=T;nt_name=g.A1501T;aa_name=p.N501Y;hgvs_nt=NC_045512.2:g.1501A>T;hgvs_aa=YP_009724390.1:p.Asn501Tyr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.621.2;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=homoplasy;source=https://www.mdpi.com/2076-0817/10/2/184/htm;citation=Flores-Alanis et al. (2021);comb_mutation=;function_description=Variant within the six key residues in the receptor binding domain (RBD). Independently reported in UK, Australia  (same origin as UK), and South Africa (independent origin).;heterozygosity=False;clade_defining=True;variant=Mu;variant_type=VOI;voi_designation_date=30-Aug-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	23063	23063	.	+	.	ID=ID_39;Name=N501Y;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=15;dp=15;sample_size=16;Reference_seq=A;Variant_seq=T;nt_name=g.A1501T;aa_name=p.N501Y;hgvs_nt=NC_045512.2:g.1501A>T;hgvs_aa=YP_009724390.1:p.Asn501Tyr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.621.2;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=antibody epitope effects;source=https://doi.org/10.1101/2021.04.26.441517;citation=Klegerman et al. (2021);comb_mutation=;function_description=Contrary to other reports on N501Y containing lineages (i.e. with additional mutations), N501Y alone may have an even greater affinity for a human monoclonal antibody specific for wild type. These results suggest that the individual N501Y mutation does not contribute to altered viral properties by itself, but may contribute to a collective conformational shift produced by multiple mutations.;heterozygosity=False;clade_defining=True;variant=Mu;variant_type=VOI;voi_designation_date=30-Aug-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	23063	23063	.	+	.	ID=ID_39;Name=N501Y;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=15;dp=15;sample_size=16;Reference_seq=A;Variant_seq=T;nt_name=g.A1501T;aa_name=p.N501Y;hgvs_nt=NC_045512.2:g.1501A>T;hgvs_aa=YP_009724390.1:p.Asn501Tyr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.621.2;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=antibody epitope effects;source=https://www.nature.com/articles/s41586-021-03412-7;citation=Collier et al. (2021);comb_mutation=;function_description=Of 50 mAbs tested, major loss of neutralization observed for S2X128, S2D8, S2X192, S2D19, S2H14, S2H19.;heterozygosity=False;clade_defining=True;variant=Mu;variant_type=VOI;voi_designation_date=30-Aug-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	23063	23063	.	+	.	ID=ID_36;Name=N501Y;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=15;dp=15;sample_size=16;Reference_seq=A;Variant_seq=T;nt_name=g.A1501T;aa_name=p.N501Y;hgvs_nt=NC_045512.2:g.1501A>T;hgvs_aa=YP_009724390.1:p.Asn501Tyr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.621.2;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=antibody epitope effects;source=https://www.nature.com/articles/s41591-021-01294-w;citation=Chen et al. (2021);comb_mutation=E484K;function_description=Ablates Class 1 receptor-binding-motif targeting antibodies COV2-2050, 1B07, COVOX-384, and S2H58. Ablates Class 3 N-terminal domain targeting antibody COV2-2489, diminishes COV2-2676.;heterozygosity=False;clade_defining=True;variant=Mu;variant_type=VOI;voi_designation_date=30-Aug-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	23063	23063	.	+	.	ID=ID_39;Name=N501Y;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=15;dp=15;sample_size=16;Reference_seq=A;Variant_seq=T;nt_name=g.A1501T;aa_name=p.N501Y;hgvs_nt=NC_045512.2:g.1501A>T;hgvs_aa=YP_009724390.1:p.Asn501Tyr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.621.2;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=antibody epitope effects;source=https://www.medrxiv.org/content/10.1101/2021.01.06.20248960v1;citation=Haynes et al. (2021);comb_mutation=;function_description=Wildtype elicits immune response, COVID-19 cohort epitope score > 99th percentile of the 497 pre-pandemic controls, mutant drops PIWAS epitope score from 3% to 1.2% (poorer immune recognition) Together with other B1.1.7 lineage mutational changes (Spike: Y144del, A570D, P681H, Nucleoprotein: D3L, S235F) resulted in only 2 or 579 individuals (0.3% of the population) having a dramatic reduction in PIWAS antigen scores, which reflects the peak epitope signal along the entire antigen.;heterozygosity=False;clade_defining=True;variant=Mu;variant_type=VOI;voi_designation_date=30-Aug-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	23063	23063	.	+	.	ID=ID_39;Name=N501Y;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=15;dp=15;sample_size=16;Reference_seq=A;Variant_seq=T;nt_name=g.A1501T;aa_name=p.N501Y;hgvs_nt=NC_045512.2:g.1501A>T;hgvs_aa=YP_009724390.1:p.Asn501Tyr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.621.2;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=antibody epitope effects;source=https://www.biorxiv.org/content/10.1101/2021.01.15.426911v2;citation=Wang et al. (2021);comb_mutation=;function_description=4 antibodies tested were less potent against K417N by ten-fold or more, in both mAb classes 1 and 3;heterozygosity=False;clade_defining=True;variant=Mu;variant_type=VOI;voi_designation_date=30-Aug-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	23063	23063	.	+	.	ID=ID_39;Name=N501Y;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=15;dp=15;sample_size=16;Reference_seq=A;Variant_seq=T;nt_name=g.A1501T;aa_name=p.N501Y;hgvs_nt=NC_045512.2:g.1501A>T;hgvs_aa=YP_009724390.1:p.Asn501Tyr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.621.2;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=antibody epitope effects;source=https://www.nature.com/articles/s41591-021-01294-w;citation=Chen et al. (2021);comb_mutation=;function_description=Ablates Class 3 N-terminal domain targeting antibody COV2-2489, diminishes COV2-2676.;heterozygosity=False;clade_defining=True;variant=Mu;variant_type=VOI;voi_designation_date=30-Aug-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	23063	23063	.	+	.	ID=ID_39;Name=N501Y;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=15;dp=15;sample_size=16;Reference_seq=A;Variant_seq=T;nt_name=g.A1501T;aa_name=p.N501Y;hgvs_nt=NC_045512.2:g.1501A>T;hgvs_aa=YP_009724390.1:p.Asn501Tyr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.621.2;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=antibody epitope effects;source=https://www.biorxiv.org/content/10.1101/2021.01.27.428516v2;citation=Shen et al. (2021);comb_mutation=;function_description=Reduction in neutralization by mAbs COVA1-18 (~4x), COVA2-15 (~9x), S309 (~3x);heterozygosity=False;clade_defining=True;variant=Mu;variant_type=VOI;voi_designation_date=30-Aug-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	23063	23063	.	+	.	ID=ID_39;Name=N501Y;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=15;dp=15;sample_size=16;Reference_seq=A;Variant_seq=T;nt_name=g.A1501T;aa_name=p.N501Y;hgvs_nt=NC_045512.2:g.1501A>T;hgvs_aa=YP_009724390.1:p.Asn501Tyr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.621.2;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=antibody epitope effects;source=https://www.biorxiv.org/content/10.1101/2021.01.15.426849v1;citation=Rees-Spear et al. (2021);comb_mutation=;function_description=Lowered the neutralization potency of mAb COVA1-12 to the limit of the assay. Decrease in potency was observed against the N501Y pseudotype for the cluster IX mAb COVA2-17.;heterozygosity=False;clade_defining=True;variant=Mu;variant_type=VOI;voi_designation_date=30-Aug-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	23063	23063	.	+	.	ID=ID_40;Name=N501Y;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=15;dp=15;sample_size=16;Reference_seq=A;Variant_seq=T;nt_name=g.A1501T;aa_name=p.N501Y;hgvs_nt=NC_045512.2:g.1501A>T;hgvs_aa=YP_009724390.1:p.Asn501Tyr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.621.2;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=syncytium formation;source=https://dx.doi.org/10.3390%2Fv13040633;citation=Kim et al. (2021);comb_mutation=D614G;function_description=Slight increase in Vero cell-cell membrane fusion assay under infection with VSV pseudotyped virus relative to wild type, no change relative to D614G.;heterozygosity=False;clade_defining=True;variant=Mu;variant_type=VOI;voi_designation_date=30-Aug-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	23063	23063	.	+	.	ID=ID_37;Name=N501Y;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=15;dp=15;sample_size=16;Reference_seq=A;Variant_seq=T;nt_name=g.A1501T;aa_name=p.N501Y;hgvs_nt=NC_045512.2:g.1501A>T;hgvs_aa=YP_009724390.1:p.Asn501Tyr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.621.2;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=syncytium formation;source=https://dx.doi.org/10.3390%2Fv13040633;citation=Kim et al. (2021);comb_mutation=E484K,D614G;function_description=~50% Vero cell-cell membrane fusion assay under infection with VSV pseudotyped virus relative to wild type, signficantly higher than D614G.;heterozygosity=False;clade_defining=True;variant=Mu;variant_type=VOI;voi_designation_date=30-Aug-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	23063	23063	.	+	.	ID=ID_39;Name=N501Y;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=15;dp=15;sample_size=16;Reference_seq=A;Variant_seq=T;nt_name=g.A1501T;aa_name=p.N501Y;hgvs_nt=NC_045512.2:g.1501A>T;hgvs_aa=YP_009724390.1:p.Asn501Tyr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.621.2;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=ACE2 receptor binding affinity;source=https://www.biorxiv.org/content/10.1101/2021.05.18.444646v1;citation=Barton et al. (2021);comb_mutation=;function_description=The N501Y mutation had the biggest effect on ACE2 affinity of any VOC mutation tested, increasing the affinity ~10 fold to KD ~7 nM, by increasing the k(on) ~1.8 fold and decreasing the k(off) by ~ 7 fold as measured by surface plasmon resonance.;heterozygosity=False;clade_defining=True;variant=Mu;variant_type=VOI;voi_designation_date=30-Aug-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	23063	23063	.	+	.	"ID=ID_40;Name=N501Y;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=15;dp=15;sample_size=16;Reference_seq=A;Variant_seq=T;nt_name=g.A1501T;aa_name=p.N501Y;hgvs_nt=NC_045512.2:g.1501A>T;hgvs_aa=YP_009724390.1:p.Asn501Tyr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.621.2;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=ACE2 receptor binding affinity;source=https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1;citation=Gong et al. (2021);comb_mutation=D614G;function_description=Using flow cytometry and ACE2 ectodomains-Fc portion IgG complex, this variant showed a 2.52x increase in binding (KD) relative to D614G, mostly due to decreased in ""off-rate"" a.k.a. dissociation rate (Kdis). Compare to full Spike variant complements for major lineages containing this variant subset: 5.43x (B.1.1.7 aka Alpha), 3.56x (B.1.351 aka Beta), 4.24x (P.1 aka Gamma).;heterozygosity=False;clade_defining=True;variant=Mu;variant_type=VOI;voi_designation_date=30-Aug-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;"
NC_045512.2	.	snp	23063	23063	.	+	.	ID=ID_36;Name=N501Y;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=15;dp=15;sample_size=16;Reference_seq=A;Variant_seq=T;nt_name=g.A1501T;aa_name=p.N501Y;hgvs_nt=NC_045512.2:g.1501A>T;hgvs_aa=YP_009724390.1:p.Asn501Tyr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.621.2;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=ACE2 receptor binding affinity;source=https://www.biorxiv.org/content/10.1101/2021.05.18.444646v1;citation=Barton et al. (2021);comb_mutation=E484K;function_description=In the case of VOC B.1.1.7+E484K, the addition of the E484K mutation to N501Y further increased the affinity, to ~15 fold higher than WT RBD (KD ~5 nM), by further increasing the k(on) as measured by surface plasmon resonance. Because the higher k(on) could result in mass transfer limiting binding, we confirmed that the kinetic measurement for this variant was not substantially affected by varying levels of immobilization.;heterozygosity=False;clade_defining=True;variant=Mu;variant_type=VOI;voi_designation_date=30-Aug-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	23063	23063	.	+	.	ID=ID_39;Name=N501Y;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=15;dp=15;sample_size=16;Reference_seq=A;Variant_seq=T;nt_name=g.A1501T;aa_name=p.N501Y;hgvs_nt=NC_045512.2:g.1501A>T;hgvs_aa=YP_009724390.1:p.Asn501Tyr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.621.2;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=ACE2 receptor binding affinity;source=https://www.biorxiv.org/content/10.1101/2021.02.05.430003v1;citation=Tada et al. (2021);comb_mutation=;function_description=This single mutation causes major increase in binding affinity vs. wild type as measured by IC50 vs pseudotyped lentivirus,  but combined with the complete set of B.1.1.7   lineage variants no major change vs wild type affnity is observed.;heterozygosity=False;clade_defining=True;variant=Mu;variant_type=VOI;voi_designation_date=30-Aug-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	23063	23063	.	+	.	ID=ID_39;Name=N501Y;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=15;dp=15;sample_size=16;Reference_seq=A;Variant_seq=T;nt_name=g.A1501T;aa_name=p.N501Y;hgvs_nt=NC_045512.2:g.1501A>T;hgvs_aa=YP_009724390.1:p.Asn501Tyr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.621.2;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=ACE2 receptor binding affinity;source=https://www.biorxiv.org/content/10.1101/2021.04.02.438288v1;citation=Motozono et al. (2021);comb_mutation=;function_description=~4-fold increase in binding affinity vs wild type.;heterozygosity=False;clade_defining=True;variant=Mu;variant_type=VOI;voi_designation_date=30-Aug-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	23063	23063	.	+	.	ID=ID_39;Name=N501Y;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=15;dp=15;sample_size=16;Reference_seq=A;Variant_seq=T;nt_name=g.A1501T;aa_name=p.N501Y;hgvs_nt=NC_045512.2:g.1501A>T;hgvs_aa=YP_009724390.1:p.Asn501Tyr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.621.2;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=ACE2 receptor binding affinity;source=https://www.biorxiv.org/content/10.1101/2020.12.29.424708v1;citation=Santos and Passos (2021);comb_mutation=;function_description=In silico methods (PyMOL and PDBePISA) involving mutagenesis (N501Y mutation) and interface analysis focusing on the Spike  RDB-ACE2 interaction showed that the SARS-CoV-2 N501Y mutant (lineage B.1.1.7) establishes a more significant number of  interactions relating to the mutant residue Y501 (Spike RDB) with residues Y41 and K353 (ACE2). This finding shows that the  increased infectivity of SARS-CoV-2 lineage B.1.1.7 is associated with the interaction force between the Spike RBD Y501  mutant residue with the ACE2 receptor, which in this strain is increased.;heterozygosity=False;clade_defining=True;variant=Mu;variant_type=VOI;voi_designation_date=30-Aug-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	23063	23063	.	+	.	ID=ID_39;Name=N501Y;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=15;dp=15;sample_size=16;Reference_seq=A;Variant_seq=T;nt_name=g.A1501T;aa_name=p.N501Y;hgvs_nt=NC_045512.2:g.1501A>T;hgvs_aa=YP_009724390.1:p.Asn501Tyr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.621.2;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=ACE2 receptor binding affinity;source=https://www.biorxiv.org/content/10.1101/2021.02.16.431305v1;citation=Liu et al. (2021);comb_mutation=;function_description=Studying the key covariants in lineage of concern 501Y.V2,  observed about 2-fold increase in ACE2 binding vs wildtype, but greatly decreased mAb binding, suggesting evolutionary optimum tension between  immune evasion and ACE2 binding affinity as the N501Y variant alone has 10x increase in affinity but no effect on tested mAb binding.;heterozygosity=False;clade_defining=True;variant=Mu;variant_type=VOI;voi_designation_date=30-Aug-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	23063	23063	.	+	.	ID=ID_39;Name=N501Y;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=15;dp=15;sample_size=16;Reference_seq=A;Variant_seq=T;nt_name=g.A1501T;aa_name=p.N501Y;hgvs_nt=NC_045512.2:g.1501A>T;hgvs_aa=YP_009724390.1:p.Asn501Tyr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.621.2;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=ACE2 receptor binding affinity;source=https://www.biorxiv.org/content/10.1101/2021.02.14.431117v2;citation=Tian et al. (2021);comb_mutation=;function_description=Reported slight increase in affinity compared to wild-type RBD on the cell surface (Kd ;heterozygosity=False;clade_defining=True;variant=Mu;variant_type=VOI;voi_designation_date=30-Aug-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	23063	23063	.	+	.	ID=ID_39;Name=N501Y;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=15;dp=15;sample_size=16;Reference_seq=A;Variant_seq=T;nt_name=g.A1501T;aa_name=p.N501Y;hgvs_nt=NC_045512.2:g.1501A>T;hgvs_aa=YP_009724390.1:p.Asn501Tyr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.621.2;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=ACE2 receptor binding affinity;source=https://www.biorxiv.org/content/10.1101/2021.03.04.433887v1;citation=Vogel et al. (2021);comb_mutation=;function_description=The affinity of ACE2 for this mutation combination was twice as high as for wild type. Having in mind that the affinity of SARS-CoV-2 for ACE2 is only 4-fold higher compared to SARS-CoV-1, this factor of 2 is expected to be biologically significant.;heterozygosity=False;clade_defining=True;variant=Mu;variant_type=VOI;voi_designation_date=30-Aug-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	23063	23063	.	+	.	ID=ID_39;Name=N501Y;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=15;dp=15;sample_size=16;Reference_seq=A;Variant_seq=T;nt_name=g.A1501T;aa_name=p.N501Y;hgvs_nt=NC_045512.2:g.1501A>T;hgvs_aa=YP_009724390.1:p.Asn501Tyr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.621.2;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=ACE2 receptor binding affinity;source=https://www.biorxiv.org/content/10.1101/2021.02.22.432357v1;citation=Laffeber et al. (2021);comb_mutation=;function_description=RBD containing the N501Y mutation results in 9-fold stronger binding to the hACE2 receptor than  wild type RBD. The E484K mutation does not significantly influence the affinity for the receptor,  while K417N attenuates affinity. As a result, RBD from B.1.351 containing all three mutations binds  3-fold stronger to hACE2 than wild type RBD but 3-fold weaker than N501Y.;heterozygosity=False;clade_defining=True;variant=Mu;variant_type=VOI;voi_designation_date=30-Aug-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	23063	23063	.	+	.	ID=ID_39;Name=N501Y;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=15;dp=15;sample_size=16;Reference_seq=A;Variant_seq=T;nt_name=g.A1501T;aa_name=p.N501Y;hgvs_nt=NC_045512.2:g.1501A>T;hgvs_aa=YP_009724390.1:p.Asn501Tyr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.621.2;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=ACE2 receptor binding affinity;source=https://www.biorxiv.org/content/10.1101/2021.02.22.432359v1;citation=Ramanathan et al. (2021);comb_mutation=;function_description=Using Mircoscale Thermopheresis, the B.1.351 variant harboring three mutations, binds ACE2 at nearly  five-fold greater affinity than the original SARS-COV-2 RBD (Kd 87.6, vs 402.5 nM).;heterozygosity=False;clade_defining=True;variant=Mu;variant_type=VOI;voi_designation_date=30-Aug-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	23063	23063	.	+	.	ID=ID_39;Name=N501Y;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=15;dp=15;sample_size=16;Reference_seq=A;Variant_seq=T;nt_name=g.A1501T;aa_name=p.N501Y;hgvs_nt=NC_045512.2:g.1501A>T;hgvs_aa=YP_009724390.1:p.Asn501Tyr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.621.2;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=ACE2 receptor binding affinity;source=https://www.nature.com/articles/s41586-021-03412-7;citation=Collier et al. (2021);comb_mutation=;function_description=This combination showed ~3x increase binding to ACE2 vs wild type, about half that of the B.1.1.7 lineage, suggesting that the K417N mutation is slightly detrimental to ACE2 binding, probably as a result of disrupting the salt bridge formed with ACE2 residue D30;heterozygosity=False;clade_defining=True;variant=Mu;variant_type=VOI;voi_designation_date=30-Aug-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	23063	23063	.	+	.	ID=ID_39;Name=N501Y;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=15;dp=15;sample_size=16;Reference_seq=A;Variant_seq=T;nt_name=g.A1501T;aa_name=p.N501Y;hgvs_nt=NC_045512.2:g.1501A>T;hgvs_aa=YP_009724390.1:p.Asn501Tyr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.621.2;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=ACE2 receptor binding affinity;source=https://doi.org/10.1016/j.cell.2020.08.012;citation=Starr et al. (2020);comb_mutation=;function_description=Experimentally, ACE2 binding affinity increased 0.24 fold;heterozygosity=False;clade_defining=True;variant=Mu;variant_type=VOI;voi_designation_date=30-Aug-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	23063	23063	.	+	.	ID=ID_39;Name=N501Y;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=15;dp=15;sample_size=16;Reference_seq=A;Variant_seq=T;nt_name=g.A1501T;aa_name=p.N501Y;hgvs_nt=NC_045512.2:g.1501A>T;hgvs_aa=YP_009724390.1:p.Asn501Tyr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.621.2;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=ACE2 receptor binding affinity;source=https://www.biorxiv.org/content/10.1101/2021.01.06.425392;citation=Zahradnik et al. (2021);comb_mutation=;function_description=Among the first selected and fixed variants in an in vitro evolution experiment for ACE2 binding. Calculated disassociation constant for this variant is nearly four fold lower than wild type (Kd ;heterozygosity=False;clade_defining=True;variant=Mu;variant_type=VOI;voi_designation_date=30-Aug-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	23063	23063	.	+	.	ID=ID_39;Name=N501Y;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=15;dp=15;sample_size=16;Reference_seq=A;Variant_seq=T;nt_name=g.A1501T;aa_name=p.N501Y;hgvs_nt=NC_045512.2:g.1501A>T;hgvs_aa=YP_009724390.1:p.Asn501Tyr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.621.2;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=ACE2 receptor binding affinity;source=https://www.biorxiv.org/content/10.1101/2021.02.02.428884v1;citation=Liu et al. (2021);comb_mutation=;function_description=Reported 10-fold increase in ACE2 binding vs wildtype (Kd ;heterozygosity=False;clade_defining=True;variant=Mu;variant_type=VOI;voi_designation_date=30-Aug-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	23063	23063	.	+	.	ID=ID_39;Name=N501Y;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=15;dp=15;sample_size=16;Reference_seq=A;Variant_seq=T;nt_name=g.A1501T;aa_name=p.N501Y;hgvs_nt=NC_045512.2:g.1501A>T;hgvs_aa=YP_009724390.1:p.Asn501Tyr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.621.2;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=ACE2 receptor binding affinity;source=https://www.biorxiv.org/content/10.1101/2021.02.14.431117v2;citation=Tian et al. (2021);comb_mutation=;function_description=Reported 4-fold increase in affinity compared to wild-type RBD on the cell surface (Kd ;heterozygosity=False;clade_defining=True;variant=Mu;variant_type=VOI;voi_designation_date=30-Aug-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	23063	23063	.	+	.	ID=ID_39;Name=N501Y;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=15;dp=15;sample_size=16;Reference_seq=A;Variant_seq=T;nt_name=g.A1501T;aa_name=p.N501Y;hgvs_nt=NC_045512.2:g.1501A>T;hgvs_aa=YP_009724390.1:p.Asn501Tyr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.621.2;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=ACE2 receptor binding affinity;source=https://www.biorxiv.org/content/10.1101/2021.01.11.426269v2;citation=Zhu et al. (2021);comb_mutation=;function_description=N501Y residue inserts into a cavity at the binding interface near Y41 of ACE2.  The additional interactions result in increased affinity of ACE2 for the N501Y mutant,  accounting for its increased infectivity.;heterozygosity=False;clade_defining=True;variant=Mu;variant_type=VOI;voi_designation_date=30-Aug-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	23063	23063	.	+	.	ID=ID_39;Name=N501Y;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=15;dp=15;sample_size=16;Reference_seq=A;Variant_seq=T;nt_name=g.A1501T;aa_name=p.N501Y;hgvs_nt=NC_045512.2:g.1501A>T;hgvs_aa=YP_009724390.1:p.Asn501Tyr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.621.2;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=ACE2 receptor binding affinity;source=https://www.biorxiv.org/content/10.1101/2021.02.22.432359v1;citation=Ramanathan et al. (2021);comb_mutation=;function_description=Using Microscale Thermopheresis, this variant binds ACE2 at nearly  two-fold greater affinity than the original SARS-COV-2 RBD (203.7 nM vs 402.5 nM).;heterozygosity=False;clade_defining=True;variant=Mu;variant_type=VOI;voi_designation_date=30-Aug-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	23063	23063	.	+	.	ID=ID_39;Name=N501Y;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=15;dp=15;sample_size=16;Reference_seq=A;Variant_seq=T;nt_name=g.A1501T;aa_name=p.N501Y;hgvs_nt=NC_045512.2:g.1501A>T;hgvs_aa=YP_009724390.1:p.Asn501Tyr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.621.2;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=ACE2 receptor binding affinity;source=https://www.biorxiv.org/content/10.1101/2021.04.09.439154v1;citation=Gamez et al. (2021);comb_mutation=;function_description=The most frequent RBM mutation N501Y (165,519 instances) makes defective the atypical N-glycosylation  sequon NGV 501-503, becoming a key RBM position for the interaction with hACE2-binding hotspot 353.;heterozygosity=False;clade_defining=True;variant=Mu;variant_type=VOI;voi_designation_date=30-Aug-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	23063	23063	.	+	.	ID=ID_40;Name=N501Y;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=15;dp=15;sample_size=16;Reference_seq=A;Variant_seq=T;nt_name=g.A1501T;aa_name=p.N501Y;hgvs_nt=NC_045512.2:g.1501A>T;hgvs_aa=YP_009724390.1:p.Asn501Tyr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.621.2;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=trafficking;source=https://dx.doi.org/10.3390%2Fv13040633;citation=Kim et al. (2021);comb_mutation=D614G;function_description=~4x more efficient S2 domain cleavage compared to wild type, no change relative to D614G alone in Caco-2 cells, mid-range of three cell line tested (Vero and Calu-3).;heterozygosity=False;clade_defining=True;variant=Mu;variant_type=VOI;voi_designation_date=30-Aug-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	23063	23063	.	+	.	ID=ID_37;Name=N501Y;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=15;dp=15;sample_size=16;Reference_seq=A;Variant_seq=T;nt_name=g.A1501T;aa_name=p.N501Y;hgvs_nt=NC_045512.2:g.1501A>T;hgvs_aa=YP_009724390.1:p.Asn501Tyr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.621.2;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=trafficking;source=https://dx.doi.org/10.3390%2Fv13040633;citation=Kim et al. (2021);comb_mutation=E484K,D614G;function_description=~6x more efficient S2 domain cleavage compared to wild type, compared to 4x by D614G alone in Caco-2 cells, mid-range of three cell line tested (Vero and Calu-3). [N501Y+D614G does not show an increase in cleavage, therefore a synergistic effect of the trio is implied];heterozygosity=False;clade_defining=True;variant=Mu;variant_type=VOI;voi_designation_date=30-Aug-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	23063	23063	.	+	.	ID=ID_40;Name=N501Y;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=15;dp=15;sample_size=16;Reference_seq=A;Variant_seq=T;nt_name=g.A1501T;aa_name=p.N501Y;hgvs_nt=NC_045512.2:g.1501A>T;hgvs_aa=YP_009724390.1:p.Asn501Tyr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.621.2;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=trafficking;source=https://dx.doi.org/10.3390%2Fv13040633;citation=Kim et al. (2021);comb_mutation=D614G;function_description=More efficient infectivity (24h) compared to wild type, in Caco-2 cells ~9x, Vero ~8x, and Calu-3 ~8x. Compare to wild type at ~5x across cell types.;heterozygosity=False;clade_defining=True;variant=Mu;variant_type=VOI;voi_designation_date=30-Aug-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	23063	23063	.	+	.	ID=ID_37;Name=N501Y;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=15;dp=15;sample_size=16;Reference_seq=A;Variant_seq=T;nt_name=g.A1501T;aa_name=p.N501Y;hgvs_nt=NC_045512.2:g.1501A>T;hgvs_aa=YP_009724390.1:p.Asn501Tyr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.621.2;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=trafficking;source=https://dx.doi.org/10.3390%2Fv13040633;citation=Kim et al. (2021);comb_mutation=E484K,D614G;function_description=More efficient infectivity (24h) compared to wild type, in Caco-2 cells ~11x, Vero ~10x, and Calu-3 ~11x. Compare to wild type at ~5x across cell types.;heterozygosity=False;clade_defining=True;variant=Mu;variant_type=VOI;voi_designation_date=30-Aug-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	23063	23063	.	+	.	ID=ID_40;Name=N501Y;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=15;dp=15;sample_size=16;Reference_seq=A;Variant_seq=T;nt_name=g.A1501T;aa_name=p.N501Y;hgvs_nt=NC_045512.2:g.1501A>T;hgvs_aa=YP_009724390.1:p.Asn501Tyr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.621.2;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=trafficking;source=https://dx.doi.org/10.1016%2Fj.chom.2021.03.008;citation=Kuzmina et al. (2021);comb_mutation=D614G;function_description=9x more infectivity than D614G alone in HEK293T-ACE2 cells 48h post-transduction.;heterozygosity=False;clade_defining=True;variant=Mu;variant_type=VOI;voi_designation_date=30-Aug-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	23063	23063	.	+	.	ID=ID_37;Name=N501Y;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=15;dp=15;sample_size=16;Reference_seq=A;Variant_seq=T;nt_name=g.A1501T;aa_name=p.N501Y;hgvs_nt=NC_045512.2:g.1501A>T;hgvs_aa=YP_009724390.1:p.Asn501Tyr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.621.2;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=trafficking;source=https://dx.doi.org/10.1016%2Fj.chom.2021.03.008;citation=Kuzmina et al. (2021);comb_mutation=E484K,D614G;function_description=~12x more infectivity than D614G alone in HEK293T-ACE2 cells 48h post-transduction (~additive effects of 501 and 484).;heterozygosity=False;clade_defining=True;variant=Mu;variant_type=VOI;voi_designation_date=30-Aug-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	23063	23063	.	+	.	ID=ID_40;Name=N501Y;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=15;dp=15;sample_size=16;Reference_seq=A;Variant_seq=T;nt_name=g.A1501T;aa_name=p.N501Y;hgvs_nt=NC_045512.2:g.1501A>T;hgvs_aa=YP_009724390.1:p.Asn501Tyr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.621.2;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=trafficking;source=https://dx.doi.org/10.1016%2Fj.chom.2021.03.008;citation=Kuzmina et al. (2021);comb_mutation=D614G;function_description=9x more infectivity than D614G alone in HEK293T-ACE2 cells 48h post-transduction.;heterozygosity=False;clade_defining=True;variant=Mu;variant_type=VOI;voi_designation_date=30-Aug-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	23063	23063	.	+	.	ID=ID_39;Name=N501Y;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=15;dp=15;sample_size=16;Reference_seq=A;Variant_seq=T;nt_name=g.A1501T;aa_name=p.N501Y;hgvs_nt=NC_045512.2:g.1501A>T;hgvs_aa=YP_009724390.1:p.Asn501Tyr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.621.2;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=trafficking;source=https://www.biorxiv.org/content/10.1101/2021.02.05.430003v1;citation=Tada et al. (2021);comb_mutation=;function_description=Lentiviral pseudotyped with this individual mutation from B.1.1.7 was tested on ACE2.293T cells. Luciferase activity was measured two days postinfection,  showing slightly increased infection rate amongst the cells.  [in what is essentially a replicate experiment in the same paper, because  each B.1.351 lineage variant was independetly evaluated and N501 is in both lineages,  a significant decrease was observed, therefore the error bars described in this paper should be interpreted carefully];heterozygosity=False;clade_defining=True;variant=Mu;variant_type=VOI;voi_designation_date=30-Aug-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	23063	23063	.	+	.	ID=ID_39;Name=N501Y;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=15;dp=15;sample_size=16;Reference_seq=A;Variant_seq=T;nt_name=g.A1501T;aa_name=p.N501Y;hgvs_nt=NC_045512.2:g.1501A>T;hgvs_aa=YP_009724390.1:p.Asn501Tyr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.621.2;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=trafficking;source=https://www.biorxiv.org/content/10.1101/2021.04.02.438288v1;citation=Motozono et al. (2021);comb_mutation=;function_description=Decreased stability of RBD expression in yeast, suggesting decreased Spike protein stability.;heterozygosity=False;clade_defining=True;variant=Mu;variant_type=VOI;voi_designation_date=30-Aug-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	23063	23063	.	+	.	ID=ID_39;Name=N501Y;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=15;dp=15;sample_size=16;Reference_seq=A;Variant_seq=T;nt_name=g.A1501T;aa_name=p.N501Y;hgvs_nt=NC_045512.2:g.1501A>T;hgvs_aa=YP_009724390.1:p.Asn501Tyr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.621.2;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=pharmaceutical effectiveness;source=https://www.biorxiv.org/content/10.1101/2021.02.16.431305v1;citation=Liu et al. (2021);comb_mutation=;function_description=This mutated version of RBD completely abolishes the binding to a therapeutic antibody, Bamlanivimab, in vitro.;heterozygosity=False;clade_defining=True;variant=Mu;variant_type=VOI;voi_designation_date=30-Aug-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	23063	23063	.	+	.	ID=ID_39;Name=N501Y;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=15;dp=15;sample_size=16;Reference_seq=A;Variant_seq=T;nt_name=g.A1501T;aa_name=p.N501Y;hgvs_nt=NC_045512.2:g.1501A>T;hgvs_aa=YP_009724390.1:p.Asn501Tyr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.621.2;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=pharmaceutical effectiveness;source=https://www.biorxiv.org/content/10.1101/2021.04.27.440939v1;citation=Engelhart et al. (2021);comb_mutation=;function_description=Tixagevimab, Regdanvimab and COR-101 display reduced binding affinity to virus pseudotyped as RBD from B.1.351.;heterozygosity=False;clade_defining=True;variant=Mu;variant_type=VOI;voi_designation_date=30-Aug-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	23063	23063	.	+	.	ID=ID_39;Name=N501Y;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=15;dp=15;sample_size=16;Reference_seq=A;Variant_seq=T;nt_name=g.A1501T;aa_name=p.N501Y;hgvs_nt=NC_045512.2:g.1501A>T;hgvs_aa=YP_009724390.1:p.Asn501Tyr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.621.2;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=pharmaceutical effectiveness;source=https://www.biorxiv.org/content/10.1101/2021.04.27.440939v1;citation=Engelhart et al. (2021);comb_mutation=;function_description=COR-101 lost ~8x binding against this isolated mutation. Regdanvimab lost ~6x binding against this isolated mutation.;heterozygosity=False;clade_defining=True;variant=Mu;variant_type=VOI;voi_designation_date=30-Aug-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	23063	23063	.	+	.	ID=ID_36;Name=N501Y;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=15;dp=15;sample_size=16;Reference_seq=A;Variant_seq=T;nt_name=g.A1501T;aa_name=p.N501Y;hgvs_nt=NC_045512.2:g.1501A>T;hgvs_aa=YP_009724390.1:p.Asn501Tyr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.621.2;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=pharmaceutical effectiveness;source=https://www.biorxiv.org/content/10.1101/2021.04.27.440939v1;citation=Engelhart et al. (2021);comb_mutation=E484K;function_description=Bamlanivimab (LY-CoV555) lost ~64x binding against this double mutation. COR-101 lost ~50x binding against this double mutation. Casirivimab lost ~250x binding against this double mutation. Estesevimab lost ~16x binding against this double mutation. Regdanvimab lost ~32x binding against this double mutation. Tixagevimab lost ~10x binding against this double mutation.;heterozygosity=False;clade_defining=True;variant=Mu;variant_type=VOI;voi_designation_date=30-Aug-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	23063	23063	.	+	.	ID=ID_39;Name=N501Y;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=15;dp=15;sample_size=16;Reference_seq=A;Variant_seq=T;nt_name=g.A1501T;aa_name=p.N501Y;hgvs_nt=NC_045512.2:g.1501A>T;hgvs_aa=YP_009724390.1:p.Asn501Tyr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.621.2;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=convalescent plasma escape;source=https://dx.doi.org/10.1016%2Fj.chom.2021.03.008;citation=Kuzmina et al. (2021);comb_mutation=;function_description=0.7x reduction in neutralization by key variant in several variants of concern in sera collected from cohort of 10 with severe  disease 21 to 63 days post-onset.;heterozygosity=False;clade_defining=True;variant=Mu;variant_type=VOI;voi_designation_date=30-Aug-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	23063	23063	.	+	.	ID=ID_39;Name=N501Y;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=15;dp=15;sample_size=16;Reference_seq=A;Variant_seq=T;nt_name=g.A1501T;aa_name=p.N501Y;hgvs_nt=NC_045512.2:g.1501A>T;hgvs_aa=YP_009724390.1:p.Asn501Tyr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.621.2;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=convalescent plasma escape;source=https://www.biorxiv.org/content/10.1101/2021.03.19.436183v1;citation=Tang et al. (2021);comb_mutation=;function_description=As measured by surface plasmon resonance, RBD with the N501Y mutation alone showed a mean 2.1x decrease in binding affinity for  six batches of hyperimmune immunoglobulin (hCoV-2IG) preparations generated from SARS-CoV-2 convalescent plasma.;heterozygosity=False;clade_defining=True;variant=Mu;variant_type=VOI;voi_designation_date=30-Aug-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	23063	23063	.	+	.	ID=ID_39;Name=N501Y;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=15;dp=15;sample_size=16;Reference_seq=A;Variant_seq=T;nt_name=g.A1501T;aa_name=p.N501Y;hgvs_nt=NC_045512.2:g.1501A>T;hgvs_aa=YP_009724390.1:p.Asn501Tyr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.621.2;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=convalescent plasma escape;source=https://www.biorxiv.org/content/10.1101/2021.02.05.430003v1;citation=Tada et al. (2021);comb_mutation=;function_description=Viruses containing the point mutations of B.1.1.7 showed that the single point mutations (Δ69-70 and N501Y) were neutralized as efficiently as D614G across 10 convalescent sera from April 2020 infectees.;heterozygosity=False;clade_defining=True;variant=Mu;variant_type=VOI;voi_designation_date=30-Aug-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	23063	23063	.	+	.	ID=ID_39;Name=N501Y;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=15;dp=15;sample_size=16;Reference_seq=A;Variant_seq=T;nt_name=g.A1501T;aa_name=p.N501Y;hgvs_nt=NC_045512.2:g.1501A>T;hgvs_aa=YP_009724390.1:p.Asn501Tyr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.621.2;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=convalescent plasma escape;source=https://www.biorxiv.org/content/10.1101/2021.01.27.428516v2;citation=Shen et al. (2021);comb_mutation=;function_description=Neutralization activity of convalescent sera tested decreased ~2x with this B.1.1.7 pseudotyped virus.;heterozygosity=False;clade_defining=True;variant=Mu;variant_type=VOI;voi_designation_date=30-Aug-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	23063	23063	.	+	.	ID=ID_39;Name=N501Y;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=15;dp=15;sample_size=16;Reference_seq=A;Variant_seq=T;nt_name=g.A1501T;aa_name=p.N501Y;hgvs_nt=NC_045512.2:g.1501A>T;hgvs_aa=YP_009724390.1:p.Asn501Tyr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.621.2;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=convalescent plasma escape;source=https://dx.doi.org/10.1101%2F2021.01.19.21249592;citation=Rathnasinghe et al. (2021);comb_mutation=;function_description=In 30 samples collected 111 to 260 days post onset of symptoms, the covalescent plasma can neutralize both  the reference USA-WA1/2020 strain and the mouse adapted strain that contains the N501Y spike mutation with similar efficiency.;heterozygosity=False;clade_defining=True;variant=Mu;variant_type=VOI;voi_designation_date=30-Aug-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	23063	23063	.	+	.	ID=ID_36;Name=N501Y;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=15;dp=15;sample_size=16;Reference_seq=A;Variant_seq=T;nt_name=g.A1501T;aa_name=p.N501Y;hgvs_nt=NC_045512.2:g.1501A>T;hgvs_aa=YP_009724390.1:p.Asn501Tyr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.621.2;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=convalescent plasma escape;source=https://www.nature.com/articles/s41591-021-01294-w;citation=Chen et al. (2021);comb_mutation=E484K;function_description=In 19 convalescent human sera ~1mo post infection had mild to moderate resistence against all samples.;heterozygosity=False;clade_defining=True;variant=Mu;variant_type=VOI;voi_designation_date=30-Aug-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	23063	23063	.	+	.	"ID=ID_39;Name=N501Y;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=15;dp=15;sample_size=16;Reference_seq=A;Variant_seq=T;nt_name=g.A1501T;aa_name=p.N501Y;hgvs_nt=NC_045512.2:g.1501A>T;hgvs_aa=YP_009724390.1:p.Asn501Tyr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.621.2;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=convalescent plasma escape;source=https://doi.org/10.1101/2021.01.18.427166;citation=Wibmer et al. (2021);comb_mutation=;function_description=Nearly half (21 of 44, 48%) of early pandemic exposure convalescent plasma/sera failed to neutralize the 501Y.V2 (""South African"") lineage pseudovirus construct Only 3 of 44 convascent sera (those with the highest titer, which correlated direectly with initial infection severity) had high neutralization against this 501Y.V2  PG: note that lineage variant R246I was excluded from the text in reference to these sera assays, not sure if that was an oversight.;heterozygosity=False;clade_defining=True;variant=Mu;variant_type=VOI;voi_designation_date=30-Aug-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;"
NC_045512.2	.	snp	23063	23063	.	+	.	ID=ID_39;Name=N501Y;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=15;dp=15;sample_size=16;Reference_seq=A;Variant_seq=T;nt_name=g.A1501T;aa_name=p.N501Y;hgvs_nt=NC_045512.2:g.1501A>T;hgvs_aa=YP_009724390.1:p.Asn501Tyr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.621.2;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=convalescent plasma escape;source=https://www.krisp.org.za/manuscripts/MEDRXIV-2021-250224v1-Sigal.pdf;citation=Cele et al. (2021);comb_mutation=;function_description=The 501Y.V2 to first wave IC50 ratio ranged from 6 to 200-fold. Averaging across all 7 participant convalescent sera highlighted the dramatic decrease in sensitivity to neutralization of authentic 501Y.V2 variants. PG: I'm purposefully ignoring D614G and A701V as contributors;heterozygosity=False;clade_defining=True;variant=Mu;variant_type=VOI;voi_designation_date=30-Aug-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	23063	23063	.	+	.	"ID=ID_39;Name=N501Y;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=15;dp=15;sample_size=16;Reference_seq=A;Variant_seq=T;nt_name=g.A1501T;aa_name=p.N501Y;hgvs_nt=NC_045512.2:g.1501A>T;hgvs_aa=YP_009724390.1:p.Asn501Tyr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.621.2;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=convalescent plasma escape;source=https://doi.org/10.1101/2021.01.18.427166;citation=Wibmer et al. (2021);comb_mutation=;function_description=27% of 44 early pandemic exposure convalescent plasma/sera lose all activity against a RBD triple mutant pseudovirus (RBD mutatants of the 501Y.V2 ""South African"" lineage), while only 23% retained high titres;heterozygosity=False;clade_defining=True;variant=Mu;variant_type=VOI;voi_designation_date=30-Aug-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;"
NC_045512.2	.	snp	23063	23063	.	+	.	ID=ID_40;Name=N501Y;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=15;dp=15;sample_size=16;Reference_seq=A;Variant_seq=T;nt_name=g.A1501T;aa_name=p.N501Y;hgvs_nt=NC_045512.2:g.1501A>T;hgvs_aa=YP_009724390.1:p.Asn501Tyr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.621.2;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=convalescent plasma binding;source=https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1;citation=Gong et al. (2021);comb_mutation=D614G;function_description=1.65x increase in Spike binding (relative to D614G alone) by 5 plasma collected 8 months post-symptom-onset.;heterozygosity=False;clade_defining=True;variant=Mu;variant_type=VOI;voi_designation_date=30-Aug-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	23063	23063	.	+	.	ID=ID_39;Name=N501Y;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=15;dp=15;sample_size=16;Reference_seq=A;Variant_seq=T;nt_name=g.A1501T;aa_name=p.N501Y;hgvs_nt=NC_045512.2:g.1501A>T;hgvs_aa=YP_009724390.1:p.Asn501Tyr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.621.2;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=vaccine neutralization efficacy;source=https://www.medrxiv.org/content/10.1101/2021.02.02.21250799v1;citation=Edara et al. (2021);comb_mutation=;function_description=1.2x drop in neutralization using sera collected from 14 healthy adult participants that received two injections of the mRNA-1273 (Moderna) vaccine  at a dose of 100 µg (18-55 years: day 1 and day 14 post-2nd dose) against a recombinant single variant virus (modified replicating WA-1 cDNA clone)  relative to contemporary circulating D614G variant (USA/GA-EHC-083E/2020) using a live-virus Focus Reduction Neutralization Test (FRNT) assay.;heterozygosity=False;clade_defining=True;variant=Mu;variant_type=VOI;voi_designation_date=30-Aug-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	23063	23063	.	+	.	ID=ID_40;Name=N501Y;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=15;dp=15;sample_size=16;Reference_seq=A;Variant_seq=T;nt_name=g.A1501T;aa_name=p.N501Y;hgvs_nt=NC_045512.2:g.1501A>T;hgvs_aa=YP_009724390.1:p.Asn501Tyr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.621.2;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=vaccine neutralization efficacy;source=https://dx.doi.org/10.1016%2Fj.chom.2021.03.008;citation=Kuzmina et al. (2021);comb_mutation=D614G;function_description=This variant showed no change in Pfizer sera (one or two dose) neutralization efficiency vs D614G (using lentivirus pseudotype).;heterozygosity=False;clade_defining=True;variant=Mu;variant_type=VOI;voi_designation_date=30-Aug-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	23063	23063	.	+	.	ID=ID_37;Name=N501Y;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=15;dp=15;sample_size=16;Reference_seq=A;Variant_seq=T;nt_name=g.A1501T;aa_name=p.N501Y;hgvs_nt=NC_045512.2:g.1501A>T;hgvs_aa=YP_009724390.1:p.Asn501Tyr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.621.2;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=vaccine neutralization efficacy;source=https://dx.doi.org/10.1016%2Fj.chom.2021.03.008;citation=Kuzmina et al. (2021);comb_mutation=E484K,D614G;function_description=This variant showed >5x decrease in Pfizer sera (3 weeks post-first dose: n ;heterozygosity=False;clade_defining=True;variant=Mu;variant_type=VOI;voi_designation_date=30-Aug-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	23063	23063	.	+	.	ID=ID_39;Name=N501Y;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=15;dp=15;sample_size=16;Reference_seq=A;Variant_seq=T;nt_name=g.A1501T;aa_name=p.N501Y;hgvs_nt=NC_045512.2:g.1501A>T;hgvs_aa=YP_009724390.1:p.Asn501Tyr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.621.2;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=vaccine neutralization efficacy;source=https://www.medrxiv.org/content/10.1101/2021.04.04.21254881v1;citation=Bates et al. (2021);comb_mutation=;function_description=Observed 1.3-fold reduction in neutralization efficiency of Pfizer vaccinee sera (collected 14 days after second dose)  against pseudotype B.1.1.7 key variant lentivirus. Compare to 2.6-fold reduction against cultured B.1.1.7 virus.;heterozygosity=False;clade_defining=True;variant=Mu;variant_type=VOI;voi_designation_date=30-Aug-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	23063	23063	.	+	.	ID=ID_39;Name=N501Y;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=15;dp=15;sample_size=16;Reference_seq=A;Variant_seq=T;nt_name=g.A1501T;aa_name=p.N501Y;hgvs_nt=NC_045512.2:g.1501A>T;hgvs_aa=YP_009724390.1:p.Asn501Tyr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.621.2;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=vaccine neutralization efficacy;source=https://dx.doi.org/10.1101%2F2021.01.19.21249592;citation=Rathnasinghe et al. (2021);comb_mutation=;function_description=Human sera from 6 two-dose Pfizer vaccinated individuals (47-68 days post 1st-dose) can neutralize both the reference  USA-WA1/2020 strain and the mouse adapted SARS-CoV-2 strain that contains the N501Y spike mutation with similar efficiency.;heterozygosity=False;clade_defining=True;variant=Mu;variant_type=VOI;voi_designation_date=30-Aug-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	23063	23063	.	+	.	ID=ID_39;Name=N501Y;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=15;dp=15;sample_size=16;Reference_seq=A;Variant_seq=T;nt_name=g.A1501T;aa_name=p.N501Y;hgvs_nt=NC_045512.2:g.1501A>T;hgvs_aa=YP_009724390.1:p.Asn501Tyr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.621.2;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=vaccine neutralization efficacy;source=https://www.medrxiv.org/content/10.1101/2021.04.14.21255431v2;citation=Jacobson et al. (2021);comb_mutation=;function_description=The presence of this variant in 189 post-mRNA-vaccination COVID-19 cases was proportionally in line with lineage prevalence in Northen California during the study period, suggesting no effect of these variants on immune escape.;heterozygosity=False;clade_defining=True;variant=Mu;variant_type=VOI;voi_designation_date=30-Aug-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	23063	23063	.	+	.	ID=ID_39;Name=N501Y;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=15;dp=15;sample_size=16;Reference_seq=A;Variant_seq=T;nt_name=g.A1501T;aa_name=p.N501Y;hgvs_nt=NC_045512.2:g.1501A>T;hgvs_aa=YP_009724390.1:p.Asn501Tyr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.621.2;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=vaccine neutralization efficacy;source=https://www.biorxiv.org/content/10.1101/2021.01.15.426911v2;citation=Wang et al. (2021);comb_mutation=;function_description=In a cohort of 20 patients 8+ weeks after second vaccine dose of Moderna (mRNA-1273) or Pfizer-BioNTech (BNT162b2) vaccines,  a modest decrease in neutralization by vaccine plasma was observed.;heterozygosity=False;clade_defining=True;variant=Mu;variant_type=VOI;voi_designation_date=30-Aug-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	23063	23063	.	+	.	ID=ID_36;Name=N501Y;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=15;dp=15;sample_size=16;Reference_seq=A;Variant_seq=T;nt_name=g.A1501T;aa_name=p.N501Y;hgvs_nt=NC_045512.2:g.1501A>T;hgvs_aa=YP_009724390.1:p.Asn501Tyr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.621.2;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=vaccine neutralization efficacy;source=https://www.nature.com/articles/s41591-021-01294-w;citation=Chen et al. (2021);comb_mutation=E484K;function_description=The neutralizing activity of vaccine was slightly to significantly lower against this variant combination in sera from all 24 patients with  the BNT162b2 mRNA vaccine. (Fig. 4) [In stark contrast to this combination plus K417N, which had no effect (P<0.0001 vs. P;heterozygosity=False;clade_defining=True;variant=Mu;variant_type=VOI;voi_designation_date=30-Aug-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	23063	23063	.	+	.	ID=ID_36;Name=N501Y;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=15;dp=15;sample_size=16;Reference_seq=A;Variant_seq=T;nt_name=g.A1501T;aa_name=p.N501Y;hgvs_nt=NC_045512.2:g.1501A>T;hgvs_aa=YP_009724390.1:p.Asn501Tyr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.621.2;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=vaccine neutralization efficacy;source=https://www.nature.com/articles/s41591-021-01270-4;citation=Xie et al. (2021);comb_mutation=E484K;function_description=In 20 sera from BNT162b2 mRNA vaccine inoculated participants, 6 displayed mild (2x) reductions in neutralization. This variant combination showed the highest reduction, but the magnitude of the differences was small  compared to the >4x differences in HA-inhibition titers that have been used to signal potential need for a strain change in influenza vaccines.;heterozygosity=False;clade_defining=True;variant=Mu;variant_type=VOI;voi_designation_date=30-Aug-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	23063	23063	.	+	.	ID=ID_39;Name=N501Y;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=15;dp=15;sample_size=16;Reference_seq=A;Variant_seq=T;nt_name=g.A1501T;aa_name=p.N501Y;hgvs_nt=NC_045512.2:g.1501A>T;hgvs_aa=YP_009724390.1:p.Asn501Tyr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.621.2;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=monoclonal antibody serial passage escape;source=https://www.biorxiv.org/content/10.1101/2021.01.15.426911v2;citation=Wang et al. (2021);comb_mutation=;function_description=In vitro selection against class 1 (Spike 'up' conformation) monoclonal antibody C663, and to a lesser extent C613.;heterozygosity=False;clade_defining=True;variant=Mu;variant_type=VOI;voi_designation_date=30-Aug-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	23063	23063	.	+	.	ID=ID_39;Name=N501Y;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=15;dp=15;sample_size=16;Reference_seq=A;Variant_seq=T;nt_name=g.A1501T;aa_name=p.N501Y;hgvs_nt=NC_045512.2:g.1501A>T;hgvs_aa=YP_009724390.1:p.Asn501Tyr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.621.2;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=environmental condition stability;source=https://www.biorxiv.org/content/10.1101/2021.02.05.430003v1;citation=Tada et al. (2021);comb_mutation=;function_description=Relative to D614G, this mutation demonstrated significant increase in infectivity (i.e. heat stability) after incubation at 50C after 30 minutes or 1 hour;heterozygosity=False;clade_defining=True;variant=Mu;variant_type=VOI;voi_designation_date=30-Aug-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	23063	23063	.	+	.	ID=ID_39;Name=N501Y;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=15;dp=15;sample_size=16;Reference_seq=A;Variant_seq=T;nt_name=g.A1501T;aa_name=p.N501Y;hgvs_nt=NC_045512.2:g.1501A>T;hgvs_aa=YP_009724390.1:p.Asn501Tyr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.621.2;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=virion structure;source=https://www.biorxiv.org/content/10.1101/2021.03.24.436850v1;citation=Spratt et al. (2021);comb_mutation=;function_description=Estimated free energy change (ddG) for this variant is 0.69 kcal/mol (i.e. stabilizing relative to wild type);heterozygosity=False;clade_defining=True;variant=Mu;variant_type=VOI;voi_designation_date=30-Aug-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	23063	23063	.	+	.	ID=ID_40;Name=N501Y;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=15;dp=15;sample_size=16;Reference_seq=A;Variant_seq=T;nt_name=g.A1501T;aa_name=p.N501Y;hgvs_nt=NC_045512.2:g.1501A>T;hgvs_aa=YP_009724390.1:p.Asn501Tyr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.621.2;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=vaccinee plasma binding;source=https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1;citation=Gong et al. (2021);comb_mutation=D614G;function_description=1.17x increase in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in previously non-seroconverted subjects.  1.09x increase in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in post-infection vaccinees.;heterozygosity=False;clade_defining=True;variant=Mu;variant_type=VOI;voi_designation_date=30-Aug-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	23311	23311	.	+	.	ID=ID_41;Name=E583D;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=15;dp=15;sample_size=16;Reference_seq=G;Variant_seq=T;nt_name=g.G1749T;aa_name=p.E583D;hgvs_nt=NC_045512.2:g.1749G>T;hgvs_aa=YP_009724390.1:p.Glu583Asp;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.621.2;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=True;variant=Mu;variant_type=VOI;voi_designation_date=30-Aug-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	23403	23403	.	+	.	ID=ID_42;Name=D614G;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=15;dp=15;sample_size=16;Reference_seq=A;Variant_seq=G;nt_name=g.A1841G;aa_name=p.D614G;hgvs_nt=NC_045512.2:g.1841A>G;hgvs_aa=YP_009724390.1:p.Asp614Gly;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.621.2;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=immunosuppression variant emergence;source=https://www.medrxiv.org/content/10.1101/2021.05.08.21256775v1;citation=Landis et al. (2021);comb_mutation=;function_description=Studying 94 COVID-19 extended infection cases with genomics April 1 to October 17, 2020, one case developed 23 mutations in a 19 day period, including this combination in Spike.;heterozygosity=False;clade_defining=True;variant=Mu;variant_type=VOI;voi_designation_date=30-Aug-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	23403	23403	.	+	.	ID=ID_42;Name=D614G;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=15;dp=15;sample_size=16;Reference_seq=A;Variant_seq=G;nt_name=g.A1841G;aa_name=p.D614G;hgvs_nt=NC_045512.2:g.1841A>G;hgvs_aa=YP_009724390.1:p.Asp614Gly;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.621.2;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=syncytium formation;source=https://dx.doi.org/10.3390%2Fv13040633;citation=Kim et al. (2021);comb_mutation=;function_description=Slight increase in Vero cell-cell membrane fusion assay under infection with VSV pseudotyped virus.;heterozygosity=False;clade_defining=True;variant=Mu;variant_type=VOI;voi_designation_date=30-Aug-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	23403	23403	.	+	.	ID=ID_40;Name=D614G;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=15;dp=15;sample_size=16;Reference_seq=A;Variant_seq=G;nt_name=g.A1841G;aa_name=p.D614G;hgvs_nt=NC_045512.2:g.1841A>G;hgvs_aa=YP_009724390.1:p.Asp614Gly;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.621.2;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=syncytium formation;source=https://dx.doi.org/10.3390%2Fv13040633;citation=Kim et al. (2021);comb_mutation=N501Y;function_description=Slight increase in Vero cell-cell membrane fusion assay under infection with VSV pseudotyped virus relative to wild type, no change relative to D614G.;heterozygosity=False;clade_defining=True;variant=Mu;variant_type=VOI;voi_designation_date=30-Aug-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	23403	23403	.	+	.	ID=ID_37;Name=D614G;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=15;dp=15;sample_size=16;Reference_seq=A;Variant_seq=G;nt_name=g.A1841G;aa_name=p.D614G;hgvs_nt=NC_045512.2:g.1841A>G;hgvs_aa=YP_009724390.1:p.Asp614Gly;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.621.2;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=syncytium formation;source=https://dx.doi.org/10.3390%2Fv13040633;citation=Kim et al. (2021);comb_mutation=E484K,N501Y;function_description=~50% Vero cell-cell membrane fusion assay under infection with VSV pseudotyped virus relative to wild type, signficantly higher than D614G.;heterozygosity=False;clade_defining=True;variant=Mu;variant_type=VOI;voi_designation_date=30-Aug-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	23403	23403	.	+	.	"ID=ID_40;Name=D614G;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=15;dp=15;sample_size=16;Reference_seq=A;Variant_seq=G;nt_name=g.A1841G;aa_name=p.D614G;hgvs_nt=NC_045512.2:g.1841A>G;hgvs_aa=YP_009724390.1:p.Asp614Gly;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.621.2;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=ACE2 receptor binding affinity;source=https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1;citation=Gong et al. (2021);comb_mutation=N501Y;function_description=Using flow cytometry and ACE2 ectodomains-Fc portion IgG complex, this variant showed a 2.52x increase in binding (KD) relative to D614G, mostly due to decreased in ""off-rate"" a.k.a. dissociation rate (Kdis). Compare to full Spike variant complements for major lineages containing this variant subset: 5.43x (B.1.1.7 aka Alpha), 3.56x (B.1.351 aka Beta), 4.24x (P.1 aka Gamma).;heterozygosity=False;clade_defining=True;variant=Mu;variant_type=VOI;voi_designation_date=30-Aug-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;"
NC_045512.2	.	snp	23403	23403	.	+	.	ID=ID_43;Name=D614G;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=15;dp=15;sample_size=16;Reference_seq=A;Variant_seq=G;nt_name=g.A1841G;aa_name=p.D614G;hgvs_nt=NC_045512.2:g.1841A>G;hgvs_aa=YP_009724390.1:p.Asp614Gly;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.621.2;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=ACE2 receptor binding affinity;source=https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1;citation=Gong et al. (2021);comb_mutation=P681H;function_description=Using flow cytometry and ACE2 ectodomains-Fc portion IgG complex, this variant showed a 1.23x decrease in binding (KD) relative to D614G.;heterozygosity=False;clade_defining=True;variant=Mu;variant_type=VOI;voi_designation_date=30-Aug-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	23403	23403	.	+	.	ID=ID_38;Name=D614G;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=15;dp=15;sample_size=16;Reference_seq=A;Variant_seq=G;nt_name=g.A1841G;aa_name=p.D614G;hgvs_nt=NC_045512.2:g.1841A>G;hgvs_aa=YP_009724390.1:p.Asp614Gly;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.621.2;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=ACE2 receptor binding affinity;source=https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1;citation=Gong et al. (2021);comb_mutation=E484K;function_description=This variant appears twice in the experiments, with slightly different affinities (both ~1.2x decrease in binding relative to D614G)  using flow cytometry and ACE2 ectodomains-Fc portion IgG complex.;heterozygosity=False;clade_defining=True;variant=Mu;variant_type=VOI;voi_designation_date=30-Aug-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	23403	23403	.	+	.	ID=ID_29;Name=D614G;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=15;dp=15;sample_size=16;Reference_seq=A;Variant_seq=G;nt_name=g.A1841G;aa_name=p.D614G;hgvs_nt=NC_045512.2:g.1841A>G;hgvs_aa=YP_009724390.1:p.Asp614Gly;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.621.2;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=ACE2 receptor binding affinity;source=https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1;citation=Gong et al. (2021);comb_mutation=T95I;function_description=Using flow cytometry and ACE2 ectodomains-Fc portion IgG complex, this variant showed a 1.33x decrease in binding (KD) relative to D614G.;heterozygosity=False;clade_defining=True;variant=Mu;variant_type=VOI;voi_designation_date=30-Aug-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	23403	23403	.	+	.	ID=ID_42;Name=D614G;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=15;dp=15;sample_size=16;Reference_seq=A;Variant_seq=G;nt_name=g.A1841G;aa_name=p.D614G;hgvs_nt=NC_045512.2:g.1841A>G;hgvs_aa=YP_009724390.1:p.Asp614Gly;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.621.2;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=ACE2 receptor binding affinity;source=https://doi.org/10.1016/j.cell.2020.07.012;citation=Li et al. (2020);comb_mutation=;function_description=In four cell lines (including 293T-hACE2 cells), this mutation combination increases infectivity vs D614G alone;heterozygosity=False;clade_defining=True;variant=Mu;variant_type=VOI;voi_designation_date=30-Aug-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	23403	23403	.	+	.	ID=ID_42;Name=D614G;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=15;dp=15;sample_size=16;Reference_seq=A;Variant_seq=G;nt_name=g.A1841G;aa_name=p.D614G;hgvs_nt=NC_045512.2:g.1841A>G;hgvs_aa=YP_009724390.1:p.Asp614Gly;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.621.2;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=trafficking;source=https://dx.doi.org/10.3390%2Fv13040633;citation=Kim et al. (2021);comb_mutation=;function_description=~4x more efficient S2 domain cleavage compared to wild type in Caco-2 cells, mid-range of three cell line tested (Vero and Calu-3).;heterozygosity=False;clade_defining=True;variant=Mu;variant_type=VOI;voi_designation_date=30-Aug-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	23403	23403	.	+	.	ID=ID_40;Name=D614G;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=15;dp=15;sample_size=16;Reference_seq=A;Variant_seq=G;nt_name=g.A1841G;aa_name=p.D614G;hgvs_nt=NC_045512.2:g.1841A>G;hgvs_aa=YP_009724390.1:p.Asp614Gly;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.621.2;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=trafficking;source=https://dx.doi.org/10.3390%2Fv13040633;citation=Kim et al. (2021);comb_mutation=N501Y;function_description=~4x more efficient S2 domain cleavage compared to wild type, no change relative to D614G alone in Caco-2 cells, mid-range of three cell line tested (Vero and Calu-3).;heterozygosity=False;clade_defining=True;variant=Mu;variant_type=VOI;voi_designation_date=30-Aug-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	23403	23403	.	+	.	ID=ID_37;Name=D614G;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=15;dp=15;sample_size=16;Reference_seq=A;Variant_seq=G;nt_name=g.A1841G;aa_name=p.D614G;hgvs_nt=NC_045512.2:g.1841A>G;hgvs_aa=YP_009724390.1:p.Asp614Gly;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.621.2;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=trafficking;source=https://dx.doi.org/10.3390%2Fv13040633;citation=Kim et al. (2021);comb_mutation=E484K,N501Y;function_description=~6x more efficient S2 domain cleavage compared to wild type, compared to 4x by D614G alone in Caco-2 cells, mid-range of three cell line tested (Vero and Calu-3). [N501Y+D614G does not show an increase in cleavage, therefore a synergistic effect of the trio is implied];heterozygosity=False;clade_defining=True;variant=Mu;variant_type=VOI;voi_designation_date=30-Aug-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	23403	23403	.	+	.	ID=ID_42;Name=D614G;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=15;dp=15;sample_size=16;Reference_seq=A;Variant_seq=G;nt_name=g.A1841G;aa_name=p.D614G;hgvs_nt=NC_045512.2:g.1841A>G;hgvs_aa=YP_009724390.1:p.Asp614Gly;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.621.2;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=trafficking;source=https://dx.doi.org/10.3390%2Fv13040633;citation=Kim et al. (2021);comb_mutation=;function_description=No change in infectivity (24h) relative to D614G alone in Caco-2 cells, Vero or Calu-3.;heterozygosity=False;clade_defining=True;variant=Mu;variant_type=VOI;voi_designation_date=30-Aug-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	23403	23403	.	+	.	ID=ID_40;Name=D614G;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=15;dp=15;sample_size=16;Reference_seq=A;Variant_seq=G;nt_name=g.A1841G;aa_name=p.D614G;hgvs_nt=NC_045512.2:g.1841A>G;hgvs_aa=YP_009724390.1:p.Asp614Gly;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.621.2;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=trafficking;source=https://dx.doi.org/10.3390%2Fv13040633;citation=Kim et al. (2021);comb_mutation=N501Y;function_description=More efficient infectivity (24h) compared to wild type, in Caco-2 cells ~9x, Vero ~8x, and Calu-3 ~8x. Compare to wild type at ~5x across cell types.;heterozygosity=False;clade_defining=True;variant=Mu;variant_type=VOI;voi_designation_date=30-Aug-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	23403	23403	.	+	.	ID=ID_37;Name=D614G;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=15;dp=15;sample_size=16;Reference_seq=A;Variant_seq=G;nt_name=g.A1841G;aa_name=p.D614G;hgvs_nt=NC_045512.2:g.1841A>G;hgvs_aa=YP_009724390.1:p.Asp614Gly;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.621.2;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=trafficking;source=https://dx.doi.org/10.3390%2Fv13040633;citation=Kim et al. (2021);comb_mutation=E484K,N501Y;function_description=More efficient infectivity (24h) compared to wild type, in Caco-2 cells ~11x, Vero ~10x, and Calu-3 ~11x. Compare to wild type at ~5x across cell types.;heterozygosity=False;clade_defining=True;variant=Mu;variant_type=VOI;voi_designation_date=30-Aug-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	23403	23403	.	+	.	ID=ID_40;Name=D614G;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=15;dp=15;sample_size=16;Reference_seq=A;Variant_seq=G;nt_name=g.A1841G;aa_name=p.D614G;hgvs_nt=NC_045512.2:g.1841A>G;hgvs_aa=YP_009724390.1:p.Asp614Gly;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.621.2;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=trafficking;source=https://dx.doi.org/10.1016%2Fj.chom.2021.03.008;citation=Kuzmina et al. (2021);comb_mutation=N501Y;function_description=9x more infectivity than D614G alone in HEK293T-ACE2 cells 48h post-transduction.;heterozygosity=False;clade_defining=True;variant=Mu;variant_type=VOI;voi_designation_date=30-Aug-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	23403	23403	.	+	.	ID=ID_38;Name=D614G;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=15;dp=15;sample_size=16;Reference_seq=A;Variant_seq=G;nt_name=g.A1841G;aa_name=p.D614G;hgvs_nt=NC_045512.2:g.1841A>G;hgvs_aa=YP_009724390.1:p.Asp614Gly;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.621.2;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=trafficking;source=https://dx.doi.org/10.1016%2Fj.chom.2021.03.008;citation=Kuzmina et al. (2021);comb_mutation=E484K;function_description=~2x more infectivity than D614G alone in HEK293T-ACE2 cells 48h post-transduction.;heterozygosity=False;clade_defining=True;variant=Mu;variant_type=VOI;voi_designation_date=30-Aug-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	23403	23403	.	+	.	ID=ID_37;Name=D614G;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=15;dp=15;sample_size=16;Reference_seq=A;Variant_seq=G;nt_name=g.A1841G;aa_name=p.D614G;hgvs_nt=NC_045512.2:g.1841A>G;hgvs_aa=YP_009724390.1:p.Asp614Gly;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.621.2;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=trafficking;source=https://dx.doi.org/10.1016%2Fj.chom.2021.03.008;citation=Kuzmina et al. (2021);comb_mutation=E484K,N501Y;function_description=~12x more infectivity than D614G alone in HEK293T-ACE2 cells 48h post-transduction (~additive effects of 501 and 484).;heterozygosity=False;clade_defining=True;variant=Mu;variant_type=VOI;voi_designation_date=30-Aug-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	23403	23403	.	+	.	ID=ID_40;Name=D614G;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=15;dp=15;sample_size=16;Reference_seq=A;Variant_seq=G;nt_name=g.A1841G;aa_name=p.D614G;hgvs_nt=NC_045512.2:g.1841A>G;hgvs_aa=YP_009724390.1:p.Asp614Gly;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.621.2;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=trafficking;source=https://dx.doi.org/10.1016%2Fj.chom.2021.03.008;citation=Kuzmina et al. (2021);comb_mutation=N501Y;function_description=9x more infectivity than D614G alone in HEK293T-ACE2 cells 48h post-transduction.;heterozygosity=False;clade_defining=True;variant=Mu;variant_type=VOI;voi_designation_date=30-Aug-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	23403	23403	.	+	.	ID=ID_42;Name=D614G;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=15;dp=15;sample_size=16;Reference_seq=A;Variant_seq=G;nt_name=g.A1841G;aa_name=p.D614G;hgvs_nt=NC_045512.2:g.1841A>G;hgvs_aa=YP_009724390.1:p.Asp614Gly;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.621.2;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=trafficking;source=https://www.biorxiv.org/content/10.1101/2021.01.24.428007v1;citation=Barrett et al. (2021);comb_mutation=;function_description=Circulating variant shown in vitro to not have major defects or enhancement of cell surface protein trafficking (i.e. Spike cleavage or fusion required for cell entry);heterozygosity=False;clade_defining=True;variant=Mu;variant_type=VOI;voi_designation_date=30-Aug-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	23403	23403	.	+	.	ID=ID_42;Name=D614G;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=15;dp=15;sample_size=16;Reference_seq=A;Variant_seq=G;nt_name=g.A1841G;aa_name=p.D614G;hgvs_nt=NC_045512.2:g.1841A>G;hgvs_aa=YP_009724390.1:p.Asp614Gly;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.621.2;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=trafficking;source=https://www.nature.com/articles/s41467-020-19808-4;citation=Zhang et l. (2020);comb_mutation=;function_description=We report here pseudoviruses carrying SG614 enter ACE2-expressing cells more efficiently than wild type (~9-fold).  This increased entry correlates with less S1-domain shedding and higher S-protein incorporation into the virion.  D614G does not alter S-protein binding to ACE2 or neutralization sensitivity of pseudoviruses. Thus, D614G may  increase infectivity by assembling more functional S protein into the virion.;heterozygosity=False;clade_defining=True;variant=Mu;variant_type=VOI;voi_designation_date=30-Aug-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	23403	23403	.	+	.	ID=ID_42;Name=D614G;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=15;dp=15;sample_size=16;Reference_seq=A;Variant_seq=G;nt_name=g.A1841G;aa_name=p.D614G;hgvs_nt=NC_045512.2:g.1841A>G;hgvs_aa=YP_009724390.1:p.Asp614Gly;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.621.2;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=trafficking;source=https://www.nature.com/articles/s41467-021-21118-2;citation=Ozono et al. (2020);comb_mutation=;function_description=Among S variants tested, the D614G mutant shows the highest cell entry (~3.5x wild type), as supported by  structural and binding analyses.;heterozygosity=False;clade_defining=True;variant=Mu;variant_type=VOI;voi_designation_date=30-Aug-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	23403	23403	.	+	.	ID=ID_42;Name=D614G;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=15;dp=15;sample_size=16;Reference_seq=A;Variant_seq=G;nt_name=g.A1841G;aa_name=p.D614G;hgvs_nt=NC_045512.2:g.1841A>G;hgvs_aa=YP_009724390.1:p.Asp614Gly;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.621.2;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=trafficking;source=https://doi.org/10.7554/elife.65365;citation=Daniloski et al. (2021);comb_mutation=;function_description=The increased transduction with Spike D614G ranged from 1.3- to 2.4-fold in Caco-2 and Calu-3 cells expressing  endogenous ACE2 and from 1.5- to 7.7-fold in A549ACE2 and Huh7.5ACE2 overexpressing ACE2.  Although there is minimal difference in ACE2 receptor binding between the D614 and G614 Spike variants,  the G614 variant is more resistant to proteolytic cleavage, suggesting a possible mechanism for the increased transduction.;heterozygosity=False;clade_defining=True;variant=Mu;variant_type=VOI;voi_designation_date=30-Aug-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	23403	23403	.	+	.	ID=ID_42;Name=D614G;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=15;dp=15;sample_size=16;Reference_seq=A;Variant_seq=G;nt_name=g.A1841G;aa_name=p.D614G;hgvs_nt=NC_045512.2:g.1841A>G;hgvs_aa=YP_009724390.1:p.Asp614Gly;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.621.2;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=tissue specific neutralization;source=https://www.nature.com/articles/s41591-021-01318-5;citation=Planas et al. (2021);comb_mutation=;function_description=The nasal mucosa of Pfizer vaccinees with time course collection was evaluated against VSV pseudotypes: results (only one nasal  swab from different previously infected vacinee neutralizing at weeks 3 and 6 against B.1.1.7 and D614G) suggest that vaccinees probably  do not elicit an early humoral response detectable at mucosal surfaces even though sera neutralization was observed. They strengthen the hypothesis that some vaccines may not protect against  viral acquisition and infection of the oral–nasal region, but may prevent severe disease associated with viral dissemination in the lower respiratory tract.;heterozygosity=False;clade_defining=True;variant=Mu;variant_type=VOI;voi_designation_date=30-Aug-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	23403	23403	.	+	.	ID=ID_42;Name=D614G;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=15;dp=15;sample_size=16;Reference_seq=A;Variant_seq=G;nt_name=g.A1841G;aa_name=p.D614G;hgvs_nt=NC_045512.2:g.1841A>G;hgvs_aa=YP_009724390.1:p.Asp614Gly;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.621.2;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=viral load;source=https://www.nature.com/articles/s41586-020-2895-3;citation=Plante et al. (2020);comb_mutation=;function_description=Hamsters infected with SARS-CoV-2 expressing spike(D614G) (G614 virus) produced higher infectious titres in nasal washes and the trachea, but not in the lungs,  supporting clinical evidence showing that the mutation enhances viral loads in the upper respiratory tract of COVID-19 patients and may increase transmission.;heterozygosity=False;clade_defining=True;variant=Mu;variant_type=VOI;voi_designation_date=30-Aug-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	23403	23403	.	+	.	ID=ID_38;Name=D614G;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=15;dp=15;sample_size=16;Reference_seq=A;Variant_seq=G;nt_name=g.A1841G;aa_name=p.D614G;hgvs_nt=NC_045512.2:g.1841A>G;hgvs_aa=YP_009724390.1:p.Asp614Gly;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.621.2;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=convalescent plasma escape;source=https://www.biorxiv.org/content/10.1101/2021.05.14.444076v1;citation=Tada et al. (2021);comb_mutation=E484K;function_description=Pseudotyped viruses for B.1.618 was 2.5-fold resistant to neutralization by convalescent sera compared to wild type - a finding that was similar to that of the 3-fold resistance of the South Africa B.1.351 variant using the same assay. The resistance of B.1.618 was caused by the E484K mutation, based on results from viruses pseudotyped for individual variants within B.1.618. [details on the convalescent patient sera collection are not abundantly clear in the preprint];heterozygosity=False;clade_defining=True;variant=Mu;variant_type=VOI;voi_designation_date=30-Aug-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	23403	23403	.	+	.	ID=ID_40;Name=D614G;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=15;dp=15;sample_size=16;Reference_seq=A;Variant_seq=G;nt_name=g.A1841G;aa_name=p.D614G;hgvs_nt=NC_045512.2:g.1841A>G;hgvs_aa=YP_009724390.1:p.Asp614Gly;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.621.2;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=convalescent plasma binding;source=https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1;citation=Gong et al. (2021);comb_mutation=N501Y;function_description=1.65x increase in Spike binding (relative to D614G alone) by 5 plasma collected 8 months post-symptom-onset.;heterozygosity=False;clade_defining=True;variant=Mu;variant_type=VOI;voi_designation_date=30-Aug-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	23403	23403	.	+	.	ID=ID_43;Name=D614G;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=15;dp=15;sample_size=16;Reference_seq=A;Variant_seq=G;nt_name=g.A1841G;aa_name=p.D614G;hgvs_nt=NC_045512.2:g.1841A>G;hgvs_aa=YP_009724390.1:p.Asp614Gly;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.621.2;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=convalescent plasma binding;source=https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1;citation=Gong et al. (2021);comb_mutation=P681H;function_description=1.26x increase in Spike binding (relative to D614G alone) by 5 plasma collected 8 months post-symptom-onset.;heterozygosity=False;clade_defining=True;variant=Mu;variant_type=VOI;voi_designation_date=30-Aug-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	23403	23403	.	+	.	ID=ID_38;Name=D614G;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=15;dp=15;sample_size=16;Reference_seq=A;Variant_seq=G;nt_name=g.A1841G;aa_name=p.D614G;hgvs_nt=NC_045512.2:g.1841A>G;hgvs_aa=YP_009724390.1:p.Asp614Gly;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.621.2;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=convalescent plasma binding;source=https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1;citation=Gong et al. (2021);comb_mutation=E484K;function_description=1.42x increase in Spike binding (relative to D614G alone) by 5 plasma collected 8 months post-symptom-onset.;heterozygosity=False;clade_defining=True;variant=Mu;variant_type=VOI;voi_designation_date=30-Aug-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	23403	23403	.	+	.	ID=ID_29;Name=D614G;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=15;dp=15;sample_size=16;Reference_seq=A;Variant_seq=G;nt_name=g.A1841G;aa_name=p.D614G;hgvs_nt=NC_045512.2:g.1841A>G;hgvs_aa=YP_009724390.1:p.Asp614Gly;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.621.2;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=convalescent plasma binding;source=https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1;citation=Gong et al. (2021);comb_mutation=T95I;function_description=No change in Spike binding (relative to D614G alone) by 5 plasma collected 8 months post-symptom-onset.;heterozygosity=False;clade_defining=True;variant=Mu;variant_type=VOI;voi_designation_date=30-Aug-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	23403	23403	.	+	.	ID=ID_38;Name=D614G;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=15;dp=15;sample_size=16;Reference_seq=A;Variant_seq=G;nt_name=g.A1841G;aa_name=p.D614G;hgvs_nt=NC_045512.2:g.1841A>G;hgvs_aa=YP_009724390.1:p.Asp614Gly;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.621.2;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=vaccine neutralization efficacy;source=https://www.biorxiv.org/content/10.1101/2021.05.14.444076v1;citation=Tada et al. (2021);comb_mutation=E484K;function_description=Pseudotyped viruses for B.1.618 was 2.7-fold resistant to neutralization by 6 BNT162b2 vaccine sera 28 days post-booster compared to wild type - a finding that was similar to that of the 3.4-fold resistance of the South Africa B.1.351 variant using the same assay. Neutralization by 3 Moderna vaccine sera 28 days post-booster was 3-fold resistant (vs. 2.2-fold for B.1.351). The resistance of B.1.618 was caused by the E484K mutation, based on results from viruses pseudotyped for individual variants within B.1.618.;heterozygosity=False;clade_defining=True;variant=Mu;variant_type=VOI;voi_designation_date=30-Aug-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	23403	23403	.	+	.	ID=ID_40;Name=D614G;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=15;dp=15;sample_size=16;Reference_seq=A;Variant_seq=G;nt_name=g.A1841G;aa_name=p.D614G;hgvs_nt=NC_045512.2:g.1841A>G;hgvs_aa=YP_009724390.1:p.Asp614Gly;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.621.2;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=vaccine neutralization efficacy;source=https://dx.doi.org/10.1016%2Fj.chom.2021.03.008;citation=Kuzmina et al. (2021);comb_mutation=N501Y;function_description=This variant showed no change in Pfizer sera (one or two dose) neutralization efficiency vs D614G (using lentivirus pseudotype).;heterozygosity=False;clade_defining=True;variant=Mu;variant_type=VOI;voi_designation_date=30-Aug-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	23403	23403	.	+	.	ID=ID_38;Name=D614G;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=15;dp=15;sample_size=16;Reference_seq=A;Variant_seq=G;nt_name=g.A1841G;aa_name=p.D614G;hgvs_nt=NC_045512.2:g.1841A>G;hgvs_aa=YP_009724390.1:p.Asp614Gly;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.621.2;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=vaccine neutralization efficacy;source=https://dx.doi.org/10.1016%2Fj.chom.2021.03.008;citation=Kuzmina et al. (2021);comb_mutation=E484K;function_description=This variant showed only minor in Pfizer sera (one or two dose) neutralization efficiency vs D614G (using lentivirus pseudotype).;heterozygosity=False;clade_defining=True;variant=Mu;variant_type=VOI;voi_designation_date=30-Aug-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	23403	23403	.	+	.	ID=ID_37;Name=D614G;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=15;dp=15;sample_size=16;Reference_seq=A;Variant_seq=G;nt_name=g.A1841G;aa_name=p.D614G;hgvs_nt=NC_045512.2:g.1841A>G;hgvs_aa=YP_009724390.1:p.Asp614Gly;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.621.2;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=vaccine neutralization efficacy;source=https://dx.doi.org/10.1016%2Fj.chom.2021.03.008;citation=Kuzmina et al. (2021);comb_mutation=E484K,N501Y;function_description=This variant showed >5x decrease in Pfizer sera (3 weeks post-first dose: n ;heterozygosity=False;clade_defining=True;variant=Mu;variant_type=VOI;voi_designation_date=30-Aug-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	23403	23403	.	+	.	ID=ID_42;Name=D614G;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=15;dp=15;sample_size=16;Reference_seq=A;Variant_seq=G;nt_name=g.A1841G;aa_name=p.D614G;hgvs_nt=NC_045512.2:g.1841A>G;hgvs_aa=YP_009724390.1:p.Asp614Gly;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.621.2;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=vaccine neutralization efficacy;source=https://dx.doi.org/10.1016%2Fj.chom.2021.03.008;citation=Kuzmina et al. (2021);comb_mutation=;function_description=Using a lentivirus virus pseudotyped with D614G Spike, sera from vaccinated individuals who received the second dose (9–11 days post-second dose of Pfizer) exhibited a robust  neutralizing potential, with a mean NT50 value of 99,000. This was an average of a 2-fold increase, relative to sera drawn from the  individuals who received one dose of vaccination—mean NT50 dilution of 51,300. Importantly, a 6-fold increase in mean NT50 dilution was  obtained when sera from the first vaccination dose was compared to convalescent sera from cohort with severe disease (NT50 51,000 vs 8,700)  21 to 63 days post-onset.;heterozygosity=False;clade_defining=True;variant=Mu;variant_type=VOI;voi_designation_date=30-Aug-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	23403	23403	.	+	.	ID=ID_43;Name=D614G;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=15;dp=15;sample_size=16;Reference_seq=A;Variant_seq=G;nt_name=g.A1841G;aa_name=p.D614G;hgvs_nt=NC_045512.2:g.1841A>G;hgvs_aa=YP_009724390.1:p.Asp614Gly;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.621.2;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=vaccine neutralization efficacy;source=https://www.medrxiv.org/content/10.1101/2021.03.25.21253908v1;citation=Zuckerman et al. (2021);comb_mutation=P681H;function_description=No significant change in virus neutralzation by 18 Pfizer two dose vaccinee sera compared to B.1.1.7. [results without including the used mutation A27S likely generalizable, as this is not a lineage defining mutation];heterozygosity=False;clade_defining=True;variant=Mu;variant_type=VOI;voi_designation_date=30-Aug-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	23403	23403	.	+	.	ID=ID_42;Name=D614G;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=15;dp=15;sample_size=16;Reference_seq=A;Variant_seq=G;nt_name=g.A1841G;aa_name=p.D614G;hgvs_nt=NC_045512.2:g.1841A>G;hgvs_aa=YP_009724390.1:p.Asp614Gly;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.621.2;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=vaccine neutralization efficacy;source=https://doi.org/10.1016/j.cell.2021.03.013;citation=Garcia-Beltran et al. (2021);comb_mutation=;function_description=Pseudotyped D614G virus has reduced neutralization activity vs wild type: 1.2x (37 sera Pfizer median 9  days post 2nd dose, 37 sera Moderna median 18 days post 2nd dose). This was NOT significant by ANOVA.;heterozygosity=False;clade_defining=True;variant=Mu;variant_type=VOI;voi_designation_date=30-Aug-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	23403	23403	.	+	.	ID=ID_42;Name=D614G;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=15;dp=15;sample_size=16;Reference_seq=A;Variant_seq=G;nt_name=g.A1841G;aa_name=p.D614G;hgvs_nt=NC_045512.2:g.1841A>G;hgvs_aa=YP_009724390.1:p.Asp614Gly;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.621.2;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=virion structure;source=https://www.nature.com/articles/s41467-020-19808-4;citation=Zhang et al. (2020);comb_mutation=;function_description=Based on pseudotyped virus experiments, D614G may increase infectivity by assembling more functional S protein into the virion.;heterozygosity=False;clade_defining=True;variant=Mu;variant_type=VOI;voi_designation_date=30-Aug-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	23403	23403	.	+	.	"ID=ID_42;Name=D614G;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=15;dp=15;sample_size=16;Reference_seq=A;Variant_seq=G;nt_name=g.A1841G;aa_name=p.D614G;hgvs_nt=NC_045512.2:g.1841A>G;hgvs_aa=YP_009724390.1:p.Asp614Gly;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.621.2;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=virion structure;source=https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7492024/;citation=Yurkovetskiy et al. (2020);comb_mutation=;function_description=CryoEM shows increased proportion of ""one-up"" trimer conformation of Spike proteins on the surface of virions, where the up  conformation is presumed to be more likely to bind ACE2.;heterozygosity=False;clade_defining=True;variant=Mu;variant_type=VOI;voi_designation_date=30-Aug-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;"
NC_045512.2	.	snp	23403	23403	.	+	.	"ID=ID_42;Name=D614G;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=15;dp=15;sample_size=16;Reference_seq=A;Variant_seq=G;nt_name=g.A1841G;aa_name=p.D614G;hgvs_nt=NC_045512.2:g.1841A>G;hgvs_aa=YP_009724390.1:p.Asp614Gly;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.621.2;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=virion structure;source=https://www.medrxiv.org/content/10.1101/2020.07.22.20159905v2;citation=Weissman et al. (2020);comb_mutation=;function_description=Negative stain EM shows increased proportion of ""one-up"" trimer conformation of Spike proteins on the surface of virions, where the up  conformation is presumed to be more likely to bind ACE2.;heterozygosity=False;clade_defining=True;variant=Mu;variant_type=VOI;voi_designation_date=30-Aug-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;"
NC_045512.2	.	snp	23403	23403	.	+	.	ID=ID_42;Name=D614G;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=15;dp=15;sample_size=16;Reference_seq=A;Variant_seq=G;nt_name=g.A1841G;aa_name=p.D614G;hgvs_nt=NC_045512.2:g.1841A>G;hgvs_aa=YP_009724390.1:p.Asp614Gly;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.621.2;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=virion structure;source=https://www.biorxiv.org/content/10.1101/2021.03.24.436850v1;citation=Spratt et al. (2021);comb_mutation=;function_description=Estimated free energy change (ddG) for this variant is 2.5 kcal/mol (i.e. stabilizing relative to wild type);heterozygosity=False;clade_defining=True;variant=Mu;variant_type=VOI;voi_designation_date=30-Aug-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	23403	23403	.	+	.	ID=ID_40;Name=D614G;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=15;dp=15;sample_size=16;Reference_seq=A;Variant_seq=G;nt_name=g.A1841G;aa_name=p.D614G;hgvs_nt=NC_045512.2:g.1841A>G;hgvs_aa=YP_009724390.1:p.Asp614Gly;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.621.2;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=vaccinee plasma binding;source=https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1;citation=Gong et al. (2021);comb_mutation=N501Y;function_description=1.17x increase in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in previously non-seroconverted subjects.  1.09x increase in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in post-infection vaccinees.;heterozygosity=False;clade_defining=True;variant=Mu;variant_type=VOI;voi_designation_date=30-Aug-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	23403	23403	.	+	.	ID=ID_43;Name=D614G;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=15;dp=15;sample_size=16;Reference_seq=A;Variant_seq=G;nt_name=g.A1841G;aa_name=p.D614G;hgvs_nt=NC_045512.2:g.1841A>G;hgvs_aa=YP_009724390.1:p.Asp614Gly;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.621.2;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=vaccinee plasma binding;source=https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1;citation=Gong et al. (2021);comb_mutation=P681H;function_description=1.14x decrease in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in previously non-seroconverted subjects.  1.11x decrease in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in post-infection vaccinees.;heterozygosity=False;clade_defining=True;variant=Mu;variant_type=VOI;voi_designation_date=30-Aug-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	23403	23403	.	+	.	ID=ID_38;Name=D614G;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=15;dp=15;sample_size=16;Reference_seq=A;Variant_seq=G;nt_name=g.A1841G;aa_name=p.D614G;hgvs_nt=NC_045512.2:g.1841A>G;hgvs_aa=YP_009724390.1:p.Asp614Gly;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.621.2;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=vaccinee plasma binding;source=https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1;citation=Gong et al. (2021);comb_mutation=E484K;function_description=1.16x increase in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in previously non-seroconverted subjects.  1.06x increase in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in post-infection vaccinees.;heterozygosity=False;clade_defining=True;variant=Mu;variant_type=VOI;voi_designation_date=30-Aug-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	23403	23403	.	+	.	ID=ID_29;Name=D614G;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=15;dp=15;sample_size=16;Reference_seq=A;Variant_seq=G;nt_name=g.A1841G;aa_name=p.D614G;hgvs_nt=NC_045512.2:g.1841A>G;hgvs_aa=YP_009724390.1:p.Asp614Gly;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.621.2;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=vaccinee plasma binding;source=https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1;citation=Gong et al. (2021);comb_mutation=T95I;function_description=1.16x increase in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in previously non-seroconverted subjects.  1.02x decrease in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in post-infection vaccinees.;heterozygosity=False;clade_defining=True;variant=Mu;variant_type=VOI;voi_designation_date=30-Aug-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	23604	23604	.	+	.	ID=ID_44;Name=P681H;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=15;dp=15;sample_size=16;Reference_seq=C;Variant_seq=A;nt_name=g.C2042A;aa_name=p.P681H;hgvs_nt=NC_045512.2:g.2042C>A;hgvs_aa=YP_009724390.1:p.Pro681His;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.621.2;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=antibody epitope effects;source=https://www.medrxiv.org/content/10.1101/2021.01.06.20248960v1;citation=Haynes et al. (2021);comb_mutation=;function_description=Wildtype elicits immune response, COVID-19 cohort epitope score > 99th percentile of the 497 pre-pandemic controls, mutant drops PIWAS epitope score from 7.8% to 1.2% (significantly poorer immune recognition) Together with other B1.1.7 lineage mutational changes (Spike: Y144del,N501Y, A570D Nucleoprotein: D3L, S235F) resulted in only 2 of 579 individuals (0.3% of the population) having a dramatic reduction in PIWAS antigen scores, which reflects the peak epitope signal along the entire antigen.;heterozygosity=False;clade_defining=True;variant=Mu;variant_type=VOI;voi_designation_date=30-Aug-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	23604	23604	.	+	.	ID=ID_44;Name=P681H;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=15;dp=15;sample_size=16;Reference_seq=C;Variant_seq=A;nt_name=g.C2042A;aa_name=p.P681H;hgvs_nt=NC_045512.2:g.2042C>A;hgvs_aa=YP_009724390.1:p.Pro681His;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.621.2;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=antibody epitope effects;source=https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7457603/;citation=Johnson et al. (2020);comb_mutation=;function_description=This variant is adjacent to the Spike protein furin cleavage site (cleavage of S into S1 and S2 subunits is required for viral membrane fusion and subsequent entry into host cells), a site shown to be highly immunogenic.;heterozygosity=False;clade_defining=True;variant=Mu;variant_type=VOI;voi_designation_date=30-Aug-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	23604	23604	.	+	.	ID=ID_44;Name=P681H;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=15;dp=15;sample_size=16;Reference_seq=C;Variant_seq=A;nt_name=g.C2042A;aa_name=p.P681H;hgvs_nt=NC_045512.2:g.2042C>A;hgvs_aa=YP_009724390.1:p.Pro681His;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.621.2;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=antibody epitope effects;source=https://www.nature.com/articles/s41591-021-01294-w;citation=Chen et al. (2021);comb_mutation=;function_description=Ablates Class 3 N-terminal domain targeting antibody COV2-2489, diminishes COV2-2676.;heterozygosity=False;clade_defining=True;variant=Mu;variant_type=VOI;voi_designation_date=30-Aug-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	23604	23604	.	+	.	ID=ID_43;Name=P681H;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=15;dp=15;sample_size=16;Reference_seq=C;Variant_seq=A;nt_name=g.C2042A;aa_name=p.P681H;hgvs_nt=NC_045512.2:g.2042C>A;hgvs_aa=YP_009724390.1:p.Pro681His;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.621.2;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=ACE2 receptor binding affinity;source=https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1;citation=Gong et al. (2021);comb_mutation=D614G;function_description=Using flow cytometry and ACE2 ectodomains-Fc portion IgG complex, this variant showed a 1.23x decrease in binding (KD) relative to D614G.;heterozygosity=False;clade_defining=True;variant=Mu;variant_type=VOI;voi_designation_date=30-Aug-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	23604	23604	.	+	.	ID=ID_44;Name=P681H;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=15;dp=15;sample_size=16;Reference_seq=C;Variant_seq=A;nt_name=g.C2042A;aa_name=p.P681H;hgvs_nt=NC_045512.2:g.2042C>A;hgvs_aa=YP_009724390.1:p.Pro681His;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.621.2;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=trafficking;source=https://www.biorxiv.org/content/10.1101/2021.02.05.430003v1;citation=Tada et al. (2021);comb_mutation=;function_description=Lentiviral pseudotyped with this individual mutation from B.1.1.7 was tested on ACE2.293T cells. Luciferase activity was measured two days postinfection,  showing NO statistically significant infection rate change amongst the cells, suggesting that furin cleavage typically used for cell entry is not affected by this change one  amino acid upstream of the RXXR recognition pattern.;heterozygosity=False;clade_defining=True;variant=Mu;variant_type=VOI;voi_designation_date=30-Aug-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	23604	23604	.	+	.	ID=ID_44;Name=P681H;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=15;dp=15;sample_size=16;Reference_seq=C;Variant_seq=A;nt_name=g.C2042A;aa_name=p.P681H;hgvs_nt=NC_045512.2:g.2042C>A;hgvs_aa=YP_009724390.1:p.Pro681His;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.621.2;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=trafficking;source=https://www.researchgate.net/publication/348943694_The_mutation_P681H_in_the_B117_variant_of_SARS-CoV-2_probably_enhances_viral_entry_and_replication;citation=Maaroufi (2021);comb_mutation=;function_description=This mutation in the first base of the furin clevage site maintains the RXXR recognition motif, and is presumed to enhance cleavage based on the removal of a proline-directed phosphotase recognition site at S680. In a homologuous site in Infectious  Bronchitis Virus (IBV, Gammacoronaviruses), abolition of S680 phosphorylation improves furin cleavage  (and presumably cell entry).;heterozygosity=False;clade_defining=True;variant=Mu;variant_type=VOI;voi_designation_date=30-Aug-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	23604	23604	.	+	.	ID=ID_44;Name=P681H;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=15;dp=15;sample_size=16;Reference_seq=C;Variant_seq=A;nt_name=g.C2042A;aa_name=p.P681H;hgvs_nt=NC_045512.2:g.2042C>A;hgvs_aa=YP_009724390.1:p.Pro681His;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.621.2;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=trafficking;source=https://www.biorxiv.org/content/10.1101/2021.04.06.438731v1;citation=Lubinski et al. (2021);comb_mutation=;function_description=While the introduction of P681H in the SARS-CoV-2 B.1.1.7 variant may increase spike cleavage by furin-like proteases,  this does not significantly impact viral entry or cell-cell spread. We consider that other factors are at play to account  for the increased in transmission and disease severity attributed to this variant of concern (VOC).;heterozygosity=False;clade_defining=True;variant=Mu;variant_type=VOI;voi_designation_date=30-Aug-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	23604	23604	.	+	.	ID=ID_43;Name=P681H;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=15;dp=15;sample_size=16;Reference_seq=C;Variant_seq=A;nt_name=g.C2042A;aa_name=p.P681H;hgvs_nt=NC_045512.2:g.2042C>A;hgvs_aa=YP_009724390.1:p.Pro681His;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.621.2;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=convalescent plasma binding;source=https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1;citation=Gong et al. (2021);comb_mutation=D614G;function_description=1.26x increase in Spike binding (relative to D614G alone) by 5 plasma collected 8 months post-symptom-onset.;heterozygosity=False;clade_defining=True;variant=Mu;variant_type=VOI;voi_designation_date=30-Aug-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	23604	23604	.	+	.	ID=ID_43;Name=P681H;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=15;dp=15;sample_size=16;Reference_seq=C;Variant_seq=A;nt_name=g.C2042A;aa_name=p.P681H;hgvs_nt=NC_045512.2:g.2042C>A;hgvs_aa=YP_009724390.1:p.Pro681His;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.621.2;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=vaccine neutralization efficacy;source=https://www.medrxiv.org/content/10.1101/2021.03.25.21253908v1;citation=Zuckerman et al. (2021);comb_mutation=D614G;function_description=No significant change in virus neutralzation by 18 Pfizer two dose vaccinee sera compared to B.1.1.7. [results without including the used mutation A27S likely generalizable, as this is not a lineage defining mutation];heterozygosity=False;clade_defining=True;variant=Mu;variant_type=VOI;voi_designation_date=30-Aug-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	23604	23604	.	+	.	ID=ID_44;Name=P681H;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=15;dp=15;sample_size=16;Reference_seq=C;Variant_seq=A;nt_name=g.C2042A;aa_name=p.P681H;hgvs_nt=NC_045512.2:g.2042C>A;hgvs_aa=YP_009724390.1:p.Pro681His;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.621.2;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=virion structure;source=https://www.biorxiv.org/content/10.1101/2021.02.05.430003v1;citation=Tada et al. (2021);comb_mutation=;function_description=The Ratio of S2 (processed Spike) to full length Spike is higher for this mutation,  due to a drop in the full length Spike measured, suggesting that this mutation compensates for decreased Spike production by improved proteolytic processing.;heterozygosity=False;clade_defining=True;variant=Mu;variant_type=VOI;voi_designation_date=30-Aug-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	23604	23604	.	+	.	ID=ID_43;Name=P681H;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=15;dp=15;sample_size=16;Reference_seq=C;Variant_seq=A;nt_name=g.C2042A;aa_name=p.P681H;hgvs_nt=NC_045512.2:g.2042C>A;hgvs_aa=YP_009724390.1:p.Pro681His;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.621.2;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=vaccinee plasma binding;source=https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1;citation=Gong et al. (2021);comb_mutation=D614G;function_description=1.14x decrease in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in previously non-seroconverted subjects.  1.11x decrease in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in post-infection vaccinees.;heterozygosity=False;clade_defining=True;variant=Mu;variant_type=VOI;voi_designation_date=30-Aug-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	25563	25563	.	+	.	ID=ID_45;Name=Q57H;alias=n/a;gene=ORF3a;protein_name=ORF3a protein;protein_symbol=ORF3a;protein_id=YP_009724391.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=15;dp=15;sample_size=16;Reference_seq=G;Variant_seq=T;nt_name=g.G171T;aa_name=p.Q57H;hgvs_nt=NC_045512.2:g.171G>T;hgvs_aa=YP_009724391.1:p.Gln57His;hgvs_alias=n/a;vcf_gene=ORF3a;mutation_type=MISSENSE;viral_lineage=B.1.621.2;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=True;variant=Mu;variant_type=VOI;voi_designation_date=30-Aug-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	25693	25693	.	+	.	ID=ID_46;Name=L101I;alias=n/a;gene=ORF3a;protein_name=ORF3a protein;protein_symbol=ORF3a;protein_id=YP_009724391.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=14;ao=1;dp=15;sample_size=16;Reference_seq=C;Variant_seq=A;nt_name=g.C301A;aa_name=p.L101I;hgvs_nt=NC_045512.2:g.301C>A;hgvs_aa=YP_009724391.1:p.Leu101Ile;hgvs_alias=n/a;vcf_gene=ORF3a;mutation_type=MISSENSE;viral_lineage=B.1.621.2;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.06666666666666667;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=False;variant=Mu;variant_type=VOI;voi_designation_date=30-Aug-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	del	26157	26157	.	+	.	ID=ID_47;Name=V256fs;alias=n/a;gene=ORF3a;protein_name=ORF3a protein;protein_symbol=ORF3a;protein_id=YP_009724391.1;ps_filter=n/a;ps_exc=n/a;mat_pep=(ORF3a|GU280_gp03|1|1.00);mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=15;dp=15;sample_size=16;Reference_seq=TGTTA;Variant_seq=T;nt_name=g.766_769delGTTA;aa_name=p.V256fs;hgvs_nt=NC_045512.2:g.766_769del;hgvs_aa=YP_009724391.1:p.Val256fs;hgvs_alias=n/a;vcf_gene=ORF3a;mutation_type=;viral_lineage=B.1.621.2;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=True;variant=Mu;variant_type=VOI;voi_designation_date=30-Aug-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	26492	26492	.	+	.	ID=ID_48;Name=g.A-31T;alias=n/a;gene=intergenic;protein_name=n/a;protein_symbol=n/a;protein_id=n/a;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=15;dp=15;sample_size=16;Reference_seq=A;Variant_seq=T;nt_name=g.A-31T;aa_name=;hgvs_nt=NC_045512.2:g.31A>T;hgvs_aa=n/a;hgvs_alias=n/a;vcf_gene=M;mutation_type=;viral_lineage=B.1.621.2;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=True;variant=Mu;variant_type=VOI;voi_designation_date=30-Aug-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	26959	26959	.	+	.	ID=ID_49;Name=R146H;alias=n/a;gene=M;protein_name=membrane glycoprotein;protein_symbol=M;protein_id=YP_009724393.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=15;dp=15;sample_size=16;Reference_seq=G;Variant_seq=A;nt_name=g.G437A;aa_name=p.R146H;hgvs_nt=NC_045512.2:g.437G>A;hgvs_aa=YP_009724393.1:p.Arg146His;hgvs_alias=n/a;vcf_gene=M;mutation_type=MISSENSE;viral_lineage=B.1.621.2;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=True;variant=Mu;variant_type=VOI;voi_designation_date=30-Aug-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	26972	26972	.	+	.	ID=ID_50;Name=R150R;alias=n/a;gene=M;protein_name=membrane glycoprotein;protein_symbol=M;protein_id=YP_009724393.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=14;ao=1;dp=15;sample_size=16;Reference_seq=T;Variant_seq=C;nt_name=g.T450C;aa_name=p.R150R;hgvs_nt=NC_045512.2:g.450T>C;hgvs_aa=YP_009724393.1:p.Arg150Arg;hgvs_alias=n/a;vcf_gene=M;mutation_type=SILENT;viral_lineage=B.1.621.2;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.06666666666666667;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=False;variant=Mu;variant_type=VOI;voi_designation_date=30-Aug-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	27675	27675	.	+	.	ID=ID_51;Name=Q94H;alias=n/a;gene=ORF7a;protein_name=ORF7a protein;protein_symbol=ORF7a;protein_id=YP_009724395.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=1;ao=14;dp=15;sample_size=16;Reference_seq=A;Variant_seq=C;nt_name=g.A282C;aa_name=p.Q94H;hgvs_nt=NC_045512.2:g.282A>C;hgvs_aa=YP_009724395.1:p.Gln94His;hgvs_alias=n/a;vcf_gene=ORF7a;mutation_type=MISSENSE;viral_lineage=B.1.621.2;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.9333333333333333;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=True;variant=Mu;variant_type=VOI;voi_designation_date=30-Aug-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	27925	27925	.	+	.	ID=ID_52;Name=T11K;alias=n/a;gene=ORF8;protein_name=ORF8 protein;protein_symbol=ORF8;protein_id=YP_009724396.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=15;dp=15;sample_size=16;Reference_seq=C;Variant_seq=A;nt_name=g.C32A;aa_name=p.T11K;hgvs_nt=NC_045512.2:g.32C>A;hgvs_aa=YP_009724396.1:p.Thr11Lys;hgvs_alias=n/a;vcf_gene=ORF8;mutation_type=MISSENSE;viral_lineage=B.1.621.2;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=True;variant=Mu;variant_type=VOI;voi_designation_date=30-Aug-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	28005	28005	.	+	.	ID=ID_53;Name=P38S;alias=n/a;gene=ORF8;protein_name=ORF8 protein;protein_symbol=ORF8;protein_id=YP_009724396.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=15;dp=15;sample_size=16;Reference_seq=C;Variant_seq=T;nt_name=g.C112T;aa_name=p.P38S;hgvs_nt=NC_045512.2:g.112C>T;hgvs_aa=YP_009724396.1:p.Pro38Ser;hgvs_alias=n/a;vcf_gene=ORF8;mutation_type=MISSENSE;viral_lineage=B.1.621.2;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=True;variant=Mu;variant_type=VOI;voi_designation_date=30-Aug-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	28093	28093	.	+	.	ID=ID_54;Name=S67F;alias=n/a;gene=ORF8;protein_name=ORF8 protein;protein_symbol=ORF8;protein_id=YP_009724396.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=15;dp=15;sample_size=16;Reference_seq=C;Variant_seq=T;nt_name=g.C200T;aa_name=p.S67F;hgvs_nt=NC_045512.2:g.200C>T;hgvs_aa=YP_009724396.1:p.Ser67Phe;hgvs_alias=n/a;vcf_gene=ORF8;mutation_type=MISSENSE;viral_lineage=B.1.621.2;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=True;variant=Mu;variant_type=VOI;voi_designation_date=30-Aug-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	28272	28272	.	+	.	ID=ID_55;Name=g.A-2T;alias=n/a;gene=intergenic;protein_name=n/a;protein_symbol=n/a;protein_id=n/a;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=15;dp=15;sample_size=16;Reference_seq=A;Variant_seq=T;nt_name=g.A-2T;aa_name=;hgvs_nt=NC_045512.2:g.2A>T;hgvs_aa=n/a;hgvs_alias=n/a;vcf_gene=N;mutation_type=;viral_lineage=B.1.621.2;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=True;variant=Mu;variant_type=VOI;voi_designation_date=30-Aug-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	28357	28357	.	+	.	ID=ID_56;Name=Q28H;alias=n/a;gene=N;protein_name=nucleocapsid phosphoprotein;protein_symbol=N;protein_id=YP_009724397.2;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=14;ao=1;dp=15;sample_size=16;Reference_seq=G;Variant_seq=T;nt_name=g.G84T;aa_name=p.Q28H;hgvs_nt=NC_045512.2:g.84G>T;hgvs_aa=YP_009724397.2:p.Gln28His;hgvs_alias=n/a;vcf_gene=N;mutation_type=MISSENSE;viral_lineage=B.1.621.2;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.06666666666666667;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=False;variant=Mu;variant_type=VOI;voi_designation_date=30-Aug-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	28851	28851	.	+	.	ID=ID_57;Name=S193T;alias=n/a;gene=N;protein_name=nucleocapsid phosphoprotein;protein_symbol=N;protein_id=YP_009724397.2;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=14;ao=1;dp=15;sample_size=16;Reference_seq=G;Variant_seq=C;nt_name=g.G578C;aa_name=p.S193T;hgvs_nt=NC_045512.2:g.578G>C;hgvs_aa=YP_009724397.2:p.Ser193Thr;hgvs_alias=n/a;vcf_gene=N;mutation_type=MISSENSE;viral_lineage=B.1.621.2;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.06666666666666667;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=False;variant=Mu;variant_type=VOI;voi_designation_date=30-Aug-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	28887	28887	.	+	.	ID=ID_58;Name=T205I;alias=n/a;gene=N;protein_name=nucleocapsid phosphoprotein;protein_symbol=N;protein_id=YP_009724397.2;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=15;dp=15;sample_size=16;Reference_seq=C;Variant_seq=T;nt_name=g.C614T;aa_name=p.T205I;hgvs_nt=NC_045512.2:g.614C>T;hgvs_aa=YP_009724397.2:p.Thr205Ile;hgvs_alias=n/a;vcf_gene=N;mutation_type=MISSENSE;viral_lineage=B.1.621.2;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=True;variant=Mu;variant_type=VOI;voi_designation_date=30-Aug-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	29445	29445	.	+	.	ID=ID_59;Name=T391I;alias=n/a;gene=N;protein_name=nucleocapsid phosphoprotein;protein_symbol=N;protein_id=YP_009724397.2;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=1;ao=14;dp=15;sample_size=16;Reference_seq=C;Variant_seq=T;nt_name=g.C1172T;aa_name=p.T391I;hgvs_nt=NC_045512.2:g.1172C>T;hgvs_aa=YP_009724397.2:p.Thr391Ile;hgvs_alias=n/a;vcf_gene=N;mutation_type=MISSENSE;viral_lineage=B.1.621.2;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.9333333333333333;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=True;variant=Mu;variant_type=VOI;voi_designation_date=30-Aug-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	29736	29736	.	+	.	ID=ID_60;Name=g.G29736A;alias=n/a;gene=intergenic;protein_name=n/a;protein_symbol=n/a;protein_id=n/a;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=15;dp=15;sample_size=16;Reference_seq=G;Variant_seq=A;nt_name=g.G29736A;aa_name=;hgvs_nt=NC_045512.2:g.29736G>A;hgvs_aa=n/a;hgvs_alias=n/a;vcf_gene=intergenic;mutation_type=;viral_lineage=B.1.621.2;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=True;variant=Mu;variant_type=VOI;voi_designation_date=30-Aug-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	29779	29779	.	+	.	ID=ID_61;Name=g.G29779T;alias=n/a;gene=intergenic;protein_name=n/a;protein_symbol=n/a;protein_id=n/a;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=1;dp=1;sample_size=16;Reference_seq=G;Variant_seq=T;nt_name=g.G29779T;aa_name=;hgvs_nt=NC_045512.2:g.29779G>T;hgvs_aa=n/a;hgvs_alias=n/a;vcf_gene=intergenic;mutation_type=;viral_lineage=B.1.621.2;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=True;variant=Mu;variant_type=VOI;voi_designation_date=30-Aug-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
